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Abstract 
This thesis describes two groups of experiments, both relating to the 
condition of distal renal tubular acidosis (dRTA). 
 
In the first, an alternative diagnostic test of dRTA to the ‘gold standard’ 
short ammonium chloride (NH4Cl) test was assessed. This was achieved 
by the simultaneous oral administration of the diuretic furosemide and 
the mineralocorticoid fludrocortisone to increase distal sodium delivery 
and a-intercalated cell proton secretion. I evaluated 11 control subjects 
and 10 patients with known dRTA by giving oral NH4Cl or 
furosemide/fludrocortisone in random order on separate days. 3 
subjects were unable to complete the study due to vomiting after the 
NH4Cl, however there were no adverse effects with 
furosemide/fludrocortisone administration. The urine pH decreased to 
less than 5.3 in the controls with both tests, whereas no patients were 
able to lower their urine pH below 5.3 with either test. The simultaneous 
administration of furosemide/fludrocortisone proved to be an easy, 
effective and well-tolerated alternative to the standard NH4Cl test for the 
diagnosis of dRTA. 
 
The second group were laboratory-based molecular physiology 
experiments. Anion exchanger 1 (AE1) mediates electroneutral anion 
exchange across cell membranes. It is the most abundant protein in the 
red cell membrane, but is also found in the basolateral membrane of 
renal a-intercalated cells, where it is required for urinary acidification. 
Point mutations have been described that convert the red cell AE1 into a 
cation conductance. AE1 mutations can also cause hereditary dRTA. I 
investigated the properties of four dRTA associated AE1 mutations 
(R586H, G609R, S613F and G701D) by heterologous expression in 
Xenopus Laevis oocytes. These mutants proved to be functional anion 
exchangers, unlike the red cell mutants, but also demonstrated a cation 
‘leak’. I found a very large leak property in the G701D mutant, which is 
prevalent in SE Asia. I hypothesised that this property might confer a   4
survival advantage. I characterised three other AR dRTA-associated AE1 
mutants found in SE Asia, S773P, Δ850 and A858D via similar transport 
experiments in AE1-expressing Xenopus oocytes. These three SE Asian 
mutants also had cation leaks of similar magnitude to that seen in 
G701D, a property that distinguishes them as a discrete group. The 
clustering of these cation-leaky AE1 mutations to malarious areas of SE 
Asia suggests that they may confer malaria resistance. 
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1.  Introduction 
1.1  Scope of the Introduction 
Broadly speaking this thesis could be said to address the physiology and 
pathophysiology of distal sodium and potassium handling in the syndrome of 
distal renal tubular acidosis (dRTA). 
 
From its inception the project set out to address these subjects in specific and 
very different ways, with quite different approaches and goals. 
 
The specific questions that I sought to answer were; 
 
1)  “Can increased delivery of sodium to the distal nephron be used to 
reliably assess distal urinary acidification in dRTA and health?” 
 
2)  “Can the urinary potassium wasting observed in inherited dRTA be 
attributed, in part, to a property of the mutated transport protein that 
causes it?” 
 
During the course of my studies, the second question supplied the most 
interesting data, and my work focussed more on the transport protein in 
question, the Anion Exchanger 1 (AE1 or band 3) its ability to function as a 
cation channel like transporter when mutated and on an evolving hypothesis 
about the possible positive advantage this may have conferred to 
heterozygotes with these mutations. 
 
My introduction attempts to set the scene for this work at the time that it was 
started. Unfortunately this involves reviewing a number of fairly disparate 
subjects, which are all somewhat esoteric. Firstly I’ll review the renal tubular 
acidoses, the history of their characterisation and classification and define 
dRTA and the syndrome of incomplete dRTA. I will then review the various 
techniques used to test distal urinary acidification in order to confirm 
incomplete dRTA. As this relates directly to sodium wasting in dRTA, I will   19
then outline the models and theories of sodium and potassium loss in dRTA. I 
will next review the important work relating to the pH regulatory function of the 
cortical collecting duct, and the intercalated cells in particular. This will be 
followed by a detailed examination of the work concerning the structure 
function relationship of AE1, AE1 function and trafficking in the α-intercalated 
cell and in the erythrocyte, and finally the work elucidating the cation leak 
property of wildtype and mutant AE1. 
The three experimental chapters will include discussions of my findings in 
relation to current literature and in the discussion I will attempt to draw these 
together and outline where I think this work leads to. 
 
1.2  History and nomenclature of RTA 
1.2.1  Definition 
 
The renal tubular acidoses are a collection of syndromes characterised by 
impairment of the ability of the renal tubules to acidify the urine, which is not 
due to an impairment of glomerular function. 
 
1.2.1.1  Distal renal tubular acidosis (dRTA, type 1 RTA),  
Distal renal tubular acidosis the focus of this thesis, is the classical and 
commonest form, and involves a failure of acid secretion in the distal nephron, 
more specifically by the acid secreting α-intercalated cells of the distal 
convoluted tubule and the cortical collecting duct.  
 
It is characterised by: 
•  An inability to acidify the urine to a pH of less than 5.3 
Which can lead to: 
•  Variable metabolic acidosis 
•  Osteomalacia and/or bone demineralisation subsequent to the acidosis   20
•  Nephrocalcinosis (calcium salt deposition in renal parenchyma) and/or 
renal calculi due to high calcium, low citrate, alkaline urine 
•  Variable hypokalemia due to urinary potassium wasting 
•  Variable salt-losing nephropathy due to urinary sodium wasting 
 
It has a number of causes, primary and secondary: 
Primary: 
•  Mutations of the anion exchanger AE1, normally present on the 
basolateral surface of the α-intercalated cell[1]. 
•  Mutations of the a4 or B1 subunit of the v H
+ATPase, normally present 
on the apical surface of the α-intercalated cell [2]. 
 
Secondary: 
•  In association with autoimmune disease, notably Sjögren’s syndrome 
[3], but also systemic lupus erythematosus [4], rheumatoid arthritis [5], 
autoimmune thyroid disease [6], primary biliary cirrhosis [7] and 
hypergammaglobulinemia [8] 
•  Due to a number of toxins, such as ifosphamide [9], toluene [10], 
lithium carbonate [11] and amphotericin B [12] 
•  Nephrocalcinosis [13](which can cause, as well as be caused by dRTA, 
presumably by mechanical disruption of the cortical collecting tubule) 
•  Sickle cell disease [14] 
•  Renal transplantation [15] (probably a toxic effect of calcineurin 
inhibitors [16]) 
•  Chronic urinary tract obstruction [17] 
•  Liver cirrhosis [18]  
  
 
 
1.2.1.2  Proximal renal tubular acidosis (pRTA, type 2 RTA)  
Proximal renal tubular acidosis is a defect of the proximal nephron, 
characterised by impairment of the ability of the proximal tubule to absorb   21
bicarbonate from the tubular lumen. It almost always accompanies the so-
called Fanconi syndrome of proximal tubular dysfunction characterised by 
aminoaciduria, phosphaturia, glycosuria, uricosuria and tubular proteinuria.  
As the defect is one of bicarbonate reabsorbtion, there will be bicarbonaturia, 
and if untreated, as the plasma bicarbonate falls, it will eventually meet the 
lowered bicarbonate reabsorbtion threshold, and then the bicarbonate will all 
be reabsorbed, and the urine will acidify normally again. It is associated with 
bone demineralisation, due to the acidosis and urinary phosphate wasting. 
 
Causes include inherited and acquired causes. 
 
Inherited: 
•  Cystinosis [19] 
•  Galactosemia [20] 
•  Hereditary fructose intolerance [21] 
•  Lowe syndrome [22] 
•  Tyrosinemia 
•  Type 1 glycogen storage disease (von Gierke's disease) [23] 
•  Wilson’s disease [24] 
 
Acquired: 
•  Amyloid [25] 
•  Myeloma [26] 
•  Paroxysmal nocturnal hemoglobinuria 
•  Toxins, such as nucleotide and nucleoside analogues (especially 
adefovir) and reverse transcriptase inhibitors [27] used for HIV, 
ifosphamide [28], lead and cadmium [29]. 
 
 
1.2.1.3  Type 3 RTA  
Type 3 RTA originally described a mixed distal and proximal RTA of infancy, 
which may, in retrospect, have been a severe dRTA (q.v.). Now Type 3 RTA,   22
if used at all, is used to describe a hereditary defect in Carbonic Anhydrase 2, 
which is found in distal nephron α-intercalated cells, proximal tubular cells and 
bone. As a result it causes both proximal and distal RTA, as well as 
osteopetrosis and cerebral calcification with subsequent mental impairment 
[30, 31]. Approximately 70% of cases are found in the Magreb region of North 
Africa, probably due to high rates of consanguinity there [32]. 
 
1.2.1.4  Type 4 RTA  
Type 4 RTA is characterised by hyperkalemia, due either to 
hypoaldosteronism, or resistance to aldosterone. There is probably a defect in 
ammonium excretion in the inner medulla [33], but measured urinary pH is 
usually normal. The commonest cause is in moderate renal impairment, 
usually secondary to diabetic nephropathy.  
 
 
1.2.2  History  
 
The first description of what would later be termed renal tubular acidosis was 
by an English paediatrician, Reginald Lightwood, whose report was an 
abstract from a meeting [34] in 1936 that did not mention acidosis, but a 
“calcium infarction of the kidneys” in infants who died of a dehydrating, salt-
wasting disease. 
 
Later the same year, Butler, Wilson and Farber of the Massachusetts General 
Hospital described "Dehydration and acidosis with calcification of renal 
tubules" [13]. The paper was chiefly concerned with infants, but the 
appendices described two adults, one of whom had recently had a parathyroid 
adenoma removed for primary hyperparathyroidism, the first report of RTA 
and nephrocalcinosis secondary to hypercalcaemic renal damage. 
 
Subsequently, Lightwood, Payne and Black added acidosis and a urinary 
acidification defect to the syndrome suffered by the sick infants with   23
Nephrocalcinosis [35]. In this paper, and others appearing at the same time, 
including those from Stapleton [36, 37] ,it was acknowledged that 
hypercalciuria was often a feature of these patients. 
 
New cases of the so-called ‘Lightwood syndrome’ failed to appear through the 
1950s-1960s, and it was also reported that the urinary acidification defect 
tended to disappear, as affected children grew older [38]. This finding raised 
the possibility that its cause had been removed from the environment, vitamin 
D or calcium excess, or mercury in teething powders were suggested. The 
Lightwood syndrome came to be regarded as an unexplained historic accident 
of the forties that no longer existed, and the interest of tubular physicians 
tended to shift more to older children, where renal acidosis with a urinary 
acidification defect seemed to be a commoner and more persistent problem. 
 
Albright, a colleague of Butler’s at the Massachusetts General Hospital 
described clearly what we would now term ‘distal renal tubular acidosis’ in his 
book with Reifenstein [39], detailing the resultant bone disease and 
nephrocalcinosis and the role of alkali treatment, and labelling it as a form of 
"tubular insufficiency without glomerular insufficiency"; he attributed the 
acidosis to renal tubular inability to make ammonia and an acid urine. 
 
Albright did not use the term ‘renal tubular acidosis’, the term was probably 
first used by Pines and Mudge [40] in 1951 (although one of the adults that 
they reported had a ureterocolic anastomosis, and so a tubular defect was an 
unlikely explanation for their acidosis). 
 
Wrong and Davies introduced the concept of an acidification defect in the 
absence of a systemic acidosis, the so-called ‘incomplete syndrome’, and also 
quantified the threshold pH that patients with a distal renal tubular acidosis 
were unable to acidify their urine below; 5.3 [41]. 
 
Although acidosis was recognised in the Fanconi syndrome, it was not initially 
described as a form of renal tubular acidosis, as it was rare and features other 
than the acidosis dominated the clinical picture. The acidosis was attributed to   24
a loss of base in the urine, either bicarbonate, or a base that would have been 
converted to bicarbonate if it were retained. The terms ‘proximal renal tubular 
acidosis’ and ‘distal renal tubular acidosis’ were coined by Rodriguez-Soriano 
and colleagues in their classification published in 1969 [42]. 
 
The nomenclature was confused somewhat when Curtis Morris introduced a 
numerical system for their classification [43]. Morris labelled distal or classical 
RTA as "Type1" RTA, proximal RTA as "Type 2", and designated "Type 3"as 
a paediatric form of RTA that was a mixture of Types 1 and 2, which most 
nephrologists regarded as a severe form of Type 1, requiring rather more 
alkali than most Type 1 patients.  
 
Morris’ ‘Type 3’ disappeared from the clinical spectrum, later to be replaced 
by the different carbonic anhydrase deficiency (see above), but its existence 
meant that hyperkalemic renal tubular acidosis had to be designated ‘Type 4’. 
 
As this is due to hyperaldosteronism, the urine pH drops appropriately in 
response to an acid load and renal insufficiency is a notable feature of the 
condition, thus there is a good argument to be made that it shouldn’t have 
been classified as a renal tubular acidosis at all. 
 
1.2.3  Conclusion 
 
•  Distal RTA (dRTA) is a syndrome comprising an inability to acidify the 
urine to a pH of less than 5.3, variable metabolic acidosis, 
nephrocalcinosis/renal stone formation, osteomalacia and variable 
hypokalemia and salt wasting. 
 
•  The numeric classification of the renal tubular acidoses is confusing 
and unhelpful. 
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1.3  Testing for dRTA 
1.3.1  History 
In those patients with a metabolic acidosis and near normal GFR, a diagnosis 
of dRTA can be made when urine pH is consistently >5.3 [41].  
 
There is a diagnostic difficulty if the acidification defect is not sufficient to 
provoke a systemic acidosis, the so-called ‘incomplete syndrome of RTA’, 
(described by Wrong and Davies [41]) leaving the clinician unable to tell 
whether a measured alkaline urine is appropriate or not. This conundrum 
required a test of urinary acidification, to demonstrate the ability, or not, of the 
kidney to acidify the urine in the face of an appropriate stressor. 
1.3.1.1  Early acid load testing 
Early studies using hydrochloric acid or ammonium chloride, as an acid load 
to examine the renal response to an acidifying stimulus had been done [44-
47], but these had lasted five or more days, and were clearly too time 
consuming for routine use. 
1.3.1.2  The short ammonium chloride test 
Wrong  and  Davies,  who  described  the  ‘incomplete  syndrome’  of  dRTA  in 
1959,  published  an  account  in  the  same  paper,  of  the  short  ammonium 
chloride test, in which oral ammonium chloride (NH4Cl ) was administered and 
serial urinary pHs measured, in order to provoke a systemic acidosis, and 
thus  reveal  a  previously  obscured  acidification  defect  [41].  The  authors 
demonstrated  consistent  lowering  of  plasma  pH  and  total  CO2  with  this 
protocol, in normal subjects, and a failure to acidify urine below a pH of 5.3 in 
those  with  dRTA. It  has  subsequently  been  adopted  internationally  as the 
‘gold standard’ diagnostic test for dRTA.  However, although the test lasts 
only 8 hours and does not require blood testing, it can be unpleasant for some 
patients; because gastric irritation, nausea and vomiting are common.   26
1.3.1.3  Sodium sulfate testing 
In 1955, Schwartz et al [48]  had described urinary acidification in response to 
intravenous  infusion  of  pH-neutral  sodium  sulfate.    The  mechanism  was 
believed  to  be  indirect  and  crucially  different  from  the  provocation  of  a 
systemic acidosis by NH4Cl, as it involved an increase in the delivery of a non-
reabsorbed anion to the distal nephron, where it was thought to increase the 
lumen-negative electrical gradient favouring increased proton (H
+) secretion.  
It produced a very acid urine, as low as 4.0 [49], whether it produces a lower 
urinary pH than a systemic acidosis does in dRTA has not been established, 
but  there  is  a  suggestion  that  it  might  [50,  51].  This  uncertainty,  and  the 
inconvenience  of  having  to  administer  sodium  sulfate  intravenously,  has 
meant that it is used infrequently, if at all. 
1.3.1.4  Urinary pCO2 
In 1974, Halperin et al [52], in a work extending earlier observations by Pak 
Poy and Wrong [53], described the use of the urine pCO2 tension to test for 
dRTA, noting that the urine pCO2 tension was greater in the urine than the 
blood in normal subjects (ie the Urine-Blood pCO2 ratio, or U-B pCO2 was 
high), but approximately similar in those with dRTA. Concerns were voiced 
about the specificity of the low urinary pCO2 for dRTA, as low pCO2 tensions 
had been observed in pRTA with Fanconi’s syndrome [53] as well as with 
advanced renal failure [54]. 
1.3.1.5  Furosemide testing 
In 1986, Batlle [55] described a variation of the sodium sulfate test using oral 
furosemide to increase distal nephron sodium delivery and enhance sodium 
reabsorbtion, thus increasing lumen negativity and stimulating H
+ secretion. 
Urine pH changes in response to an increased distal delivery of sodium have 
been  reported  to  be  greater  in  normal  subjects  when  they  are  sodium 
depleted  [56]  or  following  prior  administration  of  a  mineralocorticoid  [57]. 
Clinical experience with furosemide alone or with mineralocorticoid the night 
before  proved  it  to  be  not  as  specific  as  hoped,  later  empiric  studies 
underlined this [58].   27
 
1.3.2  Conclusions 
•  Testing  urinary  acidification  is only necessary to exclude or confirm 
incomplete dRTA. 
•  The  direct  provocation  of  a  systemic  acidosis  with  oral  ammonium 
chloride remains the gold standard test, but it is unpleasant and time 
consuming to perform. 
•  Measurement of the urine/blood ratio of pCO2 is probably unreliable. 
•  Increasing the distal sodium delivery, with intravenous sodium sulfate 
or oral furosemide, may be invasive and is also unreliable.  
 
1.4  Potassium wasting and dRTA 
 
1.4.1  Association 
That hypokalaemia occurs in dRTA secondary to urinary potassium wasting, 
is an observation that was made early in the description of the disease [39, 
40, 59, 60].  The inference was made that the hypokalemia was a reversible 
consequence of the acidification defect, based on the observation that the 
correction of the systemic acidosis with alkali therapy leads to a reduction in 
the urinary potassium loss and therefore a resolution of the hypokalaemia [39, 
40, 61]. 
 
Hypokalaemia can be observed in both dRTA and proximal RTA (pRTA) [59], 
but it is a cardinal feature of dRTA. However even in dRTA, the severity of 
hypokalaemia is not constant. Wrong et al showed that the hypokalaemia of 
immune related dRTA (chiefly related to Sjögren’s syndrome) was significantly 
more severe than that found in hereditary dRTA from the UK [62].  
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Hypokalaemia is also a prominent feature of Southeast Asian AE1 associated 
dRTA, Bruce et al found that the mean serum potassium at presentation in 
hereditary SE Asian AE1 associated dRTA was 2.7 ± 0.6 mmol/L, compared 
with an average serum potassium at presentation of 3.6 ± 0.6 mmol/L in 
patients with occidental hereditary dRTA. Indeed, two of the studied patients 
presented with hypokalaemic paralysis [63]. 
 
1.4.2  Theories 
 
Sartorius and co-workers examined the effect of the prolonged administration 
of an acid load on renal ion excretion, by the intermittent administration of 
large amounts of ammonium chloride over the course of 15 days to healthy 
adult males. They found that the provocation of a systemic acidosis stimulated 
renal potassium excretion throughout the period of acidosis and also 
stimulated sodium excretion, which decreased in a stepwise fashion after the 
first day of acidosis [64]. This was evidence that an acidosis per se could 
cause renal potassium and sodium wasting in healthy kidneys. 
 
Gill et al measured the renal losses of sodium and potassium in 5 patients 
with dRTA. They found that with dietary sodium deprivation, the dRTA 
patients were unable to conserve sodium renally and thus became sodium 
deplete. All the patients had negative potassium balances even with average 
potassium intakes; these balances persisted during sodium restriction, when 
aldosterone levels rose, presumably reflecting volume contraction and 
contributing to urinary potassium loss. However, they found that potassium 
losses were not dependent on aldosterone, as two patients did not have 
raised aldosterone levels, and rapid volume expansion with 2 litres of 
intravenous normal saline did not abolish the potassium loss. Administration 
of sodium bicarbonate or disodium phosphate reduced the negative 
potassium balance and abolished hypokalemia. The authors concluded that 
renal potassium losses in dRTA were due to a failure of H
+ secretion and (as 
they assumed that H
+ and potassium shared a common permeability) thus 
potassium losses were increased by an absence of competing protons. [61]   29
This was compounded by sodium wasting and subsequent secondary 
hyperaldosteronism, which increases potassium losses by increasing apical 
cortical collecting duct permeabilities to potassium as well as increasing the 
basolateral sodium/potassium exchanger.[65]   
 
Sebastian and co-workers however, showed that in two patients with dRTA, 
correction of their metabolic acidosis did not terminate their urinary potassium 
losses, which remained abnormally high (>80 mEq/day) despite ongoing 
hypokalemia. Urinary aldosterone was high in one dRTA subject; normal 
range in the other, measured plasma volume (determined by 
181I albumin 
dilution) was normal in both cases.[66] 
 
The same authors later studied ten subjects with dRTA, in whom they 
administered potassium bicarbonate to correct their acidosis, and then sodium 
restricted them, to reveal any underlying sodium wasting tendency. Half of the 
patients had impaired sodium conservation; the remainder appeared to have 
intact sodium conservation. Six patients had an induced water diuresis, all 
had inappropriately high minimum urinary sodium concentrations and the 
sodium excretion rates of sodium were flow-dependent. These data 
suggested strongly that the renal sodium wasting was not exclusively due to 
impaired Na
+/H
+ exchange in the cortical collecting duct, and nor could it 
apparently be ascribed just to generalised tubular damage from 
nephrocalcinosis, as not all of the sodium wasting patients had 
(radiographically evident) nephrocalcinosis.[67] 
 
A defect in apical proton excretion coupled with urinary potassium losses 
suggested the apical H
+/K
+-ATPase as a possible candidate for dysfunction, 
to several authors.[68, 69] This seemed to be supported by the finding of 
hypokalemic endemic dRTA in Northeast Thailand, which has high 
environmental levels of vanadium, a H
+/K
+-ATPase inhibitor, and the finding 
that vanadate could induce an acidification defect in a rat model.[70] 
However, H
+/K
+-ATPase appears to be far less common in the human distal 
nephron than in the rat or rabbit [71], and a H
+/K
+-ATPase mutation causing 
dRTA has yet to be described, unlike AE1 and v H
+-ATPase mutations [72].   30
1.4.3  Conclusions 
 
•  Urinary potassium wasting with subsequent hypokalaemia in dRTA is 
variable, with some causes being associated with more severe 
hypokalemia. 
 
•  Chronic acidosis can cause healthy kidneys to lose potassium and 
sodium. 
 
•  Sodium depletion and hyperaldosteronism may contribute to urinary 
potassium wasting but cannot account for all of it. It persists in dRTA 
after volume correction and normalisation of aldosterone levels.  
 
•  Urinary potassium wasting also persists after correction of chronic 
acidosis. 
 
•  No direct evidence has been offered to support the theory that 
defective proton secretion into the CCD lumen drives potassium into 
the lumen down an electrochemical gradient. 
 
•  H
+/K
+-ATPase deficiency (functional or absolute) remains unlikely, for 
reasons of its apparent scarcity in the human nephron and the lack of 
any data showing H
+/K
+-ATPase deficiency causing dRTA in humans. 
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1.5  The α-intercalated cell 
Intercalated cells in the kidney are found alongside the principal cell (the other 
segment-specific cell type) in the distal convoluted tubule, the connecting 
tubule and the collecting duct. This section will deal with the evidence 
concerning their gross structure and function. 
 
1.5.1  Control of pH in the Collecting Duct 
Early observations were made that when mammals are administered 
acidifying salts (e.g. NH4Cl) they produce acid urine, which is almost free of 
bicarbonate [73]; but when they are given bicarbonate (NaHCO3), the urine is 
alkaline and bicarbonate-rich [73-75]. However, fluid collected from the late 
distal convoluted tubules of either alkalotic or acidotic animals is neither acidic 
nor alkaline, and does not have an excess or deficit of bicarbonate [73, 75]. 
Thus, the collecting ducts were implicated in pH and bicarbonate regulation of 
the urine.  
 
This was confirmed when McKinney et al found that rabbits fed NH4Cl (as an 
oral acid) had acidic urine and that their isolated cortical collecting ducts, 
when studied in vitro, absorbed bicarbonate. Conversely, animals fed 
NaHCO3 had alkaline urine and their isolated cortical collecting ducts secreted 
bicarbonate [76].   
 
The outer medullary collecting duct reabsorbs, but does not secrete, 
bicarbonate; moreover, reabsorbtion in this nephron segment is unaffected by 
acid-base status [77-79]. Thus, acid-base responsiveness, and bicarbonate 
secretion, appears to be confined to the cortical collecting duct. 
 
1.5.2  The intercalated cells 
The two major subtypes of mitochondria-rich cells in the turtle bladder, which 
are ultrastructurally and embryologically equivalent to mammalian intercalated 
cells, were designated α and β cells by Stetson and Steinmetz [80, 81]. 
Intercalated cells were identified in mammals, ultrastructurally distinguished   32
by their high mitochondrial density, dark cytoplasm, cytoplasmic 
tubulovescicular structures and apical microprojections [82, 83]. These 
intercalated cells were designated A and B in the rat [83], and α and β in the 
rabbit [84]. 
 
The α-intercalated cell is abundant in the outer medullary collecting duct and 
is also present in the cortical collecting duct. The β-intercalated cell, by 
contrast is present only in the cortical collecting duct. 
 
There was, therefore, reason to suspect that α-intercalated cells were 
responsible for bicarbonate reabsorbtion, and β-intercalated cells for 
bicarbonate secretion.  
 
1.5.2.1  vH
+ATPases 
Expression of vacuolar H
+ATPase (vH
+ATPase) is characteristic of 
intercalated cells and one isoform of the 56-kd subunit is specific for the 
intercalated cell [85]. A subset of intercalated cells in the cortical collecting 
duct and the outer medullary collecting duct of the rat show apical staining for 
vH
+ATPase (i.e. α-intercalated cells), and another distinct subset show 
basolateral staining (i.e. β-intercalated cells) [86-89]; although other 
intermediate staining patterns are seen [86]. Rabbits do not have such well 
defined basal staining on their β-intercalated cells, although vH
+ATPase has 
been detected there by ultrastructural immunocytochemistry[90]. 
 
Functional studies using the vH
+ATPase inhibitor N-ethylmaleimide (NEM) are 
consistent with this picture, proton extrusion by rabbit α-intercalated cells is 
inhibited by apical, though not basolateral, NEM [91].  
 
1.5.2.2  Anion Exchangers-AE1 
It was shown that rabbit α-intercalated cells required basolateral 
chloride/bicarbonate exchange to achieve acidification in isolated perfused 
tubules, whereas removal of chloride from the perfusing bath inhibited   33
acidification [92]. Chloride-bicarbonate exchange (studied by measuring 
intracellular pH) in α-intercalated cells is also inhibited by the disulfonic 
stilbene anion exchange inhibitor DIDS (4,4-diisothiocyano-2,2-disulfonic 
stilbene) [92, 93], and  the affinity of DIDS binding to these cells is similar to 
DIDS binding to erythrocytes [94]. 
 
Antibodies against the anion exchanger 1 (AE1, the erythrocyte band 3, 
SLC4A1) molecule show strong immunoreactivity against the basolateral 
surface of α-intercalated cells, but not at all to β-intercalated cells [86]. I will 
discuss α-intercalated cell and erythrocyte AE1 expression in more detail in 
subsequent sections.  
 
1.5.2.3  Anion Exchangers-Pendrin 
Schwartz first reported the functional presence of an apical Cl
-/HCO3 
exchanger [95], which was not AE1. It differed in several ways, not least by 
engaging in Cl
--Cl
- exchange [84] and  its resistance to inhibition by luminal 
stilbenes [96, 97]. 
 
Pendrin, or SLC26A4, is an anion exchanger encoded by the gene pds, and 
mutations of which can cause the genetic disorder Pendred syndrome, which 
is associated with deafness and goitre. Royaux and co-workers found that 
pendrin was strongly expressed in rat kidney (as well as in the inner ear and 
thyroid gland), and localised pendrin’s expression to those vH
+ATPase-
expressing cells present in the cortical collecting duct devoid of AE1 at their 
basolateral membrane, that is, β-intercalated cells. pds knockout mice had no 
pendrin detectable in their kidneys; while tubules isolated from alkali-loaded 
wildtype mice secreted bicarbonate, those from alkali-loaded pds knockout 
mice failed to secrete bicarbonate[98]. Solemani et al found that pendrin 
mRNA was also abundant in proximal tubule suspensions from kidney cortex, 
and that when expressed in HEK-293 cells, pendrin functioned as a Cl
-/HCO3 
exchanger, a Cl
-/OH exchanger and a Cl
-/formate exchanger[99]. This 
evidence strongly suggested that the β-intercalated cell apical anion 
exchanger is pendrin. Kim and co-workers found that pendrin is also strongly   34
expressed at the apical surface of so-called “non-A-non-B” cells in the cortical 
collecting duct, which are intercalated cells expressing apical vH
+ATPase, but 
not basolateral AE1 [100]. 
 
1.5.3  Intercalated cell plasticity and Hensin 
Schwartz and co-workers suggested in their seminal 1985 paper that 
intercalated cells may be able to reverse their (functional) polarity in adapting 
to systemic acid-base changes: metabolic acidosis converting β-intercalated 
cells to α-intercalated cells [95].  
 
Some support for this concept came from the primary culture of rabbit cortical 
collecting duct cells, immunodissected and sorted into principal or β-
intercalated cells. Principal cells remained unchanged in primary culture, 
whilst cells seeded as 98% β-intercalated cells became (with new generations 
of cell division) a mixture of α and β-intercalated cells, and principal cells[101, 
102]. DNA replication was highest in those cultures seeded with sorted β-
intercalated cells, suggesting that they were dividing rapidly and giving rise to 
other cell types; indeed, surface markers allowed the identification of a single 
cell dividing mitotically into daughter principal and intercalated cells[101, 102]. 
 
Furthermore, in rabbit cortical collecting ducts incubated in acid media, β-
intercalated cells displayed reversal of polarity of their H
+ pumps and Cl
-
/HCO3
- exchangers, an effect apparently mediated by an extracellular matrix 
(ECM) protein termed hensin; anti-hensin antibodies blocked the effect (as did 
the microtubule inhibitor colchicine), and acid-loading increased hensin 
deposition in the ECM beneath adapting β-intercalated cells [103].   
 
However, these data need to be interpreted with some caution, as the defining 
feature of α-intercalated cells, namely basolateral AE1, has not been identified 
on any of the cells that have developed basolateral Cl
-/HCO3
- exchange. 
Weiner and Hamm published data consistent with a Cl
-/HCO3
- exchanger on 
the basolateral membrane of rabbit cortical collecting duct β-intercalated 
cells[104]. Emmons et al showed that the majority of rabbit cortical collecting   35
duct intercalated cells have stilbene insensitive Cl
-/HCO3
- exchangers on both 
apical and basolateral surfaces, and that these were the so called γ-
intercalated cells (i.e., “non-A-non-B” cells) [96]. It is possible that the effects 
of hensin and pH adaptation seen by Schwartz, Al-Awqati and co-workers 
could be the result of recruitment of basolateral Cl
-/HCO3
- exchangers to the 
basolateral membrane in γ-intercalated cells; it is difficult to see how this can 
be refuted without demonstrable immunoreactive AE1 at the basolateral 
membrane of a hensin-transformed cell. 
 
1.5.4  Conclusions 
•  Acid responsiveness and bicarbonate secretion is a function of the 
cortical collecting duct. 
•  There are two types of intercalated cell in the distal nephron. The α-
intercalated cell is found in the outer medullary collecting duct and 
cortical collecting duct. The β-intercalated cell is only found in the 
cortical collecting duct. 
•  α-intercalated cells have apical vH
+ATPase and basolateral AE1. 
•  β-intercalated cells have basolateral vH
+ATPase and apical pendrin. 
They have no AE1. 
•  Some workers have suggested that β-intercalated cells can convert 
into α-intercalated cells in response to systemic acid base changes. 
According to their work, β-intercalated cells appear to be able to 
reverse their polarity, to an extent, but the defining characteristic of α-
intercalated cells, namely AE1, has not been detected. Thus 
conversion of β-intercalated cells to α-intercalated cells remains 
unproven.   36
1.6  AE1 structure and function 
 
The anion exchanger 1 protein, or band 3 was discovered on the 
electrophoretic separation of human red cell plasma membrane proteins, the 
position on the sodium dodecyl sulphate gel (the third band) giving it its 
original name, band 3. It was noted at this time that it is the most abundant 
protein in the cell membrane, comprising approximately 25% of the 
membrane protein, with about 1.2 x 10
6 copies per cell [105].  
It was subsequently found that stilbene disulphonates that specifically inhibit 
red cell anion exchange covalently labelled the band 3 molecule [106]. 
 
The amino acid sequence of murine AE1 was deduced from cDNA in 1985 
[107], and the full 911 amino acid sequence of the human erythrocyte AE1 
was similarly deduced by Tanner et al in 1988 [108]. 
 
This 911 amino acid version of human AE1 is found primarily in red blood 
cells (but not exclusively, it is also found in atrial tumour cells, for example 
[109]), a truncated form, known as kAE1, produced by an alternative splicing 
of the same gene SLC4A1, is found in the kidney, at the basolateral 
membrane of α-intercalated cells in the cortical collecting duct [110, 111]. This 
form is truncated by 65 amino acid residues from the N-terminal end of the 
protein. 
 
1.6.1  AE1 Functions 
1.6.1.1  Anion exchange 
 
AE1 mediates the electroneutral 1:1 exchange of chloride for bicarbonate at 
the cell membrane. In the red cell this permits bicarbonate, formed from CO2 
in the peripheral circulatory system by the intra-erythrocytic enzyme carbonic 
anhydrase 2, to leave the cell in exchange for chloride. This effectively stores 
CO2 in the plasma in the form of dissolved bicarbonate, significantly   37
increasing the CO2 carrying capacity of the circulation. Although this process 
is very important, it is evidently not essential for life, as animals can survive 
either near complete inhibition of it by disulphonic stilbenes [112], or knockout 
of the gene for this protein [113].  
 
In the intercalated cell, this permits the extrusion of bicarbonate from the 
basolateral membrane to the systemic circulation in return for the exchange of 
a chloride ion. This allows the continued hydration of CO2 inside the cell, 
catalysed by carbonic anhydrase 2, to produce more hydrogen ions for 
extrusion by the apical vH
+ATPase to acidify the urine [114]. (See Figure 1-1) 
 
1.6.1.2  Anion Proton Cotransport 
AE1 normally electroneutrally exchanges two monovalent anions, however, 
protonation of AE1 may allow it to carry a divalent anion, such as sulphate. 
This results in sulphate and hydrogen ion symport [115], in exchange for 
chloride. 
 
1.6.1.3  Red Cell Membrane Structure 
eAE1, through its cytoplasmic N-terminal domain, plays an important 
structural role in providing a site for membrane attachment for elements of the 
red cell cytoskeleton. Conditions which lead to less AE1 being present in the 
red cell membrane result in alterations of the red cell shape and decreased 
mechanical stability of the membrane, as is seen in AE1 knockout mice [113, 
116], and hereditary hematological diseases such as hereditary Spherocytosis 
[117] and Southeast Asian ovalocytosis (SAO) [118]. 
 
It’s protein ligands include ankyrin [119-121], protein 4.1 [122, 123], protein 
4.2 [124, 125], glyceraldehydes-3-phosphate dehydrogenase (GAPDH) [126], 
phosphofructokinase [127], aldolase [128], haemoglobin [129],  hemichromes 
[130] and tyrosine kinase [131]. Perhaps unsurprisingly, each of these 
interactions plays an important function of the functioning of the red cell, from   38
the control of the cell flexibility and shape [121], regulation of glucose 
metabolism [132], ion transport [133] and cell lifespan [134].   39
 
Figure 1-1 A cartoon of the alpha-intercalated cell 
Showing the hydration of carbon dioxide in the cell interior, producing 
bicarbonate and a proton, which are extruded basolaterally by the anion 
exchanger and apically by the proton pump respectively. 
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1.6.1.4  Metabolon with carbonic anhydrase 2 
The C-terminal cytoplasmic domain binds to carbonic anhydrase 2, under 
physiological conditions, in a unit termed the ‘metabolon’, with the effect of 
greatly increasing the efficiency of bicarbonate generation and extrusion [135, 
136]. 
 
1.6.1.5  Red Cell Senescence 
 
AE1 is also involved with signalling the chronological age of the red cell and 
contributing to it being cleared at the end of its natural lifespan, hemoglobin 
degradation products bind to AE1 and, presumably via a conformational 
change, cause circulating anti-AE1 antibodies to attach to it, activating 
complement and ultimately phagocytosis of the red cell [134, 137, 138].  
 
1.6.2  Structure 
 
As mentioned above, Kopito and Lodish deduced the primary structure of 
human eAE1 from human AE1 cDNA [107].  
 
1.6.2.1  Secondary Structure 
 
Proteolysis and gene sequencing studies have demonstrated that AE1 
consists of 2 distinct structural and functional domains, divided by sites for 
cytoplasmic trypsin (Lys360) and chymotrypsin (Trp359) cleavage. 
The N-terminal domain (1-360) is cytoplasmic and has sites for hemoglobin, 
glycolytic enzyme and cytoskeleton binding [120]. The membrane spanning 
C-terminal domain (361-911) is necessary for anion exchange, and able to do 
so alone [107]. (see Figure 1-2) 
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1.6.2.1.1  The N-terminal cytoplasmic domain 
 
As stated above, the cytoplasmic domain acts as an anchor for the membrane 
to be attached to various cytoskeletal proteins, stabilising the membrane 
against mechanical stress. 
 
A study of the 2.6 angstrom resolution crystal structure of this domain was 
reported in 2000 [139], that defined most of the domain (1-356), which forms a 
dimer. However, this AE1 domain crystallised at an unphysiological pH of 4.8, 
and it seems likely that the structure is unrepresentative in important ways 
from that at physiologic pH [140]. This crystal is nonetheless useful in that it 
shows the interaction of the two monomers in the dimer, particularly 
noteworthy being the near 2-fold symmetry around an axis in the dimer 
interface.  
 
The relationship of the cytoplasmic domain to the membrane is also unclear, 
although the region of the domain that was crystallised was 1-379, the 
segment 357-379 were not resolved, possibly because this region is flexible. 
Hydropathy analysis suggests that the protein does not enter the membrane 
until approximately residue 405, this region appears to be important, as the 
mutation that causes SAO causes a deletion of residues 400-408 [141].     42
 
Figure 1-2 Schematic representation of the secondary structure of AE1. 
Yellow residues mark the sites of known point mutations that cause hereditary 
dRTA. Black marked residues signify other point mutations or deletions that 
cause red cell disease. The shaded zone represents the lipid bilayer of the 
cell membrane, with the area above it representing the cell exterior. (after 
Shayakul and Alper, Clin Exp Nephrology 2004) 
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1.6.2.1.2  Topology of the AE1 membrane domain 
 
A high-resolution structure of the membrane-spanning domain of AE1 has 
proved elusive because of the difficulties in getting well ordered crystals from 
detergent micelles.  
Low resolution images were obtained via two dimensional crystals studied by 
electron microscopy and reconstituted into a 3D construct with a very low 
resolution of 20 angstroms [142-144]. At this resolution, structures such as α-
helices were not observed; the size of the dimer was 100 x 60 x 80 
angstroms. It had two protrusions, probably on the cytosolic side of the 
membrane, between which was a stain filled ‘canyon’ at the dimer interface-
which was proposed as the anion access channel [142]. (Figure 1-3) 
 
In the absence of a high-resolution crystal structure of AE1, studies have 
been undertaken to try and elide the topology of the membrane-spanning 
region by hydropathy plots, vectorial chemical labelling, proteolysis and 
molecular biological techniques. 
 
Studies using a series of unique single cysteine AE1 mutants expressed in 
HEK cells and observed the accessibility of each mutated cysteine to biotin 
maleimide (BMA). Only cysteines outside the membrane bilayer are able to 
react with BMA [145]. External agents that are membrane impermeant, such 
as Lucifer Yellow Iodoacetamide (LYIA), were used to block the BMA 
reaction, thus distinguishing extracellular from intracellular residues [146, 
147]. The same authors used a scanning N-glycosylation method by inserting 
a consensus sequence for N-glycosylation (or a part of the (extracellular 4) 
loop containing the endogenous N-glycosylation site) into various putative 
loop regions of the protein. This enabled the degree of N-glycosylation at the 
mutated sites to be used to mark the extracellular loop regions [147]. 
 
These studies, taken together, show that AE1 traverses the bilayer 
approximately 14 times, with transmembrane (TM) segments, which are 
probably α-helical in structure.   44
 
1.6.2.1.3  The First Eight TM Segments 
The topology of the first eight TM segments is clearly and consistently 
defined. AE1 enters the membrane at Val405. The boundaries of the EC 
loops 1-4 have been demonstrated by N-glycosylation insertional 
mutagenesis [146, 147], chemical accessibility [148, 149], proteolysis [150] 
and through the observation that some natural mutations (R432W, E429D and 
E480K) can cause the production of antibodies against human red cells, and 
must therefore be external. 
 
The endogenous N-glycosylation site at Asn642 also serves as a marker 
placing this region (EC4) on the extracellular side of the membrane [108]. 
 
TM 8 contains the residue Glu681, which is crucial for anion exchange [151], 
is comprised of the residues Met664-Glu683, in which all substituted 
cysteines are poorly labelled by BMA. Cysteines substituted from Ile684-
Ser690 are labelled by BMA and this is not blocked by LYIA, indicating that 
they are on the cytoplasmic side of the membrane [152], meaning that Glu681 
is located very close to the cytoplasmic side of the membrane at TM8. 
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Figure 1-3 3D map of the dimeric transport domain of the Band 3 protein. 
(a) Perspective view and (b) top view. The bulky basal domain is embedded in 
the lipid bilayer, indicated by the two blue planes. The protrusions above it are 
probably on the cytosolic side of the membrane. They form two sides of a 
canyon the floor of which is probably the entrance to a pore. The bar 
represents 20 angstrom. (Wang EMBO journal 1994)   46
1.6.2.1.4  The Remaining TM Segments 
 
1.6.2.1.4.1  The T-Loop 
The region between Ala726 and Ile761, the so-called ‘T-loop’ (trypsin 
sensitive loop) has been the subject of much investigation and speculation. 
The centre of the loop is thought to lie on the cytoplasmic side of the 
membrane, as it is cleaved by cytoplasmic trypsin at residue Lys743. Trypsin 
treatment inside sealed ghosts, or of inside out vesicles produced the 
cleavage products, external trypsin treatment of intact red cells did not [153]. 
 
However, cysteines substitute at positions Se731, Gly742, Ser745 and Ala751 
were accessible to both BMA and LYIA, showing that these residues are 
accessible from the extracellular side of the membrane [152]. 
 
When a N-glycosylation sites were inserted into this loop, N-glycosylation was 
observed, but at levels less than seen at the endogenous site, Asn642[147]. 
Moreover, when expressed in HEK 293 cells, glycosylation was abolished, 
apart from the site at Gly754 [146]. 
 
Taken together, these data suggest that the T-loop folds back in on itself, with 
both the N-terminal and C-terminal ends of the loop on the extracellular side 
of the membrane. This agrees with two other observations, firstly that all the 
other large extracellular loops have antibody-producing mutations, such as 
EC3 and EC4, and even short loops like EC1 and EC5 have them, but none 
are evident in the T-loop, which would seem strange if it were totally 
extracellular. 
 
Secondly, as I will discuss later, His734 apparently interacts with Glu681 
during anion exchange, and a purely extracellular T-loop would place these 
residues too distant from each other for plausible interaction. 
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1.6.2.1.4.2  TM12 
Beyond TM10 and TM11, the region between Asp807 and His834 (TM12) 
also has an unusual topology. 
 
Here, substituted cysteines at Lys814 and Thr830 are unreactive with BMA, 
but Asp821 is open to BMA and extracellular LYIA [152]. 
 
A different study showed that Asp821 was labelled by an impermeant 
positively charged carbodiimide from the cytoplasmic side [154]. Thus, 
Asp821 is accessible to the negatively charged LYIA from the outside and to 
the positively charged carbodiimide from the inside. 
 
Also, a glycosylation signal inserted at Asp821 is not N-glycosylated, which is 
evidence that it is not extracellular [146].  
 
The Bric132 monoclonal antibody will (weakly) recognise the epitope Phe813-
Tyr824 only in leaky erythrocytes, suggesting that the binding occurs from the 
cytoplasmic side [155]. 
 
It should also be noted that there are an unusual concentration of positively 
charged residues in this TM region, six positive charges compared with two 
negative charges. This would be an attractive environment for anions, were it 
to form part of a channel for them to diffuse down. 
 
This region is therefore modelled as an extended helix with an attachment on 
the extracellular face of TM11 and on the intracellular face of TM13. 
 
 
1.6.2.1.4.3  TM13-14 
Cysteine accessibility scanning of the sequence from Trp831 to Gln884 show 
only two TM helices joined by an exceptionally short extracellular loop [152], 
A855C is accessible to BMA, and the mutant P854L is a blood group antigen, 
confirming the extracellular nature of this short sequence.   48
 
1.6.2.1.4.4  N-terminal cytoplasmic domain 
The residues from Arg880 onward comprise the C-terminal cytoplasmic tail, 
which as mentioned previously, binds to carbonic anhydrase 2 to form the 
metabolon, and the terminal 11 amino acids comprise an important tyrosine 
based signalling mechanism, necessary for proper trafficking of the AE1 
molecule to the basolateral cell surface in the α-intercalated cell. 
 
1.6.3  Structure/Function 
Unfortunately, it will become necessary, later on, to relate the functional 
transport properties of AE1 to structural changes. Therefore we are obliged to 
consider some of the data that relates to the structure/function of the 
molecule. The following discussion, which I have tried to keep as simple as 
possible, is however, by its very nature quite esoteric. There will be some 
mention of the permeability barrier, which is the theoretical point in the AE1 
molecule that actually forms the functional barrier between the cytoplasmic 
and external compartments through which anion transport happens. The 
transforming conformational change (TCC) is the conformational change, 
which occurs in the molecule in order to transport anions across the 
permeability barrier. 
 
1.6.3.1  Proton binding sites 
As mentioned previously, AE1 can function as a cotransporter of protons and 
sulphate ions.  
 
The anionic, carboxyl-reactive reagent, Woodward’s reagent K (WRK) inhibits 
anion transport in intact red cells when added to the extracellular medium. 
When the reaction product is cleaved with borohydride (together, W-B 
treatment), this converts the reactive carboxyl group, R-COO
- into the 
corresponding alcohol, R-CH2OH, chloride transport is still inhibited, but 
sulphate transport increases dramatically at neutral pH [156], where sulphate   49
exchange is usually slow compared to more acidic conditions (i.e. where 
incident protons are more common). This shift in pH dependency is seen for 
both internal and external pH, suggesting that the WRK reactive COO
- group 
is accessible from either side of the membrane-and thus might be the site that 
binds protons and that translocates them across the permeability barrier (and 
which itself be at the permeability barrier). 
 
These effects occur when the W-B treatment is highly specific for one 
carboxyl group in the AE1 molecule, namely Glu681 [151, 157]. As we have 
seen, there is evidence that Glu681 is located very close to the cytoplasmic 
side of the membrane-which implies that the impermeant reagent WRK is able 
to penetrate deeply into the molecule, which means that there must be an 
aqueous channel in the AE1 molecule that leads from the external surface of 
the molecule to a point almost at the cytoplasmic side of the membrane. 
 
Normally, proton and sulphate symport in exchange for chloride is 
electroneutral. After W-B treatment, chloride/sulphate exchange becomes 
electrogenic[158], resulting in a net negative flow of one charge across the 
membrane with the sulphate anion. This is what would be expected if the 
proton remained bound to AE1 and was not co-transported across the 
permeability barrier. The W-B treatment converts the carboxyl group to an 
alcohol, which binds the proton much more avidly, so that it cannot be 
released along with the sulphate. 
 
The idea that Glu681 is the site of proton transport is supported by data from 
experiments in which site directed mutants of Glu681 are expressed in 
Xenopus oocytes. Substitution of Q, T, R, K or G for Glu681 abolishes 
chloride exchange for either chloride or sulphate. Sulphate/sulphate exchange 
is also abolished, except in the case of the Q (Gln) substitution mutant, which 
has increased sulphate/sulphate exchange compared to wild type AE1, and 
even greater sulphate/chloride exchange [159]. This chloride sulphate 
exchange has a 1:1 stoichiometry and is electrogenic, similarly to the situation 
seen after W-B treatment of the wt protein, above. 
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This was echoed in a separate study, in which Gklu681 was substituted for 
Gln or Ala, and a much-decreased dependence on pH for sulphate transport 
was seen [160]. Substitution of glutamine for glutamate removes the negative 
charge from the R-COO- group, and thus prevents it from transporting a 
proton, as does W-B treatment. 
 
Furthermore, the apparently conservative substitution of Asp for Glu681 
inhibits chloride exchange [161], and alters the pK for it’s inhibition by protons. 
This is a conservative substitution, because Asp differs from Glu by a single –
CH2- group in the side chain, which implies that the structure around this 
residue is sufficiently delicate that this small change in position of its negative 
charge is enough to seriously compromise its function. 
 
1.6.3.2  Eosinyl-5-malemide probing 
The covalent modification of Lys430 by eosinyl-5-malemide (EMA) causes 
almost complete inhibition of chloride exchange [162], but does not prevent 
chloride binding [163], and mutation of the residue does not inhibit anion 
transport [164]. This suggests that the inhibition of anion transport by EMA is 
not a defacto part of its interaction with Lys430.  
 
External iodide can quench the eosin triplet fluorescence of EMA bound to 
AE1 Lys430, and negatively charged quencher were effective from the 
external side, but positively charged quenchers were effective from the 
cytoplasmic side [165]. This suggests that the hydrophobic ring moiety of 
EMA may actually insert itself into the parts of AE1 that form the permeability 
barrier, so that it is accessible to quenchers from either side of the barrier. 
As Lys430 is topologically very close to the external surface of the molecule, 
the quenching by positively charged reagents from the cytoplasmic side 
indicate that there must be an aqueous channel that runs from the 
cytoplasmic side of AE1 to almost the external side of the bilayer.  
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1.6.3.3  Histidine modification 
Inhibition of AE1 phosphate transport occurs with the cytoplasmic 
administration of the histidine sensitive reagent, diethyl pyrocarbonate 
(DEPC), and increases with increasing internal pH in red cell ghosts[166], 
indicating that the DEPC sensitive His is accessible to protons from the 
cytoplasmic side of the plasma membrane. Furthermore the binding of 4, 4-
dinitrostilbene-2, 2-disulfonate (DNDS) from the outside greatly reduced the 
ability of DEPC to inhibit anion exchange by reacting at it’s evidently inward 
facing site, and cytoplasmic DEPC binding greatly reduced labelling by 
extracellular 4,4'-diisothiocyanodihydrostilbene-2,2'-disulfonic acid (H2DIDS), 
these data are suggestive that this DEPC reactive His residue lies at the 
permeability barrier.  
The role of histidine residues was then explored by site directed mutagenesis, 
mutation of His703, His819 and His834 to Gln, greatly reduced chloride 
transport. However, none of these mutants reduced the DEPC reaction rate, 
but a mutation of His734 to Ser caused the DEPC reaction to decrease to 
approximately one third of that seen in the wildtype AE1, indicating that 
His734 is the main site for DEPC inhibition of anion exchange [167]. 
 
This H734S mutation also shifted the external pH dependence of chloride 
transport from a pK of 5.8 to 6.9 [161], very reminiscent of the pK change (5.8 
to 6.7) seen when Glu681 was changed to Asp. 
 
That His734 is accessible to protons only from the internal side of the 
membrane, but mutations at Glu681 and His734 have similar effects on the 
pK for external acidity on chloride transport is striking.  
 
This can be accounted for if the external protons are reacting with the 
carboxyl group at Glu681, which is close to and interacts with the positive 
charge at His734. A substitution of Asp for Glu681 would shorten the side 
chain by one –CH2- group, moving the negatively charged carboxyl group 
away from the positively charged His734, and tend to raise the pK, likewise 
the substitution of Ser for His734 would similarly separate the charges,   52
causing the Glu681 pK to increase just as if it had been substituted for Asp 
[161]. 
 
There is, however, a fly in the ointment, Yin et al found that with DEPC 
treatment of AE1 in red cell ghosts analysed by liquid chromatography with 
electrospray ionised mass spectrometry, that of the six His residues in the 
membrane spanning domain of AE1, only one (His834) had a large 
interaction, and was also the only one which was pH sensitive and sensitive to 
DNDS inhibition. 
 
These authors did not find that His743 was modified by DEPC, but conceded 
that it is an important residue for anion exchange [168].   
 
1.6.3.4  Evidence for anion access channels in AE1 
1.6.3.4.1  External Access Channel 
As Glu681 lies very close to the cytoplasmic side of the membrane, yet the 
bulky impermeant WRK can reach it from the outside means that there must 
be an aqueous channel in AE1 leading from the external surface almost to the 
cytoplasmic side of the phospholipid bilayer.  
 
This is consistent with the observation that some agents inhibit anion 
exchange as if they deny chloride access to the transport site, but do not 
compete directly with it [169]. 
 
The observation that chloride and DIDS are able to bind with AE1 even after 
WRK has reacted with Glu681, indicates that they are both lie on the 
extracellular side of Glu681 [170]. 
 
This idea is reinforced by a study that showed that DNDS or H2DIDS binding 
was able to block WRK from reacting with Glu681 [157]. 
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More specific information suggests that TM8 forms part of the anion access 
channel-for example the action of p-chloromercurybenzene sulphonate 
(pCMBS), a hydrophilic sulfhydryl reagent, on chloride/bicarbonate exchange 
in HEK 293 cells expressing a variety of single cysteine mutants. Mutants with 
introduced cysteine residues at Ala666, Ser667, Leu669, Leu673, Leu677 and 
Leu680 had anion exchange inhibited by pCMBS [171]. In an α helical wheel 
model of TM8, these residues line up on the same side of the helix as Glu681, 
and thus might line the external anion access channel. pCMBS had no effect 
on cysteines beyond Leu680, as would be expected if Glu681 lies at the 
innermost part of the external access channel. 
 
A different negatively charged sulfhydryl reagent 2-(sulphonatoethyl)-
methanethiosulphonate (MTSES), inhibited anion exchange in mutants with 
cysteine at Ser852 and Ala858 [152], suggesting that these residues on the 
external side of TM13 and TM14, face an aqueous region close to a 
functionally important site. They lie close to Lys851, which is the site of 
H2DIDS cross-linking to Lys539, and so must be within 15 angstrom of TM5.  
 
The extracellular span bridging the last two transmembrane domains, from 
residues 852 to 857 as well as the adjacent ends of the transmembrane 
helices form the so-called ‘anion selectivity filter’. It was demonstrated that a 
large number of cysteine substituted residues in this region were sensitive to 
sulfhydryl inhibition, but only those forming the extracellular region were 
inhibitable by a positively charged sulfhydryl inhibitor, although deeper 
residues were inhibited by the uncharged ones. Also of those residues that 
were inhibited by the uncharged pCMBS, none of the superficial extracellular 
residues had inhibition competed with by Cl
-, indicating anion selectivity in this 
region [172]. This anion selectivity was speculated to be due to the positive 
charge at residue 851, as well as possibly the σ
+ helical pole charge from the 
last transmembrane segment. 
 
We can infer then, that TM5, TM8, TM13 and TM14 may form parts of an 
aqueous channel leading from the external surface of AE1 into the molecule. 
The T-loop and TM12 may also be involved, as they can be labelled by LYIA   54
[152]. The external ends of TM13 and TM14 as well as the short segment that 
joins them may act as a positively charged filter for anions [172]. 
 
 
1.6.3.4.2  Cytoplasmic Access Channel 
A positively charged membrane-permeant reagent 2-(aminoethyl)-
methanethiosulphonate (MSTEA), inhibited anion exchange by reacting with 
cysteines substituted at Ile684 and Ile688 [171], suggesting that these 
residues might line an aqueous channel extending into AE1 from the 
cytoplasmic side. The channel is quite deep, as positively charged quenchers 
can quench the fluorescence of externally reacted EMA [165], which labels 
Lys430 [148], which is located at the external side of the phospholipid bilayer. 
 
Thus, AE1 has an anion permeable channel that reaches from the outside to 
Glu681, as well as an aqueous channel that extends from the cytoplasm to 
Lys430. This means that the permeability barrier must lie between the 
external surface of the bilayer, to a point almost at the cytoplasmic side of the 
bilayer.  
 
 
1.6.4  Conclusions 
•  AE1 is expressed chiefly in the erythrocyte (eAE1), and also as a 
truncated isoform in the kidney α-intercalated cell (kAE1), which lacks 
the N-terminal 65 amino acids. 
•  The N-terminal cytoplasmic domain binds to several cytoplasmic 
proteins associated with the cytoskeleton. 
•  The membrane-spanning domain carries out transport across the 
membrane; however, our knowledge of the topology of the membrane-
spanning domain is inexact, as it is inferred from functional studies 
rather than high-definition crystallography. 
•  The first eight transmembrane segments are well defined, 
topographically, the remaining portion of the membrane spanning   55
domain is not, possibly as it is mobile as part of the Transporting 
conformational change. 
•  The residue Glu681 is involved in proton binding in proton sulphate 
symport and is crucial for anion exchange. It is at the permeability 
barrier. 
•  It is accessible via an external aqueous channel that reaches from the 
external surface of the molecule, to Glu681, which is located very close 
to the cytoplasmic side of the membrane. 
•  There is also an internal aqueous channel that reaches from the 
cytoplasmic side of the molecule, which reaches as far as the Lys430 
residue, which seems to lie in or very near to the opening of the 
external aqueous channel. 
•  One of the histidine residues in the membrane spanning part of AE1 is 
crucial for anion exchange, and appears to interact with Glu681. This 
residue is probably His743, but may be His834. Both are clearly 
important. 
•  The external access channel is probably comprised of TM5, TM8, 
TM12, TM13 and TM14, with the external ends of TMs13 and 14 and 
the segment linking the two acting as a positively-charged ‘anion 
selectivity filter’. 
•  The internal aqueous channel appears to incorporate Ile684 and 
Ile688. 
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1.7  AE1 and the α-intercalated cell 
As mentioned before, dRTA is a clinical syndrome arising from an inability of 
acid secretion by the intercalated cells of the cortical collecting duct, causing 
decreased net acid excretion and an inability to acidify the urine to a pH of 
less than 5.3, despite spontaneous acidosis or acid loading. This leads to 
positive acid balance and subsequent chronic metabolic acidosis. This 
favours the precipitation of calcium salts in the urine or renal parenchyma (as 
renal calculi or nephrocalcinosis respectively) due to a reduction of urinary 
citrate excretion and concomitant hypercalciuria. Acidosis also favours 
metabolic bone disease, and as discussed previously, hypokalaemia.   
 
The hereditary forms of this disease can be caused by a defect in the apical 
proton extruding vH
+ATPase in the α-intercalated cell, or by a defect in the 
basolateral anion exchanger, AE1, which reclaims bicarbonate from the α-
intercalated cell to the systemic circulation. 
 
The defects in these two proteins arise because of mutations in the genes 
responsible for causing hereditary dRTA. Mutations of two genes encoding 
two subunits (B1 and a4) of the vH
+ATPase have been reported to cause 
autosomal recessive dRTA [2, 173-175].  
 
The respective genes are ATP6V1B1 (chromosome 2p13.1), which encodes 
the B1 subunit of the catalytic V1 domain and ATP6V0A4 (chromosome 7q33-
q34), which encodes the a4 subunit in the Vo domain of the vH
+ATPase. 
 
Mutations of in the human anion exchanger, or human solute carrier family 4, 
member 1 gene (AE1 or SLC4A1, found on chromosome 17q21-q22) may 
also cause dRTA, as first reported by Bruce and co-workers [1].  
 
An AE1 mutation that leads to defective basolateral bicarbonate extrusion 
through the basolateral membrane will cause bicarbonate retention in the α-
intercalated cell, facilitating the intracellular retention of hydrogen ions, and   57
thus inhibit the dissociation of carbonic acid. The resulting failure of hydrogen 
ion excretion from the α-intercalated cell would (by definition) cause dRTA. 
 
Mutations in SLC4A1 can cause autosomal dominant (AD) dRTA [1, 176-178] 
as well as autosomal recessive dRTA [63, 179-181]. The mechanisms of 
these different Mendelian inheritance patterns are being revealed by work on 
the intracellular trafficking of these various mutants. 
 
1.7.1  AE1 and the intercalated cell 
1.7.1.1  AE1 regions important for intracellular targeting (the C-terminal 
tail)  
There is a sequence (Y904DEV907) present on the c-terminal tail of AE1, which 
corresponds to a tyrosine based signalling pattern, the so-called ‘YXXΦ motif’. 
This pattern consists of tyrosine residue (the ‘Y’), two other amino acids (the 
‘XX’s) and a hydrophobic amino acid (the ‘Φ’) [182], and is involved in protein 
localisation to both clathrin and clathrin-independent (caveolae) endocytic 
mechanisms, as well as sorting to the basolateral membrane in polarised 
cells[183-185]. Other membrane proteins are known to undergo basolateral 
membrane sorting via interactions with tyrosine motifs on the cytoplasmic 
domains via adaptor-protein complexes [186, 187]. 
This motif has an important role in kAE1 sorting in polarised cell models. 
Y904, as part of this motif, has been examined in MDCK cells and rat inner 
medullary collecting duct (IMCD) cells, with an 11 amino acid deletion 
(R901X) [188] and a substitution with alanine at position 904 [189] 
respectively, with the protein being erroneously sorted to the apical 
membrane. 
The so-called ‘acidic patch’ (D905E906), and the last 4 amino acids 
(A908MPV911) at the C-terminal end of the protein may also play an important 
part in proper kAE1 localisation. The latter sequence has been proposed as a 
possible PDZ protein-binding domain (XΦXΦ). Intracellular localisation of 
kAE1 in transfected HEK 293 and non-polarised LLC-PK1 cells was the result 
of deletion of the last 5 amino acids [190].   58
 
1.7.2  Autosomal dominant dRTA 
The AE1 mutations associated with autosomal dominant (AD) dRTA were the 
first described [1, 176-178, 191], the commonest mutation in this group being 
a missense mutation at position R589, usually by histidine or cysteine, and 
more rarely serine. The frequency of different, (and on at least two occasions, 
denovo) substitutions at this position has led to the suggestion that the 
responsible codon is a ‘mutational hotspot’ [177], (possibly due to methylation 
and deamination altering cytosine to thymine). 
 
The first SLC4A1 mutations described causing AD dRTA were R589H, R589C 
and S613F, all the cases were heterozygotes and had normal red cells. Red 
cell anion transport was reduced with R589H and R589C, but markedly 
increased with S613F. The eAE1 proteins, when expressed in Xenopus 
oocytes, had normal chloride influx activity, with the exception of R589H, 
which had an approximately 40% reduction. When co-expressed with wild 
type (wt) eAE1, the mutant eAE1 did not affect the chloride influx, indicating 
that the mutant did not affect transport activity of the molecule directly. 
 
Karet et al screened 26 kindreds with hereditary dRTA for SLC4A1 mutations, 
and found none in any of the kindreds with AR dRTA, confirmed by linkage 
analysis[176]. However, they found SLC4A1 mutant heterozygotes in one 
dominant dRTA kindred, one sporadic case and one kindred with two affected 
brothers, the mutations being R589S, R589H and R901X (which resulted in a 
premature truncation of the protein, missing the last 11 amino acids from the 
C-terminal tail). However the provocative title of the paper, which suggested 
that SLC4A1 mutations could not cause AD dRTA has been proven wrong by 
subsequent data from SE Asia [63, 180, 181, 192, 193].  
 
A heterozygous SLC4A1 mutation causing a missense mutation at position 
888, followed by a premature termination codon (A888L+889X) was reported 
in two infants with dRTA and their father, who had incomplete dRTA [194].  
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A different novel missense mutation was reported in a large AD dRTA family 
who suffered with extensive nephrocalcinosis and renal impairment, G609R 
[195]. Again, this had no loss in anion transport function when expressed in 
Xenopus oocytes. 
 
As these reports show, although all of these SLC4A1 mutations clearly co-
segregate with AD dRTA, when expressed in Xenopus oocytes, all had 
normal or near normal anion transport activity, thus the loss of activity must 
arise from another mechanism than simple abolition of transport activity. 
 
1.7.3  Autosomal recessive dRTA 
The first SLC4A1 mutation to be found associated with AR dRTA was 
reported in 2 siblings in NE Thailand, who had dRTA associated with a 
hemolytic anemia and dysmorphic red cells, with normal red cell eAE1 content 
and anion transport. They had the mutation G701D, which was also 
associated with the two common polymorphisms, M31T and K56E [180]. 
When expressed in Xenopus oocytes, G701D (as both eAE1 and kAE1) 
showed a lack cell surface expression. However, when coexpressed with the 
red cell AE1 chaperone protein, Glycophorin A (GPA), the plasma membrane 
expression, and thus anion transport activity was ‘rescued’. Thus the normal 
anion transport activity in the patient’s red cells, with their abundant GPA was 
explained, and the dRTA, due to defective anion transport in the GPA-less α-
intercalated cell was understandable as well. The red cell abnormalities, and 
the hemolytic anemia seemed to be due in part to the siblings being affected 
by homozygous hemoglobin E and in part to the G701D mutation, as 
subsequent reports of G701D heterozygotes in five different Thai families 
without hemoglobin E found only slight red cell dysmorphia [193]. 
 
Compound heterozygotes for G701D and Southeast Asian Ovalocytosis 
(SAO) were described shortly afterwards; two cases of dRTA and SAO were 
reported in patients with G701D/SAO SLC4A1 mutations from two families 
from southern Thailand [181]. These had a few more red cell abnormalities 
than normally found in SAO, and a 40% decreased red cell sulfate flux.   60
 
Two novel mutations were reported in compound heterozygotes in families 
from SE Asia, AR dRTA was found in a Malaysian family due to SAO/A858D, 
and in association with SAO/ΔV850, ΔV850/ ΔV850 and ΔV850/A858D in 
patients from six families from Papua New Guinea [63]. Again haemolytic 
anemia and abnormal red cell shapes were noted. Red cell and Xenopus 
oocyte studies showed that ΔV850 and A858D mutants had severely 
decreased anion transport when expressed as a compound heterozygote. 
The heterozygous A858D mutation was found to be associated with 
incomplete dRTA by the original reporting group, and was thus assigned as 
an AD dRTA causing mutation. As will be seen later, this can cause some 
confusion, and it must be remembered that the labels AD and AR represent 
clinical phenotypes, which may be very variable in the degree of expression. 
 
Severe haemolytic anemia and dRTA in a homozygote for SLC4A1 V488M 
was the next report of an AR dRTA causing SLC4A1 mutation [179]. Another 
two novel mutations were described in two Thai families; one had dRTA due 
to a compound heterozygote G701D/S773P. The second family had two 
siblings with both SAO and dRTA (one complete, the other incomplete), both 
were compound heterozygous SLC4A1 SAO/R602H [196].  
 
As will be fairly obvious by now, the AD dRTA SLC4A1 mutations co-
segregate mainly with occidental populations, whereas the AR dRTA 
mutations are all clustered in Southeast Asia. I will return to this point later. 
 
1.7.4  Molecular mechanisms of AD dRTA 
The localization of two SLC4A1 mutants has been studied in detail in cell 
models, R589H and R901X. 
 
Quilty et al showed that a dominant negative effect could account for the AD 
dRTA phenotype [197, 198]. They transfected HEK 293 cells with wt eAE1, wt 
kAE1 or R5898H kAE1. Erythroid AE1 and kAE1 when transfected singly 
were expressed at the cell surface, but R589H was retained intracellularly, as   61
demonstrated by immunofluorescence, cell surface biotinylation and anion 
transport assays [198]. Coexpression of kAE1 and R589H reduced the 
expression of wt kAE1 due to heterodimer formation and a dominant negative 
effect, in which, it was postulated, the mutant protein in the heterodimer 
caused the whole heterodimer to be retained intracellularly. The R589H 
mutant was not grossly misfolded as it had unaffected binding to an inhibitor 
affinity resin. Other mutations at the same position (R589C and R589S) had 
the same effect, preventing the normal targeting of wt kAE1 to the cell 
surface, suggesting that the arginine at position 589 (which is evolutionarily 
conserved) is important for proper protein targeting.  
 
In studies using both transiently and stably transfected MDCK cells, it has 
been reported that the kAE1 mutant R589H and S613F are retained in the 
endoplasmic reticulum (ER) of non-polarised cells and that they fail to reach 
the cell surface in polarised cells [188, 199]. A coexpression study in MDCK 
cells showed that R589H caused wtkAE1 to be retained intracellularly, again, 
probably via heterodimer formation [199].   
 
The R901X kAE1 mutant has been studies in Xenopus oocytes, HEK 293 
cells and non-polarised MDCK cells [197, 200]. R901X demonstrates normal 
anion transport when expressed in Xenopus oocytes, however when 
expressed in MDCK cells, it was retained intracellularly, suggesting that the 
C-terminal tail, truncated in the R901X mutant is important for transport to the 
cell membrane. It was again proposed that wt kAE1 was prevented form 
reaching the cell surface when coexpressed with R901X due to heterodimer 
formation, trapping the wt protein in the cell interior [200].  
Quilty showed that mutant proteins heterodimerised with wt protein, 
preventing it’s expression at the cell surface, by showing that R901X kAE1 
colocalised with His tagged wt kAE1 form transfected cell lysates, and that 
coexpression of the wt and mutant kAE1 resulted in the intracellular retention 
of wt proteins in a pre-medial Golgi compartment of the transiently transfected 
HEK 293 cells [197].    62
Serial truncations of the AE1 C-terminus also resulted in impaired protein exit 
from the ER, the degree of impediment depending on the length of the 
truncation [190]. 
 
Wild type and R901X epitope tagged kAE1 distribution in polarised MDCK 
and rat IMCD cells was examined by Devonald and co-workers [189]. In both 
cases, wt kAE1 localised to the basolateral membrane, whilst the mutant was 
found at the basolateral and apical membrane as well as intracellularly.  This 
non polarised sorting of R901X might be due to the loss of a targeting signal 
form the truncated C-terminal end of the protein, namely the so-called “YXXΦ 
motif”, which is involved in targeting proteins to the basolateral surface of 
polarised cells. The residues YDEV at positions 904-907 correspond with this 
motif, and when the tyrosine at position 904 was mutated to an alanine, the 
distribution of the resulting protein in the polarised transfected cell was similar 
to that seen with R901X. YXXΦ motifs interact with the α subunits of adaptor 
protein (AP) complexes, on e of which is specific to polarised epithelial cells, 
AP-1B. To determine whether AP-1B was involved in sorting AE1 to the 
basolateral membrane, sorting in LLC-PK1 cells (which are derived from 
proximal tubular cells and lack the α1B subunit) was observed with two AE-
CD8 chimera proteins, constructed from the membrane reporter protein, CD8, 
and the C-terminal end of AE1, the full tail in one case and the truncated to 
lack the last 11 amino acids, as R901X does. Sorting was no different in this 
experiment, with the truncated protein being seen at the apical membrane, 
and the fully tailed protein being transported to the basolateral membrane. 
The authors concluded that AP-1B wasn’t involved in AE1 basolateral sorting 
[189]. 
 
This finding was confirmed by another study in stably transfected MDCK cells-
where it was demonstrated that the 11 terminal amino acids on the C-
terminus were not recognised by α1B containing AP-1B adaptor complexes 
[188]. Also, it appeared that the N-terminus played a role in AE1 addressing-in 
the absence of the N-terminus, the C-terminus was not sufficient to localize 
kAE1 to the basolateral membrane [188, 201].  
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A further mutation, G609R was reported in a European family [195] that 
caused AD dRTA. When kAE1 was expressed in Xenopus oocytes, had, like 
all the other dRTA causing mutants, normal anion transport function. In 
polarised MDCK cells, G609R localised sub-apically, in a manner reminiscent 
of R901X. Due to the proximity on the AE1 secondary structure to R589 and 
S613, the authors postulated that this region must be important for the 
trafficking or sorting of the protein. G609R was not examined for a dominant 
negative effect, to explain its phenotype. 
 
1.7.5  Molecular Mechanisms of AR dRTA 
The trafficking of the AR mutants G701D and S773P were studied in 
transfected HEK 293 cells [202], where it was found that S773P had 
approximately 30% of the expression of wt kAE1, and had a two fold decrease 
in its half life, being targeted by the proteosome for degradation. It could not 
be detected at the cell membrane. In contrast, it was demonstrated that when 
coexpressed with either wt kAE1 or G701D, it was able to form heterodimers 
with them, as could G701D and wt kAE1 with each other. Furthermore, these 
heterodimers were expressed on the cell membrane, unlike heterodimers of 
R589H and wt kAE1. These two mutants, then, showed a dominant positive 
effect, in being ‘rescued’ to the cell surface by the wt kAE1 that they were 
heterodimerised with. 
 
When expressed in polarised MDCK cells, the S773P and G701D mutants 
displayed distinct trafficking defects. S773P, whilst retained largely in the ER 
in non-polarised MDCK cells, was predominantly targeted to the basolateral 
membrane in polarised MDCK cells [203]. However, G701D was retained in 
the Golgi both polarised and non-polarised MDCK cells. Coexpression with wt 
kAE1, showed that, as shown before, R589H caused the retention of 
coexpressed wt kAE1, whilst the recessive dRTA mutants did not. The 
coexpression of S773P and G701D showed some co-localisation of S773P 
and G701D in the Golgi, but still with trafficking of S773P to the basolateral 
membrane, no G701D was detected at the plasma membrane, demonstrating 
that ‘rescue’ of G701D does not occur with S773P.   64
1.7.6  Conclusions 
•  The phenotypes of hereditary AE1 associated AD and AR dRTA are 
determined by SLC4A1 point mutations or deletions which affect AE1 
folding and tertiary structure without significantly changing the anion 
transport properties of the protein. 
•  These structural alterations do not seem to affect the dimerization of 
these mutant proteins as hetero- or homodimers. 
•  They do, however, affect the trafficking of the mutant homodimers, 
from the ER and the trans-Golgi network to the cell membrane. 
•  The trafficking of the mutant/wildtype heterodimer determines the 
dominant or recessive nature of the phenotype. In AD dRTA the mutant 
kAE1 in the heterodimer exerts a ‘dominant negative’ effect, inducing a 
trafficking defect on the dimerised wt kAE1. In AR dRTA, the wt kAE1 
in the heterodimer corrects the defective trafficking of the mutant kAE1, 
resulting in a ‘dominant positive’ effect and thus normal cell surface 
expression of kAE1 in the heterozygote. 
•  In two cases (R901X and G609R) the dominant mutants can exit the 
ER and a partially mis-sorted to the apical membrane. This, and the 
reduced basolateral expression of AE1, leads to the dRTA phenotype. 
1.8  AE1 and the red cell 
1.8.1  AE1 and the red cell 
As stated before, AE1 is the predominant plasma membrane protein in the red 
cell, where its main function is the extrusion of bicarbonate reclaimed by 
carbonic anhydrase 2 (CA2) from the hydration of CO2 that has diffused into 
the cell from the respiring peripheral tissues. 
 
Also, as mentioned before, it has two main domains, a N-terminal cytoplasmic 
domain that attaches to ankyrin, protein 4.2 and the red cell cytoskeleton, all 
of which affect the stability of the red cell membrane, and the cell shape [139]. 
It also binds glycolytic enzymes, altering the rate of glycolysis [204, 205], 
hemoglobin, controlling hemoglobin cooperativity [206] and hemichromes 
(partially denatured hemoglobin), affecting cell senescence signalling.   65
 
The membrane-spanning domain crosses the membrane 12-14 times and 
carries out ion transport. The short cytoplasmic C-terminal tail binds CA2. 
 
AE1 carries out a more diverse set of functions in the red cell than it appears 
to in the intercalated cell, mainly due to the other proteins that it associates 
with at the plasma membrane. Its trafficking is also a little different, in that in 
the red cell, AE1 is trafficked with the chaperone protein, Glycophorin A 
(GPA). 
 
1.8.2  AE1 interaction with Glycophorin A 
Glycophorin A (GPA) is a bitopic integral membrane sialoglycoprotein that is 
present in the red cell in similar abundance to AE1. There is a considerable 
body of evidence that GPA interacts with AE1 in the red cell membrane.  
 
Anti-GPA antibodies decrease the rotational mobility of AE1 in the red cell 
membrane [207]. Anti-Wright b (Wr
b) antibodies (against the common Wright 
b erythrocyte antigen) require both GPA and AE1 to be present to react with 
red cells and co-immunoprecipitate both GPA and AE1 [208]. The GPA 
residues 61-70 are thought to form the Wr
b antigen, along with residue 
Glu658 of AE1. 
 
GPA augments the movement of AE1 to the cell membrane in Xenopus 
oocytes, and coexpression of GPA and wt AE1 induces increased AE1 
mediated chloride influx in the oocyte, by both enhancing the amount of AE1 
at the membrane, and possibly also by increasing AE1 anion transport 
function [209]. This augmentative effect of GPA on AE1 transport activity is 
not dependent on the oligomeric state of GPA; GPA mutants that are unable 
to form stable dimers have the same effect on AE1 as wt GPA [210]. 
 
AE1 and GPA appear to interact at an early stage following the synthesis and 
processing of the two proteins [211]. The N-glycan chain of AE1 in increased 
in erythrocytes that lack GPA [212], but is decreased in red cells that have   66
more GPA than normal [213]. The sulfate transport ability of AE1 is 
diminished in human red cells that lack GPA, even though the amount of AE1 
is unchanged [212].  
 
GPA forms SDS-stable dimers by self-association of the transmembrane (TM) 
regions. Mutagenesis studies have demonstrated that seven residues in the 
GPA TM span are critical for dimer formation [214], although other residues 
may also be important for this process [215]. 
 
Work expressing GPA constructs in Xenopus oocytes also suggests that the 
C-terminal cytoplasmic tail enhances trafficking of AE1 to the cell surface, 
whereas the (extracellular) residues 68-70 increase the specific anion 
transport activity of AE1 [215]. This area is within the Wr
b antigen, and thus is 
likely to interact with Glu658 on AE1, which is probably at the extracellular 
end of TM8. How this might affect AE1 anion transport remains unclear. 
 
1.8.3  Haemoglobin 
Haemoglobin (Hb) binds weakly to the N-terminus of AE1, but as the 
concentration of Hb is so high in red cells, about 50% of AE1 molecules are 
bound to Hb under physiological conditions [216]. 
 
Hemichrome, a partially denatured form of Hb, binds to AE1 more avidly than 
normal Hb, forming AE1-hemichrome aggregates [217]. These clustered 
aggregates are thought to form a cell surface epitope that is identified by 
antibodies, which bind and signal the cell for phagocytosis [218]. 
 
This formation of a senescence antigen by AE1 copolymerisation with 
hemichromes could also mediate the clearance of sickle and β-thalassaemic 
red cells, which have unstable Hb that degrades into hemichromes.  
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1.8.4  Membrane skeletal proteins 
Ankyrin-1 links to the major membrane protein spectrin by binding to a 
number of sequences in the N-terminal cytoplasmic domain of AE1 [219]. This 
forms the basis of the skeletal membrane attachment, which is essential for 
the plastic/elastic properties of the red cell [219]. Ankyrin-1 preferentially binds 
to AE1 tetramers, and may contribute to tetramer stabilisation [220]. It has 
been estimated that about 70% of red cell AE1 exists as dimers and 30% as 
higher order oligomers, with these latter species predominantly associating 
with ankyrin-1 [221]. 
 
Protein 4.1 which links the spectrin-actin skeleton to the plasma membrane 
via interactions with Glycophorin C (GPC), has also been shown to bind to the 
cytoplasmic domain of AE1 [123] although AE1 does not seem to be 
important in linking the spectrin-actin complex to the plasma membrane [222]. 
Protein 4.1 competes with ankyrin for binding to AE1 in vitro, with 
consequences for membrane mechanical properties [122].  
 
Protein 4.2 also interacts with AE1’s cytoplasmic domain [223]. This is thought 
to strengthen the ankyrin-1 mediated linkage of the membrane skeleton to 
AE1, as protein 4.2 deficient red cell membranes have increased AE1 
rotational mobility and extractability [125].   
 
1.8.5  The Rh Complex 
AE1 interacts with the proteins of the Rhesus (Rh) complex, the polypeptides 
that comprise the antigens of the rhesus blood group system, and which are 
reduced or absent in Rhnull red cells. These include the Rhesus-associated 
glycoprotein (RhAG), the Rh polypeptides (RhD, RhCE, that carry the epitope 
for the Rh antigens; D, E/e and C/c), CD47, LW (both adhesion molecules; 
CD47 is also a marker of self) and glycophorin B. 
 
RhAG is thought to form a gas channel, although the gases that it transports 
are somewhat unclear. The discovery that RhAG has homology with the 
MEP/AMT ammonium transporters led to the hypothesis that RhAG transports   68
ammonia/ammonium [224]. Cell studies, in erythrocytes, Xenopus oocytes, 
yeast and HeLa cells described RhAG variously as a NH3/NH4 exchanger, 
ammonium exporter, an ammonium channel etc. The possibility remains that 
ammonium is not the principal substrate of this molecule and that it may 
transport nitric oxide or CO2 along with ammonium ions, a role for AE1 in the 
efflux of nitric oxide from deoxygenated erythrocytes has been reported [225, 
226]. Cysteine residues in the N-terminal cytoplasmic tail mediate the transfer 
of nitric oxide from bound deoxyhemoglobin to the cell exterior. This 
metabolon increases the efficiency of the transfer and protects the nitric oxide 
from reacting with other substrates in the cell or the membrane.  
 
CD47 is a candidate as a sensor for the extracellular environment of the red 
cell, it interacts with thrombospondin-1 and SIRPα. Is involved in cell 
recognition and cell adhesion in many cell types, and when complexed with 
integrins, can activate G protein signalling [227]. Although red cells do not 
have integrins, CD47 signalling could be mediated by protein 4.2. This is 
supported by the observation that young sickle cell erythrocytes show 
different CD47 mediated adhesion properties under static and flow conditions, 
suggesting that CD47 can sense these two differing external environments 
[228].   
 
There also appears to be a role for protein 4.2 in mediating and stabilising the 
interaction of AE1 and the RH complex-this is suggested by studies of human 
red cells with total deficiency of protein 4.2, but normal AE1. The cells almost 
completely lacked CD47 and had altered RhAG, indicating that protein 4.2 
provides a major binding site for CD47 and the Rh complex, and anchors the 
Rh complex to the cytoskeleton [229]. The observation that Rh proteins are 
associated with the red cell cytoskeleton [230] fits with this model, and 
suggests that the Rh complex selectively interacts with the ankyrin-associated 
tetrameric fraction of AE1. 
 
AE1 may thus act as a scaffold for assembling macro-complexes of proteins 
in the red cell membrane, which modulate the red cell’s metabolic, transport, 
and mechanical properties in response to the environment (Figure 1-4). This   69
may be particularly important in the microcirculation, where the red cell is in 
close contact with the endothelial wall. The red cell undergoes substantial 
morphological changes to pass through the small capillaries, and reduction of 
its rigidity during this deformation would minimise its resistance to flow. Nitric 
oxide is also released from red cells under these conditions, which acts to 
relax the tone of blood vessel walls and increase blood flow to oxygen-starved 
tissue [225]. Rapid movement of CO2 into and nitric oxide out of the cell is 
required due to the small amount of time the red cell spends in the capillary 
system (0.3-1 sec). CD47 might act as a sensor for the contact with the 
endothelium and activate CO2 and nitric oxide membrane transport via 
Rh/RhAG. CD47 may also signal the reduction in erythrocyte rigidity need for 
the red cell to pass through the capillary at all, by altering the erythrocyte 
cytoskeleton via protein 4.2. 
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Figure 1-4 A cartoon of the Rhesus complex, showing ankyrin binding to 
the spectrin skeleton and supporting the AE1 dimer/oligomer. 
This is associated in the lipid bilayer with RhAG, LW and CD47. The N-
terminal of AE-1 associates with deoxy-hemoglobin or hemichrome material. 
The C-terminal end binds carbonic anhydrase 2, forming the metabolon. 
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1.8.6  AE1 and red cell disease 
1.8.6.1  Hereditary Spherocytosis 
Hereditary Spherocytosis (HS), a condition that was first described by two 
Belgian physicians in 1871 [231]; is a common (1 in 2000) inherited hemolytic 
anaemia that causes erythrocytes to become spherical and osmotically 
fragile, due to a progressive loss of surface area, and to be destroyed 
prematurely in the spleen. 
 
HS results from mutations in protein 4.2, ankyrin or AE1.  Ankyrin and protein 
4.2 mutations result in a slight reduction in membrane AE1, however various 
mutations of SLC4A1, the AE1 gene (including missense, nonsense and 
frameshift mutations) have been reported to cause autosomal dominant HS, 
associated with a 20-40% reduction in AE1 protein levels in the red cell 
plasma membrane, with an associated decrease in protein 4.2 content [232-
237]. These mutations account for approximately 20% of HS cases. Loss of 
AE1 in the cell membrane reduces the number of anchoring interactions 
between the cell membrane and the cell cytoskeleton [113], causing areas of 
AE1-free membrane to become susceptible to ‘blebbing’, reducing the surface 
area to volume ratio and thus the spheroidal shape.  
 
Heterozygotes have a mild to moderate hemolytic anaemia, homozygotes, 
whom would be predicted to have no AE1 at their red cell membrane would 
fare much worse, with much more fragile red cells and seriously impaired CO2 
handling. 
 
Only three cases of homozygous HS have been reported; one case with the 
Val488Met mutation (band 3 Coimbra) which caused severe transfusion 
dependent hemolytic anaemia and dRTA with Nephrocalcinosis [179]; one 
with band 3 Neopolis (a mutation affecting the donor splice site of exon 2), 
which resulted in an N-terminal 11 amino acid truncated protein, causing 
severe spherocytosis, but no dRTA, due to the nature of the defect [238] and 
one with the Ser677Phe mutation (band 3 Courcouronnes) which caused 
spherocytosis and incomplete dRTA [239]. The Ser667Phe mutation is   72
interesting as it causes a trafficking defect that can be partially rescued by 
GPA and more completely rescued by wt AE1, which may explain its mild 
phenotype in heterozygotes, who have only a small reduction in their total red 
cell AE1. 
 
1.8.6.2  Hereditary Stomatocytosis 
Hereditary Stomatocytosis (HSt) and it’s allied disorders (cryohydrocytosis, 
familial pseudohyperkalemia and hereditary xerocytosis) is a group of 
dominantly inherited diseases in which red cells have an increased 
permeability to monovalent cations. Like hereditary spherocytosis, there 
appear to be a number of causes of this group of disorders, including 
mutations of AE1, and an as yet undetermined mutation that has been 
mapped to chromosome 16. 
 
Like HS, the cells have a reduced surface area to volume ratio, causing a 
typical appearance with a slit like central concavity; which looks a little like a 
mouth (figure 1-5), hence its name. Stomatocytes, macrocytosis, increased 
red cell Na
+ and decreased red cell K
+ are classical features. The cells usually 
have increased cell water content, but some variants (xerocytosis) can be 
dehydrated, osmotic fragility is increased and a degree of hemolysis is 
present, and may be severe. Splenectomy reduces the rate of hemolysis 
[240], which is presumably the site of removal of the defective red cells, it may 
not be beneficial in xerocytosis [241].  
 
Various subtypes are classified based on the temperature dependence of 
their leak [242]. Some fall under the rubric of ‘cryohydrocytosis’, which means 
that they have a leak, which is at its greatest at 4
oC, and these are caused by 
mutations in AE1 [243]. The mutant AE1 is inactive as an anion exchanger 
and has a cation channel-like activity (a ‘cation leak’) causing the red cells to 
leak monovalent cations. This is discussed later in this chapter. 
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Figure 1-5 A blood film from a patient with hereditary stomatocytosis. 
The arrow points at a stomatocyte, with its slot like central depression. 
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1.8.6.3  Southeast Asian Ovalocytosis 
Southeast Asian Ovalocytosis (SAO), also known as hereditary ovalocytosis, 
Melanesian elliptocytosis or stomatocytic elliptocytosis, is another autosomal 
dominant red cell disorder, resulting from a mutation of AE1 (the deletion of 
amino acids 400-408), homozygosity is probably lethal in utero [244, 245].  
 
It is found in the native populations of Melanesia (where it is very common 
[246, 247]) and Malaysia and in parts of Indonesia, Madagascar and the 
Philippines [247-250]. It is rare in Western populations but has been reported 
[251, 252]. 
 
The affected patient’s red cells have a reduced surface area to volume ratio, 
causing typically 20% of the red cells to be rounded elliptocytes (see figure1-
6). Stomatocytes are present in all patients including those with the AE1 
mutation who lack elliptocytes (up to 25% in one series [253]). These 
stomatocytes have characteristic ‘stoma’, which are similar to cells seen in 
cryohydrocytosis. 
 
Hemolysis is reduced or absent [247, 248, 250], and the red cell membrane is 
rigid, with a rigidity of 10-20 times that of normal [254, 255], indicating that the 
membrane rigidity is not a major determinant of erythrocyte survival. The cells 
are also unusually heat resistant [256], resistant to pharmacological induction 
of endocytosis [257] and strongly resist crenation [257]. 
The red cells are also cation leaky, with increased red cell Na
+ and K
+ 
permeability and increased glycolysis to compensate for increased cation 
pumping [250, 258], in a strikingly similar fashion to that seen in the HSt 
spectrum disorders. It has in fact been suggested that SAO be grouped with 
the HSt spectrum disorders on this basis [258]. 
 
SAO is also interesting because it is found with the highest frequency in very 
malarious areas of Papua New Guinea, where its gene frequency can be as 
high as 35% in some communities [259]. This is probably because this 
mutation is subject to a positive evolutionary selection pressure; it has been   75
shown to confer a strong protective effect against cerebral malaria by an 
unknown effect [245, 260].  
 
Malaria is endemic to the lowland areas in which SAO is commonly found in 
the aboriginal tribes of Melanesia [246, 259, 261], with rates of SAO carriage 
of 5-25%. The prevalence of SAO increases with age in populations 
challenged by malaria [262], which implies that there is a survival advantage 
for SAO affected individuals. SAO shows strong clinical protection against 
cerebral malaria, but exacerbates malarial anaemia [253, 260]. In vitro, SAO 
red cells have been shown to be resistant to invasion by falciparum parasites, 
which was attributed to the membrane rigidity [256, 263], but may, in fact be 
an artefact of ATP depletion in cold stored cells due to compensatory cation 
pumping in the face of increased membrane cation leakiness, as this is not 
seen in freshly taken SAO red cells [258, 264].   76
 
Figure 1-6 Blood films from three of the original family described with 
SAO by Honig et al in 1971. 
The elliptocytes are clearly seen in all three films. 
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1.8.7  Conclusions 
•  GPA and AE1 interact at an early stage after synthesis, GPA increases 
the amount of AE1 in the cell membrane, and it may increase AE1 
anion transport function too. 
•  Denatured haemoglobin binds to AE1 forming aggregates, which act as 
a senescence antigen, signalling for the removal of the red cell. 
•  AE1 links ankyrin to the membrane protein spectrin, forming an 
important link between the membrane and the membrane skeleton. It 
also binds protein 4.1 and 4.2 for similar structural reasons.  
•  AE1 associates in the cell membrane with the Rh complex, which 
comprises RhAG RhD, RhCE, CD47, LW and GPB. 
•  In this complex, RhAG may mediate the transport of ammonium and 
possibly CO2 and nitric oxide. 
•  CD47 may play a role in sensing the external environment of the red 
cell, possibly mediating changes in the red cell plasticity via AE1 and 
protein 4.2 to the cytoskeleton. 
•  HS results from mutations in AE1, ankyrin or protein 4.2. Resulting red 
cells are spherical and are much more fragile, prone to haemolytic 
anemia. 
•  HSt and its allied disorders have red cells with a reduced surface area 
to volume ratio and have an increased permeability to monovalent 
cations. This affects their hydration and causes a tendency toward 
haemolytic anemia. 
•  SAO also causes a reduced surface area to volume ratio and 
increased permeability to monovalent cations, but also causes 
increased cell membrane rigidity. It is strongly protective against 
cerebral malaria, but may worsen malarial anaemia. 
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1.9   AE1 and the cation leak 
Having detailed the numerous physiological functions of AE1 already, I’m now 
going to describe the work delineating a more novel physiological (and 
sometimes pathophysiological) function of AE1; it’s ability to function as an ion 
channel. 
 
1.9.1  AE1 channel permeability and cell volume regulation 
 
Most cells need to be able to adapt to changes in external osmolality by 
regulating their volume. After swelling in hypo-osmotic medium, cells recover 
their previous volume by the process of regulatory volume decrease (RVD). 
 
RVD is achieved by the loss of osmotically active molecules from the cell 
interior, followed by the osmotic loss of water. These molecules may be 
inorganic ions, such as potassium or chloride, or small organic solutes of 
varying classes, such as polyols (e.g. sorbitol or myo-inositol), amino acids 
(e.g. taurine) and methyl amines (e.g. betaine). These organic solutes may 
comprise as much as half of the RVD response [265], and the loss of these 
solutes appears to occur via a specific pathway. 
 
A number of authors have observed that the volume-activated transport of 
organic osmolytes is via a single pathway that resembles a channel and is 
inhibited by a range of anion transport inhibitors, in Madin Darby Canine 
Kidney (MDCK) cells [266], flounder erythrocytes [267] and rat C6 glioma cells 
[268]. 
 
This sensitivity to anion transport inhibitors led a number of authors to suggest 
that the anion exchanger AE1 might play a role. Goldstein et al suggested that 
AE1 was the swelling activated transport system itself, based on the close 
relationship between the dose response curves for the effect of DIDS on 
anion exchange and the volume activated transport of organic solutes [269]. 
Motais and co-workers proposed that AE1 acted as a regulatory protein, as   79
hypotonic swelling activated not only taurine and potassium efflux, but also a 
broad range of other solutes, such as sodium, choline and 
tetramethylammonium to diffuse out of the cell [265, 270, 271]. Moreover, 
these effluxes are all inhibited by DIDS (and other AE1 inhibitors), and the 
dose-response curves are identical. 
 
Its pharmacological profile led to the suggestion that this pathway was a 
swelling activated anion channel [266, 267], a suggestion that was bolstered 
by data from single channel patch clamp experiments, demonstrating that 
some amino acids, that were involved in the RVD in MDCK cells, could 
permeate a swelling activated anion channel in MDCK cells [272], work that 
was replicated in C6 glioma, and other, cells.  
 
This swelling activated channel has certain characteristics:  
1)  It is an outwardly rectifying conductance (the current-voltage 
relationship is not linear, the slope of the curve becoming steeper as 
the inside of the cell becomes more positive). 
2)  It exhibits a high permeability for anions over cations, but has a broad 
anion specificity. 
3)  The conductance is inhibited by a variety of anion exchange inhibitors, 
including stilbene derivatives (e.g. DIDS), 5-nitro-2-(3-
phenylpropylamino)benzoic acid (NPPB), tamoxifen, dideoforskalin, 
lanthanum and ketoconazole. Although the drug sensitivity varies 
between cell types. 
 
The observation was made that fish erythrocytes respond to osmotic swelling 
by undergoing the RVD, which involves the efflux of KCl and amino acids 
(mainly taurine) [265], whilst non-nucleated mammalian erythrocytes have no 
swelling activated taurine transport, with volume regulation being achieved via 
activation of K
+/Cl
- cotransport. However, both fish and mammals have AE1 in 
their red cell membranes. On this basis, the transport properties of cloned 
trout AE1 (tAE1) were compared to cloned mouse AE1 (mAE1) when 
expressed in Xenopus Laevis oocytes [273].   80
Both isoforms showed anion exchange activity, but tAE1 expression induced 
a large increase in oocyte Cl
- conductance. This conductance had a near 
linear current-voltage relationship, was not inactivated by depolarisation and 
was correlated to the amount of expressed proteins in a sigmoidal fashion. It 
also induced a large increase in Na
+ independent taurine permeability, which 
was correlated linearly with Cl
- conductance. Oocytes expressing mAE1 
induced neither Cl
- nor taurine transport.  
 
These data provided strong evidence that when expressed in the Xenopus 
oocyte, tAE1 was capable of spontaneously acting as an anion/organic 
osmolyte channel, note, however that in the trout erythrocyte, this channel 
activity is only activated by cell swelling. tAE1 is DIDS sensitive in trout 
erythrocytes, is insensitive to it when expressed in Xenopus oocytes, which is 
when it also spontaneously demonstrates channel activity. This implies that 
tAE1 adopted a different conformation when expressed in oocytes. tAE1 
differs structurally from mAE1 in that the extracellular loop connecting the 
transmembrane domains TM5 and TM6 is large in tAE1 (the so-called ‘Z-
loop’), compared to mAE1. Oocyte expression of a chimera construct tAE1, 
with the Z-loop shortened, was sensitive to DIDS and demonstrated no 
spontaneous channel activity. 
 
Guizouarn et al showed that in trout erythrocytes, the RVD had two different 
pathways, depending on how the cell swelling was activated, a broadly 
specific channel (q.v.) and a K
+/Cl
- cotransporter. The channel was activated 
by a decrease in intracellular ionic strength, the K
+/Cl
- cotransporter by cell 
enlargement, the K
+/Cl
- cotransporter was also down regulated by decreasing 
intracellular ionic strength. Therefore cells swollen by salt accumulation 
responded by activating the K
+/Cl
- cotransporter, whilst those cells swollen by 
electrolyte dilution, activated both pathways, with a resulting reduced loss of 
electrolytes and an increased loss of taurine [274]. 
 
The same author demonstrated that tAE1 when expressed in Xenopus 
oocytes also mediated a cation leak permeability of Na
+ and K
+, which, like 
the anion channel activity and anion exchange, was blocked by H2DIDS. Site   81
directed mutagenesis of Lys-522 to Arg abolished the inhibitory effect of 
H2DIDS on these transport properties. Also, the initiation of a non-tAE1 
related anion conductance (via the expression of CFTR) did not induce a 
cation permeability in the oocyte, suggesting that the cation permeability was 
mediated by tAE1 rather than an endogenous oocyte transporter activated by 
the anion transport of tAE1 [275].  
 
Martial and co-workers collected further data on tAE1, providing more 
evidence that tAE1 acts as a channel, whilst identifying specific regions in the 
protein important for the channel activity. They performed site directed 
mutagenesis at a targeted region around TM7 and identified several amino 
acid residues which when mutated, altered the anion conductance without 
altering the anion exchange ability of the protein. In contrast, point 
mutagenesis at the C-terminal domain of the protein increased the anion 
conductance and reduced the anion selectivity, increasing the Cl- influx nearly 
threefold [276, 277].  
 
 
1.9.2  AE1 channel activity in humans 
 
A definite link between AE1 channel activity and disease in humans began 
with the characterisation of the molecular defect in hereditary stomatocytosis 
and it’s allied disorders, which comprise HSt, cryohydrocytosis, familial 
pseudohyperkalemia and hereditary xerocytosis. As mentioned previously, 
these are rare syndromes characterised by stomatocytic red cell morphology 
(red cells with a mouth shaped area of central pallor-see figure 1-5), varying 
degrees of haemolytic anaemia, very large monovalent cation leaks and 
relative Na
+/K
+ pump failure.  
 
Cation permeabilities as great as 15 to 40 times greater than normal have 
been observed [240, 278, 279], these permeabilities may affect the hydration 
of the cell, which may become over-hydrated or dehydrated.  
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The cation leak is temperature dependent, and a classification system has 
been described that stratifies this group of disorders on the basis of the 
temperature dependence of the associated cation leak. In 
pseudohyperkalaemia, for example, the cation leak that is greatest at 0
oC can 
cause artefactually high serum K
+ measurements in venesected blood 
samples that have been allowed to cool. 
 
Monovalent cation transporters, such as the Na
+/K
+ pump or the K
+/Cl
- co-
transporter [280] are stimulated by the influx of Na
+, but become 
overwhelmed. Pump kinetics are normal [281], and the number of pumps is 
increased several-fold [240, 282]. The stomatocytes expend extremely large 
amounts of ATP [283] to try and correct the cationic milieu by pumping, to 
avoid osmotic rupture.  
 
Bruce et al identified 11 human families with either stomatocytic or 
spherocytic autosomal dominant haemolytic anaemias, with an increased red 
cell membrane permeability to monovalent cations. These were found to be 
associated with a number of single amino acid substitutions in AE1 (S731P, 
H734R, L687P, H705Y and R760Q). Red cells from these individuals had 
much reduced anion transport, and the cation leak in these red cells was 
inhibited by AE1 inhibitors (SITS, dipyridamole and NS1652). When the 
mutant proteins were expressed in Xenopus oocytes, they induced Na+ and 
K+ fluxes in the oocytes, and the induced Cl- flux was much lower than that 
seen in oocytes expressing wt AE1. The cation leak was temperature 
sensitive and varied between the different pedigrees [243]. 
 
Guizouarn et al further characterised the transport characteristics of 4 of these 
AE1 mutations (L687P, D705Y, S731P and H734R) by expressing the AE1 
proteins in Xenopus oocytes, demonstrating that they convert the protein from 
an anion exchanger into a cation conductance [284]. 
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1.9.3  Conclusions 
•  Cells that undergo osmotic swelling need to reduce their volume by, 
means of a regulatory cell volume decrease (RVD) by ejecting 
osmotically active molecules from the cell interior. 
•  AE1 was suspected as a stretch activated osmolyte transporter on the 
basis of its transport characteristics and pharmacokinetics. 
•  Trout AE1, when expressed in Xenopus oocytes, showed a large anion 
permeability, including taurine, and also a significant cation 
permeability. This was not seen in oocytes expressing mouse AE1. 
The properties of trout AE1 when expressed in oocytes were different 
to those seen in trout erythrocytes. Modification of the z-loop abolished 
the spontaneous permeability seen previously.  
•  Several HSt and HS AE1 mutants were shown to have a cation 
permeability that was temperature dependent when expressed in 
Xenopus oocytes, although they had much reduced anion exchange 
activity. 
 
1.10   Hypothesis 
I hope that I’ve managed to outline that both sodium and potassium losses 
occur in dRTA, for reasons that are not clearly understood, but may be 
directly related to the failure of the α-intercalated cells to acidify the urine. I 
have also summarised the molecular mechanisms of AE1 related dRTA, and 
the cation channel property that AE1 can display, in known human mutants 
and in other vertebrates, as a part of the RVD. It is in this context that I 
formulated my hypotheses. 
 
 
 
1)  The increased delivery of sodium to the CCD, with its subsequent 
uptake into principal cells is a potent and robust stimulus of urinary 
acidification and can form the basis of a test to distinguish between   84
those with incomplete dRTA and those with normal urinary 
acidification. 
2)  The AE1 mutations that cause mistrafficking in α-intercalated cells and 
thus dRTA also cause AE1 to act as a cation channel and thus 
contribute to urinary potassium losses.   85
2.  General Methods 
2.1  Introduction 
Many of the methods and materials employed in these studies were unique to 
that given set of experiments, but the last two chapters have a great deal in 
common in terms of their experimental techniques, which I will detail here and 
outline any differences in the text of the appropriate chapter. 
 
2.2  DNA synthesis 
The pSP65erythroid human AE1 (hAE1) plasmid was used to construct the 
kidney AE1 (kAE1), deleting the 65 N-terminal amino acids.  The erythroid 
construct  was  amplified  by  polymerase  chain  reaction  (PCR)  between  the 
Val65 and the Tyr390 with a forward primer introducing a SacII restriction site 
in 5’ and a reverse primer overlapping the EcoRV site in hAE1 sequence.  
The pSP65erythroid hAE1 had the N-terminal part deleted by SacII-EcoRV 
digestion with the SacII-EcoRV PCR product introduced in replacement.  The 
obtained pSP65kAE1 plasmid was checked by sequencing and used to make 
point  mutations  using  the  QuickChange  Site-Directed  Mutagenesis  kit 
(Stratagene, USA). 
For  point  mutations,  primers  where  used  with  appropriate  codon 
substitutions.  Primers were purchased from Eurogentec (Seraing, Belgium); 
polymerase chain reactions (PCRs) were performed using a Biometra “UNO 
Thermoblock” thermocycler (Göttingen, Germany).  Sequences generated by 
PCR were sequenced in their entirety to ensure that no polymerase errors 
were introduced (Gexbyweb, Meylan, France). 
HindIII  linearised  pSP65kAE1  wildtype  and  mutant  plasmids  were 
transcribed  using  SP6  polymerase  (Ambion  transcription  kit).    HindIII 
linearised  BSXG-GPA  plasmid  was  transcribed  using  T7  RNA  polymerase 
(Ambion  transcription  kit).    RNA  concentrations  were  determined  on  a 
formamide/formaldehyde  agarose  gel  in  MOPS  (3-[N-
Morpholino]propanesulphonic acid) buffer.   86
 
2.3  Agarose gel electrophoresis 
This was used for the routine separation of nucleic acids. Electrophoresis was 
performed in a Horizon 58 horizontal format tank (Life Technologies, Paisley 
UK). Power was from a Consort E831 supply (Turnhout, Belgium). All other 
materials were from Sigma unless otherwise stated. 
A 1% agarose gel was prepared by dissolving 1g of molecular biology 
agarose in 100 ml of Tris-HCl pH 8.3, 100 mM borate, 2 mM ethylene diamine 
tetra-acetic (EDTA) (Tris-borate-EDTA buffer, TBE) by heating in a microwave 
oven. The agarose solution was allowed to cool to 50
oC and cast in a gel 
deck. Samples were loaded in 0.04% bromophenol blue, 0,04% xylene 
cyanol, 5% glycerol. Gels were run at 75 V in TBE until the bromophenol blue 
and xylene cyanol had migrated an appropriate distance through the gel. 0.5 
μg/ml ethidium bromide was added to the gel solutions and running buffer to 
enable visualisation of the nucleic acid bands. Ethidium bromide-stained gels 
were photographed through a number 15 orange filter using a Polaroid 
GelCam (Wheathampstead, UK)  
 
2.4  Buffer solutions 
2.5  Xenopus oocyte harvesting 
Xenopus  laevis  frogs  were  placed  in  MS222  (0.2%)  until  completely 
anaesthetised,  according  to  the  protocol  approved  by  our  animal  ethics 
committee.    The  surgery  consisted  of  the  removal  of  5  oocyte-containing 
ovarian lobes.  After surgery, animals were put back in cold water between 0 
and  4
oC  to  recover  from  the  anaesthesia, monitored for 4 hours and then 
replaced in the aquarium. 
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2.6  Oocyte injection 
Collected oocytes were washed in Modified Barth’s Solution (MBS) 
composition:  
NaCl      85 mM  
KCl      1 mM 
NaHCO3    2.4 mM  
MgSO4    0.82 mM 
Ca(NO3)2    0.33 mM 
CaCl2     0.41 mM 
HEPES    10 mM 
NaOH     4.5 mM 
pH      7.4 
Penicillin     10 U/ml  
Streptomycin   10 mg/ml   
After washing in MBS, defolliculation was carried out by 16h incubation in 
18
oC MBS containing 1.3 mg/ml collagenase (SERVA, Heidelberg, Germany), 
followed by 30 minutes incubation in Ca
2+ free MBS. Stage V-VI oocytes were 
then injected with a mixture of 10 ng of kAE1 and 2.5 ng GPA cRNA, and 
were maintained in 18
oC MBS for three days before starting the experiments. 
2.7  Western blot of oocyte membrane proteins 
Oocyte membranes were prepared by homogenization of 20 oocytes (control 
or injected) in cooled Tris-HCl buffer, 20 mM, pH 7.4, 250 mM sucrose, and 
0.5 mM of a protease inhibitor Pefabloc (Roche, Paris, France).  
The mixture was centrifuged (3 X 10 min) at 4
oC; 350g, then 1,400g and 
ﬁnally 3,000g in an Eppendorf  tube;  after  each  centrifugation,  the  pellet  
was discarded. The third supernatant was ultracentrifugated at 255,000g, 2 h, 
48C and membrane pellet solubilised in the homogenisation buffer. Protein 
concentration was measured with the BioRad (Hercules, CA) kit and 50 mg of 
proteins were then loaded/lane of SDS–PAGE electrophoresis gel. Western 
blot transfer was done with a semi-dry transfer system from Biometra on nylon 
membrane (Hybond-C extra, Amersham, Orsay, France).    88
The presence of kAE1 was detected by antibody Bric 170 directed against the 
C-terminus of kAE1. The secondary antibody was anti-mouse IgG-peroxidase, 
which  was  detected  by  chemiluminescence  using  a  Fujifilm  Las-3000 
Luminescence image analyser. 
 
2.8  Intracellular Cation Measurements 
Injected oocytes were incubated in MBS containing ouabain (0.5 mM) and 
bumetanide (5 μM) at 19
oC for 3 days. Five oocytes were quickly washed in 
7.5 ml of milliQ water (Millipore) and dried on aluminium foil for 7 hours at 
80
oC after removing excess extracellular fluid. Dried oocytes were measured 
to determine dry cell solids. Intracellular ions were extracted by suspending 
dried oocytes in 4 ml of milliQ water overnight at 4
oC. Perchloric acid (80μl of 
70% v/v) was then added to the suspension. After centrifugation at 30 000g 
for  10  minutes  the  clear  supernatant  was  saved  for  analysis  of  cations. 
Measurements  of  sodium  and  potassium  were  done  with  a  flame 
spectrophotometer (Eppendorf). Results were expressed as micromoles per 
gram dry cell solids (µmol/g d. wt.). 
 
2.9  Intracellular pH measurements 
Oocyte intracellular pH was measured using selective microelectrodes made 
as follows. Glass micropipettes were pulled from clean borosilicate capillaries 
(GC 150F-10) (Harvard Apparatus), placed in an oven, and dried at 120
oC for 
one hour. The microelectrodes were vapour-silanised with N,N-
Dimethyltrimethylsilylamine (Fluka 41716) and then baked for 2 hours at 
150oC. A small drop (0.3 μl) of a proton ion exchanger (hydrogen ionophore I-
Cocktail A: ref Fluka 95291) was introduced into the electrode shank. The 
selective microelectrodes were kept in the dark overnight, tips downwards, to 
allow the exchanger to reach the tip and then were back filled with phosphate 
buffer (pH 7.0) and calibrated in solutions of pH 6.8 and 8.0. A standard 
microelectrode filled with 3M KCl was used for measurement of membrane 
potential. The electrodes were connected to a high-impedance probe of a two   89
channel FD 223 electrometer (World Precision Instruments). The bath was 
grounded via a 3M KCl agar bridge connected to an Ag-AgCl wire.  The slope 
of the pH microelectrodes was between 54 and 58 mV per pH unit. 
The ability of the expressed AE1 proteins to regulate intracellular pH was 
assessed by measuring intracellular pH of oocytes kept in MBS without HCO3
-
then incubated in the following medium: 
NaCl      63.4 mM 
KCl       1 mM 
Na HCO3
-    24 mM 
MgSO4    0.82 mM 
Ca(NO3)2    0.33 mM 
CaCl2     0.41 mM 
HEPES/NaOH  5 mM 
pH      7.35 
CO2      5% 
O2      95% 
 
The oocytes were then bathed in MBS without Cl
-, composed as follows: 
Na-gluconate   63.4 mM  
K-gluconate    1 mM  
NaHCO3
-     24 mM 
MgSO4     0.82 mM 
Ca(NO3)2     0.74 mM  
HEPES/NaOH   5 mM  
pH       7.35 
CO2       5% 
O2       95% 
 
Results were given in ΔpHi per min ± standard error. ΔpHi was measured 
when acidified oocytes were exposed to the Cl
- free mediumThis corresponds 
to the initial slope of the alkalinisation phase of the curve (Figure 2-1). . 
Expression of proteins was assumed to have an equal effect on intracellular 
buffer capacity, which was not measured. 
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Figure 2-1 An example intracellular pH trace for an oocyte expressing wt 
AE1. 
There is an initial decrease in intracellular pH during CO2 irrigation when the 
extracellular medium contains chloride. When this is removed, the intracellular 
pH rises again due to bicarbonate transport from the oocyte ceasing, 
demonstrating that it is chloride dependent.  
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3.  Novel Clinical Assessment of Urinary Acidification  
3.1  Introduction 
As outlined previously, the clinical features of dRTA can vary, ranging from an 
asymptomatic urinary acidification defect without systemic acidosis (so-called 
‘incomplete’  dRTA),  with  or  without  the  incidental  finding  of  renal  tract 
calcification, to major effects in childhood with acidosis, growth retardation, 
rickets and extensive medullary nephrocalcinosis, sometimes progressing to 
renal  failure.    Detection  and  diagnosis  are  worthwhile,  even  in  those  with 
asymptomatic or incomplete dRTA, so as to minimize future skeletal and renal 
complications [285], and in familial cases to assist genetic counselling. 
In those patients with a metabolic acidosis and near normal GFR, a diagnosis 
of dRTA can be made when urine pH is consistently >5.3 [286]; but if there is 
no  systemic  acidosis  and  plasma  bicarbonate  concentration  is  within  the 
normal range, a test of urinary acidification is required.   
The history of the different assays tried for these have been described in the 
introductory chapter. Briefly, they comprise 3 approaches. 
Firstly, acidification can be tested by inducing a systemic acidosis, this was 
the approach taken by Wrong and Davies with the short ammonium chloride 
test [41]. This remains the ‘gold standard’ test for incomplete dRTA, but due to 
gastric irritation is unpleasant, takes 8 hours to complete, and may induce 
vomiting which can render the test invalid. 
Secondly,  examination  of  the  difference  between  blood  and  urine  CO2 
tensions (U-B pCO2) was suggested by Halperin and colleagues [52]. This 
has  been  criticised  as  a  low  U-B  pCO2  has  been  observed  in  pRTA and 
advanced renal failure[53, 54], the test therefore has low specificity. 
Finally,  assays  based  on  an  indirect  and  elegant  approach  of  simply 
increasing the load of sodium ions reaching the distal nephron have been 
described. Sodium is absorbed rapidly in the CCD by principal cells via apical 
ENaC  channels,  whilst  chloride  diffuses  slowly  from  the  lumen  via  the 
paracellular  route;  this  disparity  in  diffusion  potentials  generates  a  net   92
negative electrochemical gradient in the lumen, which drives proton secretion 
into the lumen via the apical proton pump in the intercalated cell (see Figure 
3-1).  This method is the basis of the intravenous sodium sulfate test [48], and 
also the oral furosemide test [55] (in which furosemide inhibits NaCl uptake in 
the loop of Henle, thus increasing distal delivery). Experience has found these 
methods are unsatisfactory due to inconvenience and unreliability, even when 
urine pH changes in response to an increased distal delivery of sodium have 
been  reported  to  be  greater  in  normal  subjects  when  they  are  sodium 
depleted [56] or following prior administration of a mineralocorticoid [57].   
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Figure 3-1 A cartoon of the mechanism of action of the furosemide and 
fludrocortisone test. 
Furosemide increases delivery of NaCl to the CCD, which is represented by 
the arrows running from left to right in the figure. Aldosterone increases the 
uptake  of  Na
+  from  the  lumen  by  increasing  the  amount  of  ENaC  at  the 
principal  cell  apical  surface  and  the  amount  and  activity  of  basolateral 
Na
+K
+ATPase. The slow paracellular absorption of Cl
- ions results in a net 
negative  luminal  charge,  which  favours  alpha  intercalated  cell  proton 
extrusion by the apical proton pump, which is also increased by aldosterone.  
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Although  our  own  initial  observations  suggested  that  the  addition  of 
fludrocortisone led to a more consistent effect than furosemide alone [287], 
the timing of the mineralocorticoid seemed to be important.  This is because 
the  relevant  action  of  a  mineralocorticoid  like  aldosterone  is  in  part  ‘non-
genomic’  and  can  occur  more  rapidly  than  was  originally  supposed.  
Aldosterone increases epithelial sodium channel (ENaC) density on the apical 
surface of principal cells within 30 minutes of administration via mobilization of 
endocytic  stores  of  pre-formed  EnaC  [288].    Basolateral  Na
+,K
+-ATPase 
activity  is  also  increased  acutely  following  mineralocorticoid  administration 
[289], as is α-intercalated cell vH
+-ATPase activity; the latter has been shown 
to occur within 15 minutes of exposure [290-292]. 
With these observations in mind, we hypothesised that simultaneous dosing 
of furosemide (to increase distal tubular sodium delivery) and fludrocortisone 
(to enhance principal cell sodium reabsorption and α-intercalated cell H
+ 
secretion) should provide a sufficient and consistent stimulus to unmask an 
acidification defect in dRTA, without the need for NH4Cl. (see Figure 3-1) To 
test this, we examined urinary acidification in response to the standard short 
NH4Cl test and compared it with the response to the 
furosemide/fludrocortisone test in healthy subjects and in a group of patients 
with known dRTA. 
3.2  Aims 
1)  To compare the sensitivity and specificity of the novel simultaneous 
furosemide and fludrocortisone test against the short ammonium 
chloride test in a group of healthy control subjects and a group of 
patients with dRTA. 
2)  To ascertain the urinary physiological parameters of individuals 
undergoing each test, namely urinary ammonium, titratable acidity, 
potassium and sodium concentrations as well as flow rates. 
3)  To compare both tests for adverse effects and convenience.   95
3.3  Methods and Materials 
3.3.1  Subject selection 
Ten patients with previously diagnosed dRTA were recruited (see Table 3-1), 
along with 11 healthy volunteers.  Of those who completed the study, mean 
creatinine clearance (adjusted for weight) was 69 ± 8 ml/min (± SE) in the 
dRTA patients and 100 ± 11 ml/min in the controls. 
Those  from  the  dRTA  group  had  their  diagnoses  confirmed  by  either  a 
previous  ammonium  chloride  test  or  failure  to  acidify  their  urine  in  the 
presence of systemic acidaemia.  Two had autoimmune-associated dRTA, 4 
had familial dRTA and 4 had idiopathic dRTA. The group comprised 2 males 
and  8  females,  age  range  26  to  56  years.    All  patients  in  this  group had 
hypokalemic  or  normokalaemic  dRTA;  patients  with  hyperkalaemic  dRTA 
were  not  selected  (even  if  the  diagnosis  of  a  complicating  type  1  dRTA 
seemed likely) to exclude any confounding effect of a potentially coincident 
type  4  RTA.    The  control  group (8 males, 2 females, aged from 21 to 51 
years) comprised healthy volunteers recruited from the medical school and 
junior medical staff. 
All subjects underwent a short NH4Cl test and a furosemide/fludrocortisone 
test on separate days, and in random order, without fasting, with at least one 
week between tests.   
3.3.2  The NH   4Cl protocol 
The NH4Cl test involved taking a baseline urine sample, followed by oral 
NH4Cl at a dose of 100 mg/kg body weight given as 500 mg gelatine 
capsules.  This dose was taken over 1 hour (hours 0-1 in each figure) with 
water to minimise gastric irritation.  Urine was then collected every hour, 
starting 2 hours after dosing began, until 8 hours after the baseline sample. 
3.3.3  The furosemide/fludrocortisone protocol 
The furosemide/fludrocortisone test involved taking a baseline urine sample, 
followed by oral administration of furosemide (40 mg) and fludrocortisone (1   96
mg).  Fluid intake was ad libitum.  Urine was collected hourly for 6 hours after 
the hour following drug dosing. 
3.3.4  Urine collection and measurement 
Subjects  were  instructed  to  note  the  time  at  which they had passed urine 
before the baseline urine sample, to allow baseline values to be determined.  
Urine  pH was measured immediately with an electrode pH meter (Hannah 
piccolo 
tm), as was urine titratable acidity (against 0.1M NaOH, titrated to a pH 
of 7.4).  Each sample was also analysed for urine sodium, potassium and 
ammonium concentrations.  Sodium and potassium were measured by flame 
photometry and ammonium by a variation of the indophenol detection method 
using a spectrophotometer (Tecan Sunrise 96-well plate reader)[293]. 
3.3.5  Ethical approval 
Protocols were approved by the University College London Hospital Ethics 
Committee and informed consent was obtained from all subjects. 
3.3.6  Statistical analysis 
Statistical analysis was by Student’s t-test for unpaired data, or by ANOVA 
followed by Student’s t test for paired data, as appropriate.  Values are given 
as means ± SE; P<0.05 significant and NS non-significant differences.   97
Table 3-1 Biochemical parameters for patients with dRTA who 
completed the study 
Patient 
number 
Diagnosis  Plasma  Na 
(mmol/L) 
Plasma  K 
(mmol/L) 
Plasma  HCO3 
(mmol/L) 
1  Sjögren’s 
syndrome 
 
136  3.8  14 
2  Idiopathic 
 
137  3.9  21 
3  Familial 
 
140  4.7  19 
4  Idiopathic 
 
136  3.2  25 
5  Idiopathic 
 
139  3.7  22 
6  Idiopathic 
 
139  3.9  23 
7  Familial  
 
140  3.1  16 
8  Familial 
 
141  3.3  19   98
3.4  Results 
Three subjects (2 from the dRTA group and 1 from the control group) had to 
withdraw from the study because of vomiting after taking NH4Cl.  Eight 
subjects remained in the dRTA group and 10 in the control group.  Six 
subjects (3 in each group) reported nausea following NH4Cl, while one subject 
in the dRTA group had difficulty swallowing the required number of NH4Cl-
containing capsules.  No subjects reported any difficulties with the 
furosemide/fludrocortisone test. 
3.4.1  Urinary acidification 
All subjects in the control group acidified their urine to a pH of less than 5.3 
when  given  the  NH4Cl  test  and  also  when  given  the 
furosemide/fludrocortisone  test  (Figures  3-2  and  3-3).    The  minimum  pH 
values  were  4.87  ±  0.07  after  NH4Cl  and  4.92  ±  0.10  after 
furosemide/fludrocortisone (NS). 
Urinary acidification appeared to be more rapid after the 
furosemide/fludrocortisone test than after NH4Cl, although it should be noted 
that the complete dose of NH4Cl took an hour to ingest, unlike the dosing of 
furosemide plus fludrocortisone.  All control subjects acidified their urine to a 
pH <5.3 by 3-4 hours after furosemide/fludrocortisone, whereas this was 
achieved 5-6 hours after NH4Cl (Figure 3-4), that is, 4-5 hours following the 
end of NH4Cl ingestion.  In the dRTA group all patients failed to acidify their 
urine to pH <5.3 with either test.  Minimum pH values were 6.83 ± 0.10 after 
NH4Cl and 6.59 ± 0.13 after furosemide/fludrocortisone (NS). 
3.4.2  Ammonium excretion 
In the control group ammonium excretion increased during both tests.  For the 
NH4Cl test ammonium excretion increased from a baseline of 26 ± 9 µmol/min 
to  a  maximum  of  64  ±  17  µmol/min  (at  6  hours).    For  the 
furosemide/fludrocortisone  test  baseline  ammonium  excretion  was  33  ±  8 
µmol/min, rising to a transient peak of 85 ± 23 µmol/min at 2 hours (Figure 3-6 
A).   99
In the dRTA group changes in ammonium excretion were less striking.  After 
NH4Cl, ammonium excretion was variable, but increased significantly at 4 and 
7 hours; no significant increase in ammonium excretion was seen with the 
furosemide/fludrocortisone test. (Figure 3-6 B). 
 
3.4.3  Titratable acidity 
In the control group titratable acidity (TA) increased during both tests (Figure 
3-6).  With NH4Cl TA rose from a baseline of 11 ± 3 µmol/min to a peak of 48 
± 9 µmol/min (at 6 hours).  With furosemide/fludrocortisone TA rose from a 
baseline of 10 ± 3 µmol/min to a peak of 42 ± 5 µmol/min (at 3 hours). 
In the dRTA group there were much smaller, but significant, rises in TA during 
both tests. 
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Figure 3-2 Time-course of changes in urine pH after the NH4Cl and 
furosemide/fludrocortisone tests 
Values are means ± SE.  The dotted line indicates the threshold pH of 5.3. 
Asterisks indicate significantly (p<0.05, ANOVA) lower pH than baseline (time 
0 hrs).    101
 
Figure 3-3 Baseline to minimum urinary pH achieved in individual 
subjects undergoing the NH4Cl and furosemide/fludrocortisone tests. 
The dotted line indicates the threshold pH of 5.3. Asterisks indicate 
significantly (p<0.05, paired t-test) lower pHs than in the corresponding dRTA 
group.   102
 
Figure 3-4 Individual sequential urine pH measurements in control 
subjects. 
Each line connects individual values in a single subject.  The dotted line 
indicates the threshold pH of 5.3.   103
Urine flow rate and electrolyte excretion 
Baseline  urine  flow  rates  were  higher  in  dRTA  patients  than  in  control 
subjects.  Urine flow rates were generally raised following NH4Cl, reflecting 
the usually higher fluid intake at the time of NH4Cl ingestion.  As expected, a 
diuresis,  natriuresis  and  kaliuresis  followed  furosemide/fludrocortisone 
administration in control subjects and dRTA patients, reaching a peak at 2 
hours (Fig 3.4.4 C).  The natriuretic response was similar in the dRTA group 
to that previously described[55] and somewhat greater in the control group, 
possibly reflecting the furosemide naїvety of our controls. 
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Figure 3-5 Electrolyte excretion and urine flow rate 
A: sodium excretion; B: potassium excretion; C: urine flow rate during the 
NH4Cl and furosemide/fludrocortisone tests. Closed circles: control subjects; 
open circles: dRTA patients. The asterisk indicates a result significantly 
(p<0.05) greater in the control group than the dRTA group.   105
 
Figure 3-6 Ammonium and titratable acid excretion. 
A: ammonium excretion; B: titratable acid excretion during the NH4Cl and 
furosemide/fludrocortisone tests.  Closed circles: control subjects; open 
circles: dRTA patients. An asterisk indicates a value significantly higher 
(P<0.05 or less) than the baseline measurement.   106
3.5  Conclusion 
3.5.1  Efficacy 
The purpose of this study was to assess the efficacy and reliability of the 
furosemide/fludrocortisone  test  compared  with  the  well-established  short 
NH4Cl test, and whether or not it had any practical advantage.  In terms of 
efficacy, the furosemide/fludrocortisone test performed as well as the short 
NH4Cl test.  The control subjects all acidified their urine to a pH below 5.3, 
whereas all the dRTA patients failed to acidify to pH <5.3 with either test (see 
Figures 3-2 and 3-3).   
As Wrong and Davies defined the syndrome of ‘incomplete dRTA’ using the 
short ammonium chloride test, defining it as an inability to reduce the urine pH 
to less than 5.3 following the administration of ammonium chloride[41], the 
test  itself  by  definition  has  a  sensitivity  and  specificity  of  100%,  with  the 
caveat that the test must be successfully completed, in other words all of the 
ammonium chloride must be ingested (and not vomited).  
Therefore,  the  simultaneous  furosemide  and  fludrocortisone  test,  in  this 
assessment has a sensitivity and specificity of 100% (albeit in a study of 8 
cases and 10 controls) -which would be remarkable apart from the fact that 
the condition of incomplete dRTA is defined by the urinary pH response to the 
acidifying  stimulus  of  ammonium  chloride.  It  appears  form  our  data  that 
simultaneous  furosemide  and  fludrocortisone  is  as  potent  a  stimulus  for 
urinary acidification as systemic acidosis, at least in the limited groups that we 
have tested. 
 
3.5.2  Physiological parameters 
As  anticipated,  in  control  subjects  the  NH4Cl  test  caused  significant  and 
sustained  increases  in  titratable  acid  and  ammonium  excretion,  as  they 
excreted the acid load.   107
 Following  furosemide/fludrocortisone,  control  subjects  showed  smaller 
increases in titratable acid and ammonium excretion compared with NH4Cl, 
although there was a striking peak in ammonium excretion at 2 hours, and in 
titratable  acidity  at  2-3  hours  (Figure  3-6).    This  peak  coincided  with  the 
maximum urine flow rate and excretion rates of sodium and potassium (figure 
3-5), occurring at the time of maximal delivery of sodium and chloride to the 
CCD. The minimum urine pH occurred 1 hour later, which is compatible with a 
dilutional effect from the pronounced diuresis in the second hour reducing the 
urinary pH.  This is a similar pattern to that observed by Batlle [55]. Titratable 
acidity remained elevated until the end of the test, presumably relating to the 
continuing effect of mineralocorticoid. 
In the dRTA patients, the pattern of urinary acidification was similar for each 
test.  Both tests evoked smaller increases in titratable acid and ammonium 
excretion  compared  with  those  seen  in  control  subjects,  there  was  no 
observed rise at all in ammonium excretion in the peak second hour seen in 
the dRTA patients with the simultaneous furosemide and fludrocortisone test, 
and minor non-significant rise in titratable acidity.  
Although  a  natriuresis  and  kaliuresis  occurred  following 
furosemide/fludrocortisone in the dRTA group (Figure 3-5), the magnitude of 
the natriuresis was less than in the control group. The difference between the 
sodium  excretion  rates  was  quite  large,  but  in  our  analysis  did  not  reach 
statistical significance. The reason for this difference is not clear, it is possible 
that our dRTA patients were more sodium deplete that our controls and thus 
had a higher basal uptake of sodium in the CCD, although one would expect 
this to be a small effect compared to the increased sodium uptake stimulated 
by the mineralocorticoid. Batlle, using furosemide alone, found similar rates of 
sodium excretion in controls and dRTA patients[55], so perhaps there is a 
differential response to mineralocorticoid in those with dRTA; possibly due to 
low level chronic salt wasting. 
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3.5.3  Adverse effects 
 
The furosemide/fludrocortisone test was advantageous in that its side-effect 
profile was much better than that of the NH4Cl test: no subject in either group 
had any side effects from furosemide/fludrocortisone, whereas 3 subjects (2 
dRTA and 1 control) had to abandon the NH4Cl test due to vomiting, and 6 
subjects (3 dRTA, 3 controls) experienced nausea.  One dRTA subject had 
difficulty swallowing the NH4Cl capsules, which are large and numerous (the 
protocol dose was 14 large 500mg capsules for a 70kg subject). 
 
3.5.4  Convenience 
 
The furosemide/fludrocortisone test is a quicker test to complete than the 
NH4Cl test: 9 out of 10 control subjects had achieved a urine pH <5.3 by 3 
hours after furosemide/fludrocortisone administration, and all had achieved it 
by 4 hours; and the majority then quickly returned to a normal (baseline) urine 
pH (Figure 3-4).  In contrast, with the NH4Cl test, only half the subjects had 
acidified their urine to pH <5.3 by 4 hours after NH4Cl administration began, 
although most had achieved this by 5 hours (i.e. within 4 hours of completing 
NH4Cl ingestion); with this test, urine pH continued to fall or remained low for 
up to 8 hours. 
 
With simultaneous dosing of furosemide and fludrocortisone, one can also be 
sure  that  the  mineralocorticoid  is  taken,  rather  than  with  the  dosing  of 
mineralocorticoid the evening before as had been tried before [287]. 
 
 
3.5.5  Physiologic basis 
As already mentioned, it should also be borne in mind that the NH4Cl and 
furosemide/fludrocortisone tests assess urinary acidification in different ways:   109
one by providing an acid load for the distal nephron to excrete and the other 
by producing direct and indirect stimulation of distal nephron H
+ secretion.   
 
This assumes that increasing the distal delivery of NaCl is equivalent to 
inducing a systemic acidosis, as far as the secretion of protons by the α-
intercalated cell is concerned. Our knowledge of the molecular mechanisms of 
acid secretion by the α-intercalated cell would tend to support such an 
assumption, but a number of older theories concerning dRTA, (albeit in 
unusual circumstances, such as amphotericin, toluene or vanadium toxicity) 
posited mechanisms such as increased apical permeability of the intercalated 
cell permitting ‘back leak’ of protons from the urine [294] or inhibition of 
H
+K
+ATPase[70]. One can fairly easily construct thought experiments in which 
increasing luminal electrochemical negativity would have different effects to a 
systemic acidosis on urinary acidification in these circumstances. Thus, 
comparison of the two tests in clinical subgroups of patients with dRTA will 
need to be made to see if they can provide any further insights into underlying 
mechanisms of abnormal urine acidification. 
 
3.5.6  Conclusion 
In conclusion, the simultaneous furosemide/fludrocortisone test differentiated 
between  patients  with  distal  acidification  defects  and  normal  subjects  as 
reliably as the short NH4Cl test.  It did so without causing side effects, a major 
drawback  of  the  NH4Cl  test.    Moreover,  the  simultaneous 
furosemide/fludrocortisone test took less time to complete, with differences 
between normal and impaired urinary acidification apparent by 3-4 hours from 
the start of the test, as the acidification effect is relatively transitory; whereas 
with NH4Cl, urine pH can remain low for up to 8 hours or more.  
Therefore  the  furosemide/fludrocortisone  test  should  last  a  maximum  of  4 
hours, with hourly urine pH measurements being made starting immediately 
before  dosing.    The  test  can  be  terminated  at  4  hours  (after  the  maximal 
acidification effect has passed), or after the urine pH falls below 5.3, signifying 
normal urinary acidification.     110
No other measurements would need to be made, unless hypokalemia was 
known  to  be  present  beforehand,  in  which  case,  oral  potassium 
supplementation prior to the test in case the furosemide and fludrocortisone 
cause a transient depression in serum potassium might be prudent. 
This would be possible to do in a half day, for instance, during the course of 
an outpatient clinic, if trained nursing staff were available (necessary for 
accurate calibrated pH measurements), which would enable new patients to 
have incomplete dRTA excluded at clinic and be discharged without follow up, 
a considerable advantage compared to current practice. 
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4.  The Cation Leak Activity of dRTA Associated AE1 
Mutants 
4.1  Introduction 
As previously detailed, in the red cell, AE1 has an N-terminal cytoplasmic 
domain that acts as an anchorage site for the cell membrane cytoskeleton, 
and a membrane-associated domain (predicted to span the membrane 12-14 
times) that carries out anion exchange [152, 295].  A kidney isoform of AE1 
(kAE1) is present in the a-intercalated cell (α-IC) of the distal nephron.  It 
differs from the erythroid form (eAE1) in lacking the 65 N-terminal amino acids 
and is located in the basolateral membrane of the α-IC, where it plays a key 
role  in  normal  urinary  acidification  linked  to apical membrane electrogenic 
proton (H
+) secretion [296].  Mutations in AE1 protein can cause two distinct 
phenotypes: erythroid and renal. 
Of  the  erythroid  phenotypes,  one  group  encodes  polymorphisms  of  blood 
group antigens; another group is associated with autosomal dominant (AD) 
spherocytosis  (in  which  red  cells  are  characterised  by  increased  osmotic 
fragility and reduced membrane surface area); and a third group consists of 
the hereditary stomatocytoses and their allied disorders (HSt), and Southeast 
Asian ovalocytosis (SAO). Both are AD red cell defects characterised by cold-
induced cation leaks [242, 258, 283] in which the mutant protein is expressed 
normally  at  the  cell  surface,  but  has  reduced  or  absent  anion  exchange 
activity [63, 243].  Several AE1 mutations (L687P, D705Y, S731P, H734R) 
associated with HSt or spherocytosis appear to abolish the anion transport 
property  of  the  protein,  which  is  converted  to  a  non-selective  Na
+  and  K
+ 
conductance [297]. 
The renal phenotype associated with AE1 mutations is distal renal tubular 
acidosis  (dRTA),  a  disorder  characterised  by  impaired urinary acidification 
and  increased  urinary  losses  of  potassium  and  sodium  [296].    These 
mutations are distinct from the mutations causing HSt and SAO, in that anion 
exchange activity is preserved or only moderately reduced when expressed in 
Xenopus oocytes.     112
Studies  in  polarised  cells  show  that  the  defect  associated  with  these 
mutations is due to cytosolic retention or mistargeting of the AE1 protein.  In 
the α-IC, kAE1 is synthesised in the endoplasmic reticulum (ER) before being 
trafficked to the basolateral membrane in oligomeric form [201].  Known AD 
dRTA-associated  mutations  cause  disease  in heterozygotes by the mutant 
kAE1 ‘capturing’ the wildtype kAE1 as a heterodimer, which is retained in the 
ER [199] or is mis-sorted to the apical membrane [188].   
Autosomal  recessive  (AR)  dRTA-associated  mutations  (G701D,  S773P, 
DV850 and A858D) have been found only in Southeast Asia [63, 188, 202] 
and seem to exhibit different trafficking behaviour. Polarised mammalian cells 
co-expressing wildtype AE1 with G701D or other AR mutant show ‘rescue’ of 
the mutant and expression at the cell surface [199, 203]. 
 
4.1.1  The hypokalaemia hypothesis. 
Hypokalaemia  due  to  potassium  wasting  is  a  feature  of  dRTA.  We 
hypothesised that a dRTA-associated AE1 mutant might also have a cation 
leak property, and be involved in a pathological transport of potassium from 
the α-intercalated cell to the urine, either directly mediating the transport via 
mis-sorting to the apical membrane, as has been observed in some dRTA 
associated mutants in polarised cell models[188], or alternatively by activating 
another apical transporter system. 
Therefore, we decided to characterise the anion and cation transport 
properties of four dRTA-associated kAE1 mutations, selected on the basis of 
their proximity to the red cell disease mutations on the primary structure of the 
AE1 molecule - R589H, G609R, S613F and G701D - using the Xenopus 
oocyte expression system. 
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4.2  Aims 
1)  To express the selected kAE1 mutants (R589H, G609R, S613F and 
G701D) in Xenopus oocytes. 
 
2)  To characterise the anion transport characteristics of the selected 
kAE1 mutants by observation of 
36Cl
- uptake into oocytes and by 
measurement of intra-oocyte pH during CO2 acidification with and 
without chloride containing extracellular medium. 
 
3)  To examine the expressed mutants for a possible cation channel 
activity by observation of 
86Rb
+ uptake into oocytes at 0
oC and room 
temperature, and measurement of intracellular cation contents of 
oocytes after prolonged incubation in standard incubation medium. 
 
4)  Electrophysiological characterisation by twin electrode voltage 
clamping of any cation conductances that we found. 
 
4.3  Methods and materials 
4.3.1  Xenopus oocyte harvesting 
Xenopus laevis oocytes were harvested as detailed in the general methods 
chapter. 
4.3.2  Oocyte injection 
Collected oocytes were washed and defolliculated as detailed in the general 
methods chapter. 
 Stage V-VI oocytes were then injected with a mixture of 10 ng of kAE1 and 
2.5 ng GPA cRNA, when co-injected with GPA cRNA, and were maintained in 
18
oC MBS for two or three days before starting the experiments.   114
4.3.3  Plasmid and DNA construction 
The pSP65erythroid human AE1 (hAE1) plasmid was used to construct the 
kidney AE1 (kAE1), deleting the 65 N-terminal amino acids, as described in 
the General Methods chapter. For point mutations, primers were used with the 
following codon substitutions: G609R: GGG/CGG, R589H: CGC/CAC, S613F: 
TCC/TTC,  G701D:  GGC/GAC.    Primers  were  purchased  from  Eurogentec 
(Seraing, Belgium); polymerase chain reactions (PCRs) were performed using 
a  Biometra  “UNO  Thermoblock”  thermocycler  (Göttingen,  Germany).  
Sequences generated by PCR were sequenced in their entirety to ensure that 
no polymerase errors were introduced (Gexbyweb, Meylan, France). 
HindIII  linearised  pSP65kAE1  wildtype  and  mutant  plasmids  were 
transcribed  using  SP6  polymerase  (Ambion  transcription  kit).    HindIII 
linearised  BSXG-GPA  plasmid  was  transcribed  using  T7  RNA  polymerase 
(Ambion  transcription  kit).    RNA  concentrations  were  determined  on  a 
formamide/formaldehyde  agarose  gel  in  MOPS  (3-[N-
Morpholino]propanesulphonic acid) buffer. 
4.3.4  Western blot 
Oocyte membranes were prepared by homogenization of 20 oocytes (control 
or injected) in cooled Tris-HCl buffer, 20 mM, pH 7.4, 250 mM sucrose and 5 
mM protease inhibitor, Pefablock (Roche, Paris, France), as described in the 
general methods chapter.  The presence of kAE1 was detected by antibody 
Bric 170 directed against the C-terminus of kAE1.  The secondary antibody 
was anti-mouse IgG-peroxidase, which was detected by chemiluminescence 
using a Fujifilm Las-3000 Luminescence image analyser. 
4.3.5  Chloride  influx experiments 
For chloride influx experiments, eight oocytes were incubated at 18
oC in 80 μl 
MBS containing 
36Cl
- (Amersham) with a specific activity of 360 d.p.m. (nmol 
chloride)
–1. After a 15 minute incubation, the oocytes were washed twice in 
ice-cold  MBS  and  transferred individually into counting vials. The washing 
procedure took less than 30s. The volume of extracellular fluid dropped with 
each oocyte being variable, it was quickly removed and 20 μl of SDS was   115
added  before  vortexing.    Radioactive  chloride  uptake  by  each oocyte was 
determined after scintillation counting with an external procedure to account 
for  quenching.  The  incubation  medium  was  counted  in  duplicate  in  5  μl 
aliquots, using the same protocol to determine the specific activity in each 
experiment. Chloride uptake was calculated as the mean of eight values and 
expressed as pmol per minute per oocyte.   
4.3.6  Intracellular pH measurements 
Oocyte  intracellular  pH  was  measured  using  selective  microelectrodes,  as 
described in the general methods chapter.  The ability of wt and mutant kAE1 
to regulate intracellular pH was assessed by measuring intracellular pH of 
oocytes adapted in MBS without HCO3
-, then incubated in media as described 
in the general methods chapter. Results are given as ΔpHi per min ± s.e. 
ΔpHi was measured when acidified oocytes were exposed to Cl
- free medium 
and corresponds to the initial slope of the alkalinization. 
4.3.7  Rubidium influx experiments 
For the Rb
+ influx measurements, eight oocytes were incubated for 2 hours at 
22
oC or 0
oC in 80 µl of MBS with ouabain (0.5 mM) and bumetanide (5 µM), 
containing 
86Rb with a specific activity of 32000 dpm/nmol. After this 2-hour 
incubation, the oocytes were washed twice in ice-cold MBS and transferred 
individually into counting vials. The washing procedure took less than 30s. 
The volume of extracellular fluid dropped with each oocyte being variable, it 
was  quickly  removed  and  20  μl  of  SDS  was  added  before  vortexing.  
Radioactive rubidium uptake by each oocyte was determined after scintillation 
counting with an external procedure to account for quenching. The incubation 
medium was counted in duplicate in 5 μl aliquots, using the same protocol to 
determine  the  specific  activity  in  each  experiment.  Rubidium  uptake  was 
calculated as the mean of eight values and expressed as pmol per hour per 
oocyte.   
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4.3.8  Intracellular cation measurements 
Injected oocytes were incubated in MBS containing ouabain (0.5 mM) and 
bumetanide (5 μM) at 19
oC for 3 days.  Na
+ and K
+ content of oocytes was 
measured by flame spectrophotometry, as previously described in the general 
methods section.  In some experiments, the Na
+ in the MBS was substituted 
with NMDG (N-methyl-D glucamine).   
 
The final NMDG MBS medium was:  
NMDGCl:   85 mM 
KCl:     1 mM 
KHCO3:  2.4 mM 
MgSO4:   0.82 mM 
Ca (NO3) 2:   0.33 mM 
CaCl2:   0.41 mM 
HEPES:   10 mM 
KOH:    4.5 mM 
pH:     7.4 
Cation contents were expressed as µmol per gram of dry weight (µmol/g d. 
wt.). 
4.3.9  Electrophysiology experiments 
Electrophysiological  parameters  were  measured  at  room  temperature  
using  the  2-electrode  voltage  clamp  technique  with  a  TEV  200  ampliﬁer  
(Dagan,  Minneapolis,  MN)  monitored  by  computer through Digidata 1200 
A/D  converter/PC  clamp  software  (Axon  Instruments,  Foster  City,  CA).9  
Current and potential electrodes ﬁlled with 3 M KCl had a resistance of 1.8 to 
2.3  MOhm.  A  KCl  agar-agar  bridge  (3  M)  was  used  in  order  to  minimize   117
junction  potentials.  The  offset  potential  between  bath  and  electrodes  was 
zeroed before measuring oocyte resting potential. 
Resting potential was measured by reading the voltage value on the ampliﬁer 
display  after  impaling  the  oocytes  by  the  2  electrodes.  Following  resting 
potential  (Em) determination, oocytes were clamped at holding potentials of -
30 mV and clamping potentials from -100 to +80 mV; 
20-mV increments were applied for 800 ms and the current values recorded. 
Im was plotted versus Vm and the mean slope of the I/V curve between -100 
mV and -20 mV was taken as an index of the membrane conductance and 
expressed as microsiemens (μS). 
In some experiments, the Na
+ in MBS was substituted by NMDG (N-methyl-D-
glucamine) or K.  
For NMDG MBS, the ﬁnal medium was:  
NMDGCl   85 mM  
KCl    1 mM 
KHCO3    2.4 mM 
MgSO4    0.82 mM 
Ca(NO3)2   0.33 mM 
CaCl2    0.41 mM  
HEPES   10 mM 
KOH     4.5 mM  
pH      7.4   
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For  KCl  MBS,  the  ﬁnal medium was:  
KCl     86 mM 
KHCO3   2.4 mM 
MgSO4   0.82 mM 
Ca(NO3)2  0.33 mM 
CaCl2   0.41 mM 
HEPES  10 mM 
KOH    4.5 mM 
pH     7.4  
 
For  experiments  where  Cl
-  was  substituted  by  gluconate  the  gluconate 
containing MBS was: 
Na Gluconate  88 mM 
K Gluconate   1 mM 
MgSO4    0.82 mM 
Ca(NO3)2    0.33 mM 
CaCl2     0.41 mM 
HEPES    10 mM 
KOH      4.5 mM 
pH       7.4 
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When using inhibitors (La
3+, Zn
2+, 1 mM), the MBS was devoid of HCO3
- and 
SO4
2+: 
NaCl      87.5 mM  
KCl      1 mM 
MgCl2     1 mM  
CaCl2      1.8 mM 
HEPES/NaOH  10 mM  
pH       7.4 
 
4.3.10  Chemicals 
Unless otherwise stated, all chemicals were purchased from Sigma (St Louis, 
MO).  Agarose was purchased from GIBCO BRL (Life technologies, 
Gaithersburg, MD).  Minipreps of DNA were done with a Quiagen kit (Hilden, 
Germany).  Anti-AE1 antibodies BRIC170 and BSXG-GPA plasmid were a 
kind gift of Dr. Ashley Toye (University of Bristol, UK).  Plasmid 
pSP65erythroid AE1 was a kind gift of Dr. H. Appelhans. 
   120
4.4  Results 
4.4.1  Western blot results 
Mutant  kAE1  constructs  were  co-expressed  in  oocytes  with  the  AE1 
chaperonin glycophorin A (GPA), because without GPA there is no plasma 
membrane  expression  of  G701D-  kAE1  in  oocytes  [180].    For  the  other 
mutants that were studied, functional expression could be observed without 
GPA,  as  previously  observed  [1,  191,  195].    In  order  to  compare  similar 
experimental conditions we chose to co-express all the dRTA-mutants with 
GPA.    Oocyte  membrane  expression  of  wildtype  and  mutant  kAE1  was 
confirmed by detecting bands of the appropriate molecular mass on western 
blotting  (Figure  4-1).    No  signal  was  detected  on  lanes  charged  with 
membrane  of  oocytes  expressing  mutant  G701D  kAE1  alone  without  GPA 
(not shown). The western blots were done at the same time as the functional 
studies. 
 
4.4.2  Chloride influx experiments 
To detect functional expression of the dRTA-associated mutants, 
36Cl
- influx 
experiments were carried out in oocytes co-expressing GPA and wildtype or 
mutant kAE1.  Cl
- influx in wildtype kAE1 expressing oocytes was more than 
18 times that measured in non-injected controls; Cl
- influx was well preserved 
in the dRTA mutants (see Figure 4-2 A), as previously reported [1, 180, 195]. 
 
4.4.3  Intracellular pH measurements 
To confirm that Cl
- transport was dependent on Cl
-/HCO3
- exchange activity in 
oocytes  expressing  wildtype  or  mutant  AE1,  we  measured  the  change  in 
intracellular  pH  (pHi)  following  acute  exposure  to  a  solution  containing
 
CO2/HCO3
- (in the presence of extracellular Cl
-), which caused an initial and 
rapid fall in pHi that stabilised as CO2 reached equilibrium across the cell 
membrane.    On  replacing  extracellular  Cl
-  with  gluconate,  pHi  promptly   121
recovered in the presence of functional anion exchange activity, due to HCO3
- 
uptake in exchange for intracellular Cl
-. Oocytes expressing wildtype kAE1 
showed a fall in intracellular pHi in Cl
--containing medium that rose again on 
replacing extracellular Cl
- with the impermeant anion gluconate, as shown in 
Figure 4.4.2 B.  This pattern was seen with all 4 mutants, indicating functional 
plasma membrane expression of Cl
-/HCO3
- exchange.  To compare the Cl
-
/HCO3
- exchange activity of wildtype with mutant kAE1, the initial rate of pHi 
recovery after acid loading was estimated as ΔpHi/minute (Figure 4.4.2 C).  
Mutant recovery rates were not significantly different from wildtype kAE1. It 
was assumend that all expressed AE1 proteins would have a similar effect on 
the oocyte buffering capacity, which was not measured. 
 
4.4.4  Rubidium uptake experiments 
86Rb
+ was used as a measure of K
+ flux, to demonstrate K
+ permeability of the 
oocyte membrane.  Rb
+ uptake experiments were performed initially at 0
oC, 
as previous work had demonstrated an AE1-mediated cation leak that was 
maximum  at  0
oC  in  HSt-associated  AE1  mutants  [243].    The  extracellular 
medium  contained  ouabain  and  bumetanide  to  inhibit  any  Rb  movement 
through the Na
+/K
+-ATPase and the Na
+-K
+-2Cl
- co-transporter, respectively.  
Rb
+ uptake (Figure 4.4.4 A) was low in both non-injected and wildtype kAE1-
expressing oocytes.  In contrast, there was significant Rb
+ uptake in all the 
dRTA-associated  kAE1-expressing  oocytes.    A  large  Rb
+  uptake  was 
recorded  with  one  mutant,  G701D.  Compared  with  measurements done at 
0°C, Rb
+ uptake measured at room temperature (22
oC) showed similar values 
for mutant kAE1-expressing oocytes; however, basal uptake (NI oocytes or 
expressing  wt  kAE1)  is  significantly  raised  by  the  increased  temperature 
(Figure 4.4.4 B), obscuring any increase in Rb
+ uptake induced by expression 
of the R589H, G609R and S613F mutants. 
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Figure 4-1 A representative western-blot of an oocyte plasma membrane 
probed with anti-AE1 antibodies (BRIC170). 
From left to right: a) non-injected; b) wildtype kAE1+GPA; c) R589H+GPA; d) 
G609D+GPA;  e)  S613F+GPA;  and  f)  G701D+GPA  expressing  oocytes. 
Representative of 3 experiments.   123
 
Figure 4-2 Composite figure of anion transport experiments 
(A) shows 
36Cl
- uptake at 22
oC, into non-injected, wildtype kAE1- and mutant 
kAE1-expressing oocytes at day 3 post-injection.  All injected oocytes are co-
expressing GPA.  Data are means+/-s.e.m of 8 experiments. (B) and (C) show 
representative plots of intracellular pH vs. time of an oocyte acidified with CO2 
in  the  presence  and  then  absence  of  extracellular  Cl
-.  The  oocytes  are 
expressing wildtype kAE1 and the G609R mutation, respectively with GPA. 
(D) illustrates the pHi recovery rate after an acid load of control oocytes (NI) or 
oocytes  co-expressing  GPA  with  wildtype  or  the  different  kAE1  point 
mutations.  Data are means of 9 oocytes +/- s.e.m.   124
4.4.5  Pharmacological blockade 
The kAE1 mutants tested are known to have stilbene-sensitive anion transport 
a finding supported by our observation of SITS (4-acetamido-4’isothiocyanato-
stilbene-2,2’disulfonic acid)-sensitive Cl
- influx in all mutants (data not shown).  
The Rb
+ uptake of oocytes expressing mutant kAE1 was sensitive to 0.1 mM 
SITS (Figure 4-3 C: a reduction in Rb
+ uptake of 85% for R589H and S613F, 
99% for G609R, and 74% for G701D).  Figure 4-3 D is a dose-response curve 
of SITS inhibition of Rb
+ uptake in oocytes expressing the G701D mutation 
with GPA.  It should be noted that the inhibition seen in the inhibition curve 
data at equivalent SITS concentration (0.1mM) is less than that seen in the 
preceding experiment (performed with a different batch of oocytes), stilbene 
inhibition  of  the  G701D  mutant  is  quite  variable,  possibly  reflecting 
conformational differences with the wt protein. 
 
4.4.6  Intracellular cations 
Na
+  and  K
+  content  of  oocytes  expressing  wildtype  or  mutant  kAE1  was 
measured after 3 days of incubation in control medium (MBS), or in medium in 
which  Na
+  had  been  substituted  with  the  impermeant  cation  N-Methyl-D-
Glucamine  (NMDG).    Both  media  contained  ouabain  and  bumetanide.  
Intracellular cation measurements (Figure 4-4) showed reversal of the normal 
ratio of intracellular Na
+ to K
+ content in mutant-expressing oocytes compared 
with controls.  All dRTA-associated mutants showed reversal of this ratio, with 
the  largest  change  occurring  in G701D-expressing oocytes, the amount of 
reversal seen correlating with the Rb
+ influx results.  There was no fall in 
intracellular K
+ when extracellular Na
+ was replaced with NMDG (Table 4-1). 
The cation flux was large enough to produce a reversal of intracellular cation 
contents  even  after  3  days  incubation  in  MBS  without  ouabain  and 
bumetanide (oocytes co-expressing GPA and; wt kAE1: Na=43.4 ± 3, K=80.4 
± 5; R589H: Na=68.3 ± 5.7 K=52.9 ± 1.1; G701D: Na=104.9 ± 2.6 K=2.6 ± 1.9 
μmol/g.d.w.).   125
 
Table 4-1 Intracellular cation content after incubation in NMDG 
 
Mean Na
+ ± s.e.m. 
(μmol/g dry wt.) 
Mean K
+ ± s.e.m. 
(μmol/g dry wt.) 
 
with ext. Na
+  with NMDG  with  ext. 
Na
+ 
with NMDG 
N.I.  71.0±11.8  63.0±3.8  77.3±7.1  97.2±2.3 
wt 
kAE1 
74.8±4.8  65.2±0.6  75.0±1.1  95.5±0.9 
R589H  151.7±4.9 
#  67.6±4.4  9.6±7.6 
#  84.2±4.3 
S613F  127.1±8.7 
#  63.2±5.3  38.6±2.3 
#  90.1±3.4 
G701D  175.7±1.9 
#  74.2±10.2  U  94.0±13.9 
 
The intracellular cation measurements for non-injected, wildtype (wt) and 
mutant kAE1-expressing oocytes after 3 days incubation in MBS with either 
Na
+ or NMDG.  Both media contained 0.5 mM ouabain and 5 µM bumetanide.  
Note the lack of K
+ loss seen in intracellular cation content of oocytes 
incubated in NMDG medium compared with oocytes incubated in Na
+ 
containing MBS.  (U = undetectable).  Data are means ± s.e.m. of 15 
experiments. In each column cation content measurements were compared 
# 
indicates a significant statistical difference (p<0.05) between the relevant 
cation measurements compared to non-injected oocytes.   126
4.4.7  Oocyte electrophysiology 
The  cation  leak  induced  by  the  erythroid  AE1  mutations  has  been 
characterised  definitively  as  a  non-selective  cation  conductance  [284].  
Therefore, we investigated the conductive properties of the dRTA-associated 
kAE1 mutant G701D, as it exhibited the highest cation permeability. As shown 
in  Figure  4-5  A,  co-expression  of  G701D  with  GPA  increased  oocyte 
membrane  conductance  compared  with  non-injected  oocytes,  or  those 
expressing wildtype kAE1 with GPA.  The resting membrane potential was 
depolarised by 7 mV in oocytes expressing G701D compared with wildtype 
kAE1 (Table 4-2).  The conductance in oocytes expressing G701D and GPA 
was sensitive to SITS (Figure 4-5 B). 
Next,  extracellular  NaCl  was  replaced  with  KCl,  Na
+  with  the  impermeant 
cation  NMDG,  and  extracellular  Cl
-  with  the  impermeant  anion  gluconate 
(Table  4-2).    These  manipulations  showed  that  the  resting  membrane 
potential  of  non-injected  oocytes,  or  oocytes  expressing  wildtype  kAE1,  is 
largely  sensitive  to  changes  in  extracellular  K
+  concentration  (high 
extracellular  K
+  caused  a  42  mV  depolarisation)  and  to  a  lesser  extent 
extracellular Cl
- (Cl
- removal caused a 4 mV depolarisation); but in G701D-
expressing oocytes it is sensitive to both Na
+ and K
+ concentrations.  In these 
oocytes,  resting  membrane  potential  was  hyperpolarised  (by  7  mV)  in  the 
absence  of  extracellular  Na
+,  but  it  was  depolarised  (by  24mV)  in  the 
presence of high extracellular K
+. 
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Table 4-2 Measurements of resting membrane potential as a function of 
the ionic composition of the extracellular medium 
 
Em (mV) 
Medium 
NI  kAE1 wildtype  G701D 
NaCl/KCl  -50.6±3.3  -54.6±2.5  -47.6±2.5 
* 
NMDGCl  -53.8±2.9  -52.9±0.9  -54.3±3.6 
# 
KCl  -7.9±0.9 
#  -13.1±0.5 
#  -23.3±1.7 
#& 
Gluconate  -40.8±3.0 
#  -49.7±0.8 
#  -44.4±2.0
&   
 
Resting  membrane  potentials  (Em  in  mV)  of  oocytes  expressing  either 
wildtype  kAE1  or  G701D  with  GPA  incubated  in  different  media.  Regular 
MBS  with  85mM  NaCl  and  1  mM  KCl  (NaCl/KCl),  no  extracellular  NaCl 
substituted with NMDGCl and 1 mM KCl (NMDGCl), no extracellular NaCl and 
85 mM KCl (KCl) and MBS, where NaCl
 and KCl were substituted with Na 
gluconate and K gluconate. 
Data are means±sem of 5 oocytes.  In each column, Em mean values were 
compared; 
#indicates a significant statistical difference (p<0.05) between Em 
of indicated oocytes, compared to equivalent oocytes in NaCl/KCl medium; 
*indicates a significant statistical difference (p<0.05) between Em of oocytes 
expressing wildtype kAE1 and G701D mutation in regular MBS; 
&indicates a 
significant statistical difference (p<0.05) between Em
 in KCl or in gluconate for 
G701D compared to wtkAE1 expressing oocytes. 
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Figure 4-3 Composite figure of 
86Rb
+ uptake experiments. 
Representative  experiment  of  ouabain-  and  bumetanide-resistant 
86Rb
+ 
uptake is given at 0°C (A) and at 22°C (B) into non-injected, wildtype kAE1- 
and  mutant  kAE1-expressing  oocytes  3  days  after  injection.    All  injected 
oocytes are co-expressing GPA.  Data are means +/- s.e.m. of 8 oocytes. (C) 
Shows a representative experiment of ouabain- and bumetanide-resistant Rb
+ 
uptake at 0
oC into non-injected, wildtype kAE1- and mutant kAE1-expressing 
oocytes without (white bars) and with 10
-4M SITS (black bars).  All injected 
oocytes are co-expressing GPA and measurements were done 3 days after 
injection.  Data are means +/- s.e.m. of 8 oocytes. (D) Dose-response curve of 
SITS-inhibition of ouabain and bumetanide resistant Rb
+ uptake induced by 
G701D and GPA expression.  The Rb
+ uptake measured in control oocytes 
(NI) was subtracted and data are means +/- s.e.m. of 8 oocytes.   129
 
 
Figure 4-4 Intracellular cation contents. 
Na
+ (white bars) and K
+ (black bars) content was measured in oocytes that 
were either non-injected or expressing wildtype or mutant kAE1, and GPA, 3 
days  after  incubation  in  MBS  at  19
oC,  with  0.5  mM  ouabain  and  5  µM 
bumetanide.  Data expressed in µmol per g of dry weight (dry wt.) are means 
+/- s.e.m. of 15 oocytes. 
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Figure 4-5 Composite figure of electrophysiology experiments. 
A) Current-voltage (I/V) curves of oocytes non-injected (black circles) or co-
expressing  GPA  and  wildtype  kAE1  (black  diamonds)  or  G701D  mutation 
(white circles).  The basal currents in non-injected oocytes are superimposed 
on the currents recorded in oocytes co-expressing GPA and wildtype kAE1. 
Currents were recorded at 500 ms of clamped potential in regular MBS.  Data 
are means +/- s.e.m. of 28 oocytes (G701D mutant) or 15 oocytes (wildtype 
kAE1) or 8 oocytes (NI). B) Current-voltage curves of oocytes co-expressing 
GPA and G701D mutation in the absence (white triangles) or in the presence 
of  10
-4  M  SITS  (black  triangles).    Data  are  means  +/-  s.e.m.  of  5  paired 
oocytes and differences (below -40 mV and above 40 mV) were statistically 
significant  with  p=0.05  (t-test).  C)  Inset:  current  recordings  of  wildtype 
kAE1+GPA and G701D+GPA expressing oocytes (left and right, respectively). 
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4.4.8  Oocytes co-expressing AE1 and wildtype AE1 
To investigate the effect of AE1 heterodimer formation on the cation leak 
property of the G701D mutant, Rb
+ uptake experiments were done in oocytes 
co-expressing G701D with wildtype kAE1, but without GPA.  Rb
+ uptake was 
57% of that observed with the same amount of G701D co-expressed with 
GPA (Figure 4-6).  This is consistent with a ‘rescue’ effect of wildtype kAE1 on 
G701D (by forming heterodimers with G701D kAE1) and successful trafficking 
to the plasma membrane.  Rb
+ uptake (though reduced) indicates that surface 
membrane-expressed heterodimers of G701D (homodimers are not surface 
expressed in the absence of GPA) and wildtype kAE1 still possess a cation 
transport property. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   132
 
Figure 4-6 Further 
86Rb
+ uptake in G701D expressing oocytes with and 
without GPA. 
86Rb
+ uptake was measured in non-injected (NI) oocytes and oocytes 
expressing wildtype kAE1, G701D kAE1 alone, or co-expressing GPA and 
G701D or wildtype and G701D kAE1. A similar amount of wildtype or mutant 
kAE1 cRNA was injected (6 ng).  For co-injection, 6 ng of G701D was injected 
with either 2.5 ng of GPA or 6 ng of wildtype kAE1.  Data are means of 8 
oocytes +/- s.e.m. 
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4.5  Conclusions 
We have found that the four dRTA-associated kAE1 mutants we investigated 
are capable of inducing a monovalent cation leak when expressed in Xenopus 
oocytes, which is not present in oocytes expressing wildtype kAE1.  The leak 
of Na
+ and K
+ in mutant-expressing oocytes depends on the electrochemical 
gradients for Na
+ and K
+, with Na
+ influx counterbalancing K
+ efflux.  
Electrophysiological experiments in G701D-expressing oocytes demonstrated 
an  electrogenic  leak  sensitive  to  variations  in  extracellular  Na
+  and  K
+ 
concentrations, indicating the presence of a non-selective cation conductance 
property.  Previously, it has been shown that four point mutations in erythroid 
AE1 converted the anion exchanger to a non-selective cation conductance 
(the alternative explanation of a coincidentally activated endogenous oocyte 
transporter having been discounted [297]).   
We have now shown that four other point mutations associated with a renal 
phenotype also have a cation leak property; although in contrast to the four 
erythroid AE1 mutants studied previously, the renal AE1 mutants retain 
normal or near normal, anion exchange activity. This is the first time that 
these transport properties have been shown to co-exist in human AE1. 
4.5.1  Structure function implications 
 
The four dRTA-associated mutations all occur on highly conserved sequences 
in the primary structure of kAE1: in the putative transmembrane (TM) helices 
6 (R589H), 7 (G609R and S613F) and 9, or the region adjacent to it (G701D) 
[152].  These point mutations are not essential for anion exchange function, 
which is preserved.  This is in accordance with previous observations showing 
that the TM segments 6 and 7 seem to be unnecessary for anion transport, 
since non-complementary fragments of AE1 lacking this segment could still 
induce anion transport when co-expressed in Xenopus oocytes [298].  
However, G701D lies in a region critical for anion exchange.  This region is 
also  the  least  well  defined  topologically;  it  is  thought  to  be  involved  in  a 
transport-related  conformational  change  (TCC)  and  to  be  structurally   134
labile[295].  Certain residues appear to be important for anion transport in this 
region.  E681 is thought to act as the proton binding site in H
+ and SO4
2- 
symport  [158]  -  even  conservative  site-directed  mutagenesis  at  this  site 
(E681D) abolishes anion exchange [161].  Another crucial amino acid site for 
anion exchange appears to be H734 [167].  It appears to interact with the 
negative charge of the E681 residue [161], apparently because of their close 
physical proximity [295].  The erythroid mutants L687P, S731P, and H734R 
are closely associated with these sites and they have been shown to abolish 
anion exchange [243, 297].  Indeed, these mutations should be expected to 
disrupt the spatial position or charge of the 734 and 681 residues.   
G701D  and  the  erythroid  D705Y  are  also  close  to  E681  in  the  primary 
sequence and both mutations mediate large cation leaks.  The intact anion 
exchange  activity  of  the  G701D  mutant  suggests  that  this  residue  is  not 
essential for anion exchange function, perhaps because it is situated further 
from the E681 residue in three-dimensional space. 
If  TM  9  constitutes  an  a-helix,  as  is  commonly  supposed,  and  we  further 
suppose that it extends in an N-terminal direction as far as the proline residue 
at position 692. If we construct a helical wheel model of the cytoplasmic end 
of this proposed structure, from P692 to L708 (which is predicted to lie in the 
lipid bilayer [152]) we can see that D705 and G701, along with K698 and 
R694 are closely associated on one narrow, hydrophilic face which has a net 
positive  charge  (see  figure  4-7),  which  would  tend  to  align  toward  the 
cytoplasm. The G701D mutation adds a negative charge, negating the net 
charge of this face, implying that the net charge on this face is important for 
the  anion  selectivity  of  the  exchange  mechanism.  The  D705Y  mutation 
removes  a  negative  charge  from  this face, rendering the net charge more 
positive,  but  also  adds  a  hydrophobic  residue,  and  which  could  alter  the 
rotational alignment of the helix. If the TCC of AE1 is similar to Tanford’s helix 
rotational model [299], as has been suggested [295], then such a mal-rotation 
of a helix closely related to crucial binding sites (such as E681) could abolish 
anion transport function by altering how they are revealed in the TCC. Site 
directed mutagenesis experiments to insert charged or hydrophobic residues   135
at these positions or K698 or R694 would be required to provide evidence for 
this model. 
 
There is growing evidence for the existence of ion channel activity in what 
until recently were considered to be exclusive symporters or antiporters [300], 
and that these transporters and ion channels can have structural similarities 
[301].    Indeed,  trout  AE1  may  act  as  an  ion  channel  [275,  276],  which 
illustrates how closely related the AE1 exchanger is to a channel.  Therefore, 
point mutations that directly alter the conformation of the region involved in 
AE1’s  TCC  can  elicit  cation  transport  and  (with  at  least  one  exception  - 
G701D) abolish anion transport; whereas mutations distant from this region 
(R589H,  G609R  and  S613F)  induce  a  small  cation  leak  without  affecting 
anion transport.  These mutants are thought to be misfolded [201] and it is 
likely that such conformational changes are sufficient to provoke a cation leak, 
as AE1’s structure is already so closely related to that of an ion channel (cf. 
trout AE1). 
Conformational change in the region of the TCC provides an explanation for 
the partial inhibition of the cation permeability observed in the G701D mutant 
by SITS, which also occurs in the erythroid mutants (L687P, D705Y, S731P 
and H734R) [297].  SITS binding and inhibition of AE1 depends on its 
conformation, indeed, SITS affinity chromatography is used to detect mis-
folding of AE1 mutants [302]. 
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Figure 4-7 Helical wheel model of the hypothetical α-helix extending 
from the bottom of TM9 to residue 692. 
The helical wheel model represents the helix imagined from above, with 
amino acid residues represented by circles showing their position on the face 
of the helix. Plus and minus signs denote charged amino acid residues, 
concentric circles denote hydrophobic residues. The numbers indicate the 
position number of the residue in the secondary structure. 
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4.5.2  Cation leak behaviour and the erythrocyte in AE1-associated 
dRTA 
Prior to this work, cation leaky AE1 has been associated solely with red cell 
pathology; the cation leak described by Bruce et al in the mutants L687P, 
D705Y, S731P, H734R and R760Q [243] was postulated to be responsible for 
the dysmorphic red cells seen in patients with these mutations.  Here we have 
described  four  other  point  mutations  of  AE1  (R589H,  S613F,  G609R  and 
G701D) inducing a cation leak, which are associated with dRTA. There have 
been  no  reports  of  erythrocyte  abnormalities  or  evidence  of  haemolytic 
anemia  for  these  dRTA-associated  AE1  mutations  except,  for  G701D 
homozygotes  [63,  180].  It may be that the cation leak is compensated in 
heterozygote erythrocytes and, therefore, causes no red cell dysmorphism; 
whereas compensation is overcome in homozygotes due to a larger cation 
leak mediated by the two mutant alleles. Moreover, there is a recent report of 
haemolytic anemia and erythrocyte abnormalities in patients with G701D (and 
other SE Asian AE1 mutations) and dRTA, which appears to be related to the 
degree  of  acidaemia  [303];  the  red  cell  abnormalities  resolve  with  alkali 
treatment, and the lack of acidaemia in G701D heterozygotes could explain 
their normal red cell phenotype. 
 
4.5.3  Cation leaky AE1 in the α-intercalated cell in dRTA 
In contrast to red cells in which GPA acts as a chaperonin to address dRTA-
associated AE1 mutations to the plasma membrane, the α-intercalated cell (α-
IC) does not express GPA, and kAE1 is believed to be transported to the cell 
surface as an oligomer [188].  We simulated this in the non-polarised oocyte 
by co-expressing G701D kAE1 with wildtype kAE1 (without GPA) by using 
equal amounts of mRNA.  This resulted in a smaller cation leak, 
approximately half the magnitude seen in the paired experiment using G701D 
and GPA (Figure 4-6), which is consistent with cation leaky heterodimerised 
G701D and wildtype kAE1 at the cell membrane - non-leaky homodimerised   138
wildtype kAE1 at the cell surface and homodimerised G701D retained 
intracellularly.  However, the cation transport property of G701D is still present 
when heterodimerised, suggesting that functional cation leaky kAE1 may be 
present in the α-IC membrane of G701D heterozygotes. 
 
4.5.4  Hypokalaemia 
Is  it  possible  that  the  mutations  described  have  any  pathophysiological 
significance  for  the  α-IC  cell,  perhaps  mediating  potassium  efflux  into  the 
urine?    The  AD  mutants  do  show  a  cation  leak  when  intracellular  cation 
contents  are  measured  at  19°C.    Although  largely  retained  intracellularly, 
R589H, S613F and G609R have all been observed (in varying amounts) at 
the  apical  membrane  in  polarised  cell  models  [188,  195,  199],  but  we 
acknowledge the likely differences between over-expressing cell models and 
native α-IC cells.  Moreover, the small amount of AE1 expressed at the apical 
membrane  in  these  cells  models  (especially  R589H  and  S613F),  and  the 
relatively small cation leak seen with S613F and G609R (and the modest leak 
seen  with  R589H)  make  a  significant  pathophysiological  role  for  these 
mutants in potassium wasting in dRTA less likely.  Hypokalaemia is also a 
more variable clinical in patients with European AE1-associated dRTA. 
The G701D mutation is perhaps more likely to have some pathophysiological 
significance, since its cation leak is much higher than that the AD mutants.  If 
G701D were mistargetted to the apical membrane of α-IC, a potassium leak 
into urine could occur; if it were expressed on the basolateral membrane only, 
it may cause enough membrane depolarization to activate apical maxi-K 
channels [304] and facilitate flow-dependent potassium secretion [305].   
 
4.5.5  Disease distribution 
In  Southeast  Asian  AE1-associated  dRTA,  including  G701D,  severe 
hypokalaemia  is  more  severe  than  European  AE1-associated  dRTA  [63].  
G701D has a gene frequency of 0.7% in Northeastern Thailand [192], where 
dRTA is endemic [306], and hypokalaemia with hypokalaemic paralysis and   139
sudden  unexplained  nocturnal  death  (SUND)  are  common  [307-309]. 
Moreover, relatives and survivors of SUND episodes in N.E.Thailand have 
been shown to have high red cell Na and abnormal red cell Na,K-ATPase 
activity [310], a finding consistent with cation leaky red cells [258]. 
 
However, whether the red cell abnormalities seen in the Southeast Asian AE1 
mutations are associated with cation leak activity or if hypokalaemic disease 
in Northeastern Thailand is linked to G701D heterozygosity are questions that 
need addressing in future studies. 
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5.  The Cation Leak Activity of Other Southeast dRTA 
Associated AE1 mutants 
5.1  Introduction 
There  are  2  phenotypes  of  AE1-associated  dRTA;  the  rare  European 
autosomal  dominant  (AD)  dRTA,  where  one  mutant  allele  will  generate  a 
mutant protein that is able to ‘capture’ a wild type protein in the cytosol when 
heterodimerised with it, when expressed in a polarised cell model [199]. The 
other is the commoner Southeast Asian autosomal recessive (AR) dRTA, in 
which  one  wild  type  allele  is  capable  of  ‘rescuing’  a  mutant  protein  when 
heterodimerised  with  it,  resulting  in  cell  membrane  expression  of  the 
heterodimer [199, 203]. 
 
In the previous chapter, I have shown that when expressed in Xenopus laevis 
oocytes,  dRTA  associated  AE1  mutants  are  ‘cation  leaky’.  This  effect  is 
demonstrable in the 3 European AD mutants that we characterised (R589H, 
G609R  and  S613F),  but  much  greater  in  G701D,  the  only  SE  Asian  AR 
mutant that I examined [311]. 
 
The  magnitude  of  the  cation  leak  property  was  so  much  larger  in  the  AR 
G701D mutant than the AD European mutants, and the G701D mutation is so 
much more common in southeast Asia (it has a gene frequency of 0.7% in 
Northeast  Thailand  [192])  than  the  AD  mutants  are  in  Europe  (sporadic 
kindreds only). On the basis of these observations, I hypothesised that the 
G701D mutation had undergone positive selection pressure on the basis of its 
large cation leak property.  
 
There  are  other  AE1  mutations,  which  also  cause  AR dRTA in  Southeast 
Asia,  and  these  too,  appear  to  be  quite  common.  Amongst  these  are  the 
mutations S773P, ΔV850 and A858D, which are found in Northeast Thailand 
and Papua New Guinea [63, 180, 202], both malarious regions. I decided to   141
characterise  these  three  other  described  SE  Asian mutants, alongside the 
G701D mutant, using the Xenopus laevis expression system.  
 
My results show that these 3 other AE1 mutations also induce a large cation 
leak (of the same order of magnitude as G701D) in these still functional anion 
exchangers. The effect of these mutations on the anion exchange structure of 
the protein is then discussed as the consequences of this cation leak in cells 
expressing AE1. 
 
5.2  Aims 
 
1)  To express the selected kAE1 mutants (G701D, S773P, ΔV850 and 
A858D) in Xenopus oocytes. 
 
2)  To characterise the anion transport characteristics of the selected 
kAE1 mutants by observation of 
36Cl
- uptake into oocytes and by 
measurement of intra-oocyte pH during CO2 acidification with and 
without chloride containing extracellular medium. 
 
3)  To demonstrate and quantify any cation leak activity by lithium influx 
and intracellular cation measurements in these mutants and compare 
these directly to the leak activity in G701D. 
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5.3  Methods and materials 
5.3.1  Xenopus oocyte harvesting 
Xenopus laevis oocytes were harvested as detailed in the general methods 
chapter. 
5.3.2  Oocyte injection 
Collected oocytes were washed and defolliculated as detailed in the general 
methods chapter. Stage V-VI oocytes were then injected with a mixture of 10 
ng of kAE1 and 2.5 ng GPA cRNA, and were maintained in 18
oC MBS for 
three days before starting the experiments. 
 
5.3.3  Plasmid and DNA construction 
The pSP65erythroid human AE1 (hAE1) plasmid was used to construct the 
kidney AE1 (kAE1), deleting the 65 N-terminal amino acids, as described in 
the General Methods chapter. For point mutations, primers were used with the 
following codon substitutions:  
S773P: TCC/CCC, ∆V850: GTG was deleted, A858D: GCC/GAC. 
Primers  were  purchased  from  Eurogentec  (Seraing,  Belgium);  polymerase 
chain reactions (PCRs) were performed using a Biometra “UNO Thermoblock” 
thermocycler  (Göttingen,  Germany).    Sequences  generated  by  PCR  were 
sequenced  in  their  entirety  to  ensure  that  no  polymerase  errors  were 
introduced (Gexbyweb, Meylan, France). 
HindIII linearised pSP65kAE1 wildtype and mutant plasmids were transcribed 
using SP6 polymerase (Ambion transcription kit).  HindIII linearised BSXG-
GPA  plasmid  was  transcribed  using  T7  RNA  polymerase  (Ambion 
transcription  kit).    RNA  concentrations  were  determined  on  a 
formamide/formaldehyde  agarose  gel  in  MOPS  (3-[N-
Morpholino]propanesulphonic acid) buffer. 
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5.3.4  Western blot 
Oocyte membranes were prepared by homogenization of 20 oocytes (control 
or injected) in cooled Tris-HCl buffer, 20 mM, pH 7.4, 250 mM sucrose and 5 
mM protease inhibitor, Pefablock (Roche, Paris, France), as described in the 
general methods chapter.  The presence of kAE1 was detected by antibody 
Bric 170 directed against the C-terminus of kAE1.  The secondary antibody 
was anti-mouse IgG-peroxidase, which was detected by chemiluminescence 
using a Fujifilm Las-3000 Luminescence image analyser. 
 
5.3.5  Lithium influx 
Lithium  influx  measurements  were  performed  by  atomic  absorption 
spectrometry: eight oocytes were incubated at 19
oC in Li-MBS (NaCl and KCl 
replaced by LiNO3 and KNO3 respectively, and HEPES-NaOH replaced by 
Tris-HNO3 15mM, pH 7.4). It was decided to use NO3
- instead of Cl
- to avoid 
any cation movements coupled with Cl
-. However, experiments done in LiCl 
containing medium gave similar results to those in LiNO3 containing medium. 
After 2 h incubation (uptake is linear up to 6 h), the oocytes were rapidly 
washed  3  times  in  ice-cold  milliQ  water  (plus  ouabain,  5.10
-4  M)  and 
transferred  individually  into  microcentrifuge  tubes.  Extracellular  water  was 
quickly  removed  and  oocytes  were  dried at 95
oC for 3 minutes in a block 
heater, then oocytes were incubated for 10 minutes at 95
oC in 50 μl of 0.1M 
NaOH  and  finally  250  μl  of  milliQ  water  was  added  to  each  oocyte. 
Intracellular lithium concentration was determined by graphite furnace atomic 
absorption spectrometry (Perkin Elmer AAS 3110). 
 
5.3.6  Intracellular cation measurements 
Injected oocytes were incubated in MBS containing ouabain (0.5 mM) and 
bumetanide (5 μM) at 19
oC for 3 days.  Na
+ and K
+ content of oocytes was 
measured by flame spectrophotometry, as previously described in the general 
methods section.   144
In some experiments, the Na
+ in the MBS was substituted with NMDG (N-
methyl-D glucamine).  The final NMDG MBS medium was (in mM): NMDGCl: 
85; KCl: 1; KHCO3: 2.4; MgSO4: 0.82; Ca (NO3) 2: 0.33; CaCl2: 0.41; HEPES: 
10; KOH: 4.5; pH: 7.4. Cation contents were expressed as µmol per gram of 
dry weight (µmol/g d. wt.). 
 
5.3.7  Intracellular pH measurements 
Oocyte  intracellular  pH  was  measured  using  selective  microelectrodes,  as 
described in the general methods chapter.  The ability of wt and mutant kAE1 
to regulate intracellular pH was assessed by measuring intracellular pH of 
oocytes  adapted  in  MBS  without  HCO3
-,  then  incubated  in  the  following 
medium:  NaCl  63.4  mM;  KCl  1  mM;  NaHCO3
-  24  mM;  MgSO4  0.82  mM; 
Ca(NO3)2 0.33 mM; CaCl2 0.41 mM; HEPES/NaOH 5 mM pH 7.35; CO2 5%, 
O2  95%  and  then  bathed  in  MBS  without  Cl
-  (Na-gluconate  63.4  mM;  K-
gluconate  1  mM;  NaHCO3
  24  mM;  MgSO4  0.82  mM;  Ca(NO3)2  0.74  mM 
HEPES/NaOH 5 mM pH 7.35, CO2 5%, O2 95%).  Results are given as ΔpHi 
per min ± s.e. ΔpHi was measured when acidified oocytes were exposed to 
Cl
- free medium and corresponds to the initial slope of the alkalinisation. 
 
5.3.8  Chemicals 
Unless otherwise stated, all chemicals were purchased from Sigma (St Louis, 
MO).  Agarose was purchased from GIBCO BRL (Life technologies, 
Gaithersburg, MD).  Minipreps of DNA were done with a Macherey Nagel, 
(Düren, Germany).  Anti-AE1 antibodies BRIC170 and BSXG-GPA plasmid 
were a kind gift of Dr. Ashley Toye (University of Bristol, UK).   145
5.4  Results 
5.4.1  Western Blot 
Mutant  kAE1  constructs  were  co-expressed  in  oocytes  with  the  AE1 
chaperonin  glycophorin  A  (GPA),  because  without  GPA  there  is  absent 
membrane  expression  of  G701D-  kAE1  in  oocytes[180].  Oocyte  plasma 
membrane  expression  of  wildtype  and  mutant  kAE1  was  confirmed  by 
detecting bands of the appropriate molecular mass on western blotting (Figure 
5-1). The western blots were done at the same time as the functional studies. 
 
5.4.2  Anion Transport; 
5.4.2.1  Intracellular pH recordings 
To confirm that Cl
-/HCO3
- exchange activity occurred in oocytes expressing 
wildtype or mutant AE1, we measured the change in intracellular pH (pHi) 
following acute exposure to a solution containing
 CO2/HCO3
- (in the presence 
of extracellular Cl
-), which caused an initial and rapid fall in pHi that stabilised 
as  CO2  reached  equilibrium  across  the  cell  membrane.    On  replacing 
extracellular  Cl
-  with  gluconate,  pHi  promptly  rose  in  the  presence  of 
functional anion exchange activity, due to HCO3
- extrusion being dependent 
on exchange for intracellular Cl
-. Oocytes expressing wildtype kAE1 showed a 
fall in intracellular pHi in Cl
--containing medium that recovered on replacing 
extracellular Cl
- with the impermeant anion gluconate (Figure 5-2 A).  This 
pattern was seen with all 4 mutants, indicating functional plasma membrane 
expression  of  Cl
-/HCO3
-  exchange.    To  compare  the  Cl
-/HCO3
-  exchange 
activity of wildtype with mutant kAE1, the initial rate of pHi recovery after acid 
loading  was  estimated  as  ΔpHi/minute  (Figure  5-2  B).  There  was  no 
significant difference between wtkAE1 and the mutants. It was assumend that 
all expressed AE1 proteins would have a similar effect on the oocyte buffering 
capacity, which was not measured. 
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Figure 5-1 A representative western blot of an oocyte membrane probed 
with anti-AE1 antibodies (BRIC170). 
From left to right: a) non-injected; b) wild-type kAE1+GPA; c) G701D+GPA; d) 
S773P+GPA;  e)  Δ850+GPA;  and  f)  A858D+GPA  expressing  oocytes. 
Representative of 3 experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
   147
 
Figure 5-2 Composite figure of intracellular pH data. 
A) pHi recovery rate after an acid load of control oocytes (NI) or oocytes co-
expressing GPA with wild-type or the different kAE1 point mutations.  Data 
are means of 4 oocytes +/- s.e.m.  
B)  plots of intracellular pH vs. time of an oocyte acidified with CO2 in the 
presence and then absence of extracellular Cl
-.  The oocytes are expressing 
wt kAE1 and the Δ850 mutation respectively with GPA.    148
5.4.3  Cation Transport; 
 
5.4.3.1  Lithium influx 
 
We  measured  lithium  influx  into  the  oocytes,  using  Li  as  a  surrogate 
monovalent cation for sodium. The extracellular medium contained ouabain 
and bumetanide to inhibit any cation movement through the Na
+/K
+-ATPase 
and the Na
+-K
+-2Cl
- co-transporter, respectively.   
Li  influx  (Figure  5-3)  was  low  in  both  non-injected  and  wildtype  kAE1-
expressing  oocytes,  in  contrast  to  the  influx  seen  in  all  4  of  the  tested 
mutants, who had similar Li influx to G701D. 
 
5.4.3.2  Intracellular cation contents 
Na
+  and  K
+  content  of  oocytes  expressing  wildtype  or  mutant  kAE1  was 
measured after 3 days of incubation in control medium (MBS), or in medium in 
which  Na
+  had  been  substituted  with  the  impermeant  cation  N-Methyl-D-
Glucamine  (NMDG).    Both  media  contained  ouabain  and  bumetanide.  
Intracellular  cation  measurements  (Figure  5-4  A)  showed  reversal  of  the 
normal ratio of intracellular Na
+ to K
+ content in mutant-expressing oocytes 
compared with controls. All dRTA-associated mutants showed reversal of this 
ratio, with the changes being similar in all of the mutants tested. Moreover the 
Na
+ uptake is balanced by the K
+ loss with a 1/1 stoichiometry. There was no 
fall in intracellular K
+ when extracellular Na
+ was replaced with NMDG (Figure 
5-4 B) indicating that outward flux of K
+ required a countering inward flux of 
Na
+ to maintain electrical
 neutrality. 
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Figure 5-3 Representative experiment of ouabain- and bumetanide-
resistant Li influx. 
Performed at 22°C into non-injected, wild-type kAE1- and mutant kAE1-
expressing oocytes three days after injection. All injected oocytes are co-
expressing GPA.  Data are means +/- s.e.m. of 8 oocytes. 
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Figure 5-4 Composite figure of intracellular cation content 
measurements. 
Na
+ (white bars) and K
+ (black bars) content was measured in oocytes that 
were either non-injected or expressing wild-type or mutant kAE1, and GPA, 
three days after incubation in Na
+ (A) or NMDG (B) containing MBS at 19
oC, 
with 0.5 mM ouabain and 5 µM bumetanide. Data expressed in µmol per g of 
dry weight (dry wt.) are means +/- s.e.m. of 15 oocytes.   151
5.5  Conclusions 
I have demonstrated that in addition to G701D the 3 other AR dRTA AE1 
associated  mutants  (S773P,  ∆V85O  and  A858D)  are  all  functional  anion 
exchangers and all have a ‘cation leak’ that is of similar magnitude. I chose 
these mutants on the basis that they have autosomal recessive phenotypes 
and were all found in Southeast Asia, just like the G701D mutation in which I 
demonstrated  a  large  cation  leak  [311].  S773P  was  found  in  Northeast 
Thailand [202], the same region that G701D is prevalent in [180]. Δ850 was 
found in several families from the malarious Northern coast of Papua New 
Guinea (PNG), and A858D was found in families from both Northern PNG and 
peninsula Malaysia [63] (see Figure 5-5). 
 
5.5.1  Structure function implications 
 
All  of  the  mutants  that  I  have  used  are  on  highly  evolutionary  conserved 
sequences  of  the  primary  structure  of  AE1,  and  are  in  a  region  that  is 
important  for  anion  exchange,  namely  the  transmembrane  portion  of  the 
molecule on the C-terminal side of transmembrane domain 8 [312]. Two of the 
mutants, Δ850 and A858D, are adjacent to the residue K851, which appears 
to be a crucial residue for anion exchange. Pyridoxal phosphate, a known 
inhibitor of AE1 anion exchange, binds to K851 [313] and the AE1 inhibitor 
H2DIDS, which binds to AE1 in a one-one manner, covalently binds both K539 
and  K851,  abolishing anion exchange [150]. Furthermore, the extracellular 
span from residues 852 to 857 bridging the last two putative transmembrane 
domains (TM12 and 13 according to the topology from Zhu et al [312]), as 
well as the adjacent ends of the transmembrane helices form the so-called 
anion  selectivity  filter-a  region  that  constitutes  part  of  the  opening  of  the 
putative ion translocation pore and which is involved in repelling cations [172]. 
It was demonstrated that a large number of cysteine substituted residues in 
this region were sensitive to sulfhydryl inhibition, but only those forming the 
extracellular  region  were  inhibitable  by  a  positively  charged  sulfhydryl 
inhibitor,  although  deeper  residues  were  inhibited  by the uncharged ones.   152
Also, of those residues that were inhibited by the uncharged pCMBS, none of 
the superficial extracellular residues had inhibition competed by Cl
-, indicating 
anion selectivity in this region [172]. This anion selectivity was speculated to 
be due to the positive charge at residue 851, as well as possibly the σ
+ helical 
pole  charge  from  the  last  transmembrane  segment.  This  is  of  interest, 
because  the  deletion  mutation  ΔV850,  in  effect  replaces  the  positively 
charged lysine at position 851 with a non-charged serine, which results in a 
cation leaky but functional AE1. It implies that the precise conformation of the 
extracellular domain, 852 to 857, which is likely to have been altered by the 
deletion  mutation,  is  probably  not  important  for  anion  exchange,  which  is 
preserved in this mutant.    153
 
 
Figure 5-5 Distribution of AE1 mutations in SE Asia. 
The area shown covers 5200 miles from west to east and 3400 miles from 
north to south. Coloured arrows represent individual families with dRTA and 
an AE1 mutation. The PNG family shown with the A858D mutation also had 
members with the Δ850 mutation.   154
The  A858D  mutation replaces a small non-charged alanine residue with a 
negatively charged aspartate-this would disrupt the σ
+ helical pole charge and 
probably  interfere  with  the  positive  charge  at  851.  But  as  for  the  ∆V850 
mutation, this does not prevent the Cl
-/HCO3
- exchange activity. 
 
The substitution mutation S773P lies at the C terminal end of TM 10, which is 
predominantly hydrophobic, with a 4 charged residues at the N-terminal end, 
and has been speculated to form part of the lining of the anion translocation 
pore [314], introducing a proline residue may induce a conformational change 
in this region. 
 
5.5.2  Large cation leak a class effect of SE Asian dRTA-associated 
AE1 
 
I have now described a number of point mutations in AE1 associated with 
dRTA, which cause a cation leak in oocytes expressing these proteins, all of 
which have anion exchange function. Some of these are found in European 
families, have an autosomal dominant phenotype, and when expressed with 
GPA  in  Xenopus  oocytes  have  a  small  to  moderate  cation  leak  (R589H, 
G609R, S613P) [311]. The others are found in Southeast Asian populations, 
have an autosomal recessive phenotype, and when expressed with GPA in 
Xenopus oocytes demonstrate a large cation leak (G701D, S773P, ΔV850, 
A858D). It is tempting to speculate that the European mutations, located in 
TM segments 6-7, cause conformational changes that are more deleterious to 
intracellular  trafficking  than  to  normal  ion  transport,  whilst  the  SE  Asian 
mutations, located on the less well defined, and probably more mobile, C-
terminal region of the molecule cause structural changes that affect trafficking 
to a lesser degree, but induce a larger cation leak. 
 
That these mutations (S773P, ΔV850, A858D) cause large cation leaks, in the 
same order of magnitude as the G701D mutation, is intriguing.  All are found   155
in  malarious  areas  of  Southeast  Asia  (NE  Thailand  and  PNG).  Previous 
authors  have  speculated  on  a  protective  effect  of  these  dRTA-causing 
mutations against malaria [63, 315]. 
 
Could  such  an  effect  be  attributed  to  the  cation  leak  property  that  I  have 
demonstrated? AE1 is present in the intercalated cell and the erythrocyte, the 
isoforms differing only in that the renal isoform lacks the first 65 N-terminal 
amino acids. Thus, the red cell would have cation leaky band 3 at its cell 
membrane,  even  in  heterozygotes.  This  is  reminiscent  of  Southeast  Asian 
Ovalocytosis, a hereditary red cell disorder caused by a 9 amino-acid deletion 
in AE1, in which red cells exhibit an abnormal cold-induced cation leak [258]. 
SAO is known to be protective against cerebral malaria [245, 260], but does 
not appear to protect erythrocytes against invasion by malaria parasites[258, 
264].   
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6.  Discussion 
6.1  Testing Urinary Acidification 
6.1.1  How good is it? 
In Chapter 3 I described my data on urinary acidification following the 
simultaneous administration of furosemide and fludrocortisone. As I implied in 
that chapter, there are some other published data on urinary acidification 
induced by the sequential administration of fludrocortisone then furosemide. 
6.1.1.1  Walter 
Walter et al described the use of fludrocortisone and furosemide to induce 
urinary acidification [287]. In a small study using only 8 healthy subjects, with 
normal measured creatinine clearances were studied on 4 different occasions, 
where they were given a) control, b) ammonium chloride, c) furosemide alone 
(40mg), or d) furosemide with fludrocortisone (1mg) administered the 
preceding evening. Each subject drank at least 500 ml of water between 9 
and 11 am, after that, water intake was ad libitum. Urine volume and pH were 
measured at hourly intervals. They found that in their subjects furosemide with 
fludrocortisone given the evening before achieved a minimum urine pH as low 
as that found after ammonium chloride administration, and all below a pH of 
5.5. This was considerably better than the minimum urinary pHs achieved with 
furosemide alone. (See Figure 6-1)  
6.1.1.2  Viljoen 
In 2007, Viljoen and colleagues in a letter [316] outlined their data looking at 
10 healthy controls and 10 patients with recurrent nephrolithiasis or 
nephrocalcinosis, 3 of whom had a family history of nephrolithiasis. All 
subjects underwent both the short ammonium chloride test and the same 
sequential fludrocortisone and furosemide test that Walter et al used (i.e. 
fludrocortisone given the evening before the test).  
They found that all 10 controls were able to acidify their urine to a pH of less 
than 5.3 with both tests, but whilst all 10 patients could acidify their urine to a 
pH below 5.3 with ammonium chloride, only 3 could do so with sequential   157
fludrocortisone and furosemide. (See figure 6-2) They thus concluded that the 
test had a negative predictive value of 100%, but that its positive predictive 
value was much less. 
6.1.1.3  Audit 
In Appendix one, I detail the data from the Royal Free renal unit’s subsequent 
experience with the simultaneous furosemide and fludrocortisone test, which 
has been very consistent with 47 patients tested and ammonium chloride 
tests confirming the veracity of the furosemide and fludrocortisone test when 
they are done in the same patient. 
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Figure 6-1 Schematic showing minimum pHs of individuals undergoing 
urinary acidification with control/sham, ammonium chloride, furosemide 
alone and furosemide and fludrocortisone. 
Results from the same individual are connected by a line.   159
 
 
Figure 6-2 Paired pre-test and nadir urine pH values. 
Shown for normal controls (closed symbols) and patients with nephrolithiasis 
and/or nephrocalcinosis (open symbols) subjected to NH4Cl (diamonds) and 
fludrocortisone/furosemide (squares) tests. 
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6.1.1.4  Potassium excretion in AE1-associated dRTA 
Unfortunately, the second of the initial questions that I asked at the beginning 
of this thesis; “Can the urinary potassium wasting observed in inherited dRTA 
be attributed, in part, to a property of the mutated transport protein that 
causes it?” is still unanswered. In Chapters 4 and 5, I have demonstrated that 
dRTA-associated AE1 mutations can act as a cation conductance, but that 
finding led to a different route of enquiry, and the role of cation leaky AE1 in 
the hypokalaemia of dRTA remains elusive. In Appendix 2, I have analysed 
subgroups of patients that I examined for the experiments detailed in Chapter 
3, and the results are consistent with the patients with AE1 associated dRTA 
having increased urinary potassium wasting, but the numbers are so low that 
no firm conclusion can be drawn. 
This question could be answered by stable transfection of polarised cell 
models, or better, animal work with a knock-in mouse, or measurements in 
more patients with the appropriate AE1 mutation, too rare in Western Europe 
to be easily achievable. These experiments are unfortunately beyond the 
scope of this thesis. 
 
6.2  Molecular structure/function implications 
6.2.1  Phylogeny 
The SLC4 (Solute Carrier 4) family of transporters, also known as the 
bicarbonate transporter superfamily-includes the products of 10 human 
genes. These encode membrane proteins with very similar hydropathy plots, 
consistent with the presence of 10-14 transmembrane helices. At least 8 
SLC4 proteins transport HCO3
- (or CO2) across the plasma membrane. These 
proteins fall into two functional groups: three Cl-HCO3
 exchangers (AE1-3) 
and five Na coupled HCO3
- transporters (NBCe1, NBCe2, NBCn1, NDCBE 
and NCBE). The two remaining SLC4 members (AE4 and BTR1) do not yet 
have a properly established function, and homologically they fall between the 
other groups. 
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The SLC4 superfamily are ubiquitous amongst vertebrates; however, it is 
possible to trace SLC4-related genes to invertebrates [317, 318], yeast [319] 
and plants [320, 321]. These seem to perform a diverse set of functions, for 
example one plant SLC4 homologue, BOR1, mediates the transport of boron 
[321]. 
 
Guizouarn et al constructed a phylogenetic tree (Figure 6-3) of genes from the 
SLC4 family based on publicly available gene sequences from a number of 
different characterised species to investigate the observation that trout AE1, 
when expressed in Xenopus oocytes, acted spontaneously as an anion (and 
osmolyte) channel [322]. Their data supported the contention that the genes 
coding for the anion exchange proteins and the NBC co-transporters form two 
lineages (or morphophyletic clusters) that probably descended from a 
common ancestral gene.   162
 
 
Figure 6-3 Unrooted phylogenetic tree of Cl/HCO3
- exchangers 
Inclusion of sequences for electrogenic Na
+ bicarbonate cotransporter allows 
a proposal of a scenario for the duplication events within the AE families.    163
The topology of the tree that they constructed suggested that two rounds of 
gene duplication formed the three AE1 genes, the first giving rise to AE1 and 
the putative ancestor gene A”, which then itself was duplicated to form the 
AE2 and AE3 ancestral genes. 
The distances between gene sequences was lowest in the AE2 sub family, 
which suggests that AE2 is under a stronger selection pressure and that it is 
more likely to have retained the ancestral function of the protein. AE2 is 
widely distributed throughout different tissues and is thought to play an 
important role in intracellular pH regulation. The AE1 sub family in contrast 
had a higher variability between species, and those from fish species 
appeared to have an accelerated rate of mutation. 
Of the represented fish species (trout, skate and zebrafish), only trout AE1 
had the spontaneous anion and osmolyte channel property when expressed 
in Xenopus oocytes, although both trout and skate erythrocytes developed 
swelling activated osmolyte loss [323]. This led the authors to speculate that 
the expression of trout AE1 in Xenopus oocytes caused a conformational 
change, which caused it to act as an anion channel that was irreversibly 
‘activated’, in contrast to its state in trout erythrocytes, which was activation 
dependent. This was supported by a number of observations: that trout AE1 
expressed in Xenopus oocytes is nearly DIDS insensitive, whilst in trout 
erythrocytes, AE1 is DIDS sensitive [324] suggesting that there is a 
conformational difference between the two differently expressed proteins, also 
that in trout erythrocytes the anion and osmolyte conductive properties are 
only activated by a decrease in intracellular ionic strength [271, 274].  
 
 
6.2.2  Evidence for wt AE1 acting as a cation transporter  
Is it possible that wtAE1 in humans might also act as an ion (anion or 
monovalent cation) and/or osmolyte conductance? There is evidence to 
suggest that this might be the case. 
In the human red cell, in a number of disease states, organic osmolyte 
permeabilities or Na
+ and K
+ leaks have been observed and inhibited by AE1   164
inhibitors, in malaria [325], Southeast Asian Ovalocytosis [258] and sickle cell 
anemia [326]. Human red cells also exhibit Na
+ and K
+ fluxes when incubated 
in low ionic strength media, and these fluxes are also inhibited by AE1 
inhibitors and are thought to be mediated by AE1 [327]. Similar observations 
have been made about red cells undergoing deformational stress [328]. 
Thus, one could envisage a scenario where AE1 acted as a regulator of red 
cell volume, in addition to its other roles in the erythrocyte, by acting as a 
permeability to two critical determinants of red cell volume, organic osmolytes, 
and monovalent cations, which determine the hydration state of the red cell. 
This permeability would be activated by a conformational change caused by 
plasma membrane deformation (that could occur with red cell swelling in 
times of osmotic stress, or red cell deformation when passing through 
capillaries, for example) and possibly by other mechanisms caused by 
decreasing intracellular osmolality. 
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6.3  Malaria resistance hypothesis 
 
One of the most important causes of child mortality worldwide is malaria due 
to Plasmodium falciparum, which kills over 1 million children a year in Africa 
alone. This death toll is only one aspect of the global burden of malaria. P. 
falciparum is estimated to cause about half a billion episodes of disease each 
year[329] and there are hundreds of millions of cases due to other parasite 
species—Plasmodium vivax, malariae, and ovale. When this enormous 
burden of mortality and morbidity is considered, it is unsurprising that malaria 
acts as a strong evolutionary selection pressure, as first proposed by JBS 
Haldane [330].  
 
 
Several human hereditary diseases have undergone a positive selection by 
Plasmodium species (chiefly P. falciparum), because they confer a survival 
advantage in those infected with malaria; these include mutations in the gene 
for β-globin, HBB, which cause sickle cell disease (HbS) [331, 332], and the 
other HBB gene variants, HbC [333, 334] and HbE [335, 336], alpha [337, 
338]and beta thalassaemia, G-6-PD deficiency [339-343] and variations in the 
chemokine receptor FY, which cause the Duffy negative blood group [344-
346].  Southeast Asian Ovalocytosis (SAO), caused by a deletion mutation in 
the red cell anion exchanger AE1, is another example; it has been shown to 
reduce the incidence and severity of cerebral malaria [260]. 
 
6.3.1  Epidemiology 
6.3.1.1  Malaria in Thailand 
Thailand has, like the other countries of Southeast Asia, endemic malaria, 
with 152,240 reported cases in 1992 (which is probably a significant 
underestimate of the true number, as no prescription is necessary to buy 
antimalarial drugs in Thailand).    166
The Thai government has designated “malaria control zones” where efforts 
are concentrated to control transmission, where the disease burden is 
heaviest. These control zones are on the western Thai-Myanmar border and 
the northeastern Thai-Laos and Thai-Cambodian borders. Approximately 12.7 
million Thai people live in these control zones [347]. The majority of Thai 
malarial cases are Plasmodium falciparum (approximately 60%), the 
remainder almost exclusively Plasmodium vivax. 
6.3.1.2  Lao-thai ethnic distribution 
The Northeast Thailand, also known as Isan, is located on the Khorat plateau, 
which is bordered by Laos (which is separated from Isan by the Mekong river) 
to the north and east, by Cambodia to the southeast. It is separated from 
Northern and Central Thailand by the Phetchabun mountain range. It covers 
approximately 160, 000km
2, making it about half the size of Germany (figure 
6-4). 
The Lao-speaking people of this region, who comprise a large fraction of the 
population are known as Lao-Thai or Khon Isan. The traditional language 
spoken by these people is known as Isan, which may be considered a dialect 
of Laotian, but which is written in the Thai alphabet. 
The region was dominated by the Lao Lan Xang kingdom after the Khmer 
empire began to decline in the 13
th century. After that it was increasingly 
settled by Lao and Thai migrants, and when Thailand (or Siam as it was then) 
became dominant, it carried out forced population transfers from Laos to Isan 
in the 18
th and 19
th centuries. 
In the 20
th century, successive Thai governments have enforced a policy of 
‘Thaification’ to promote the incorporation of Isan as an integral part of 
Thailand and to de-emphasise the Lao origins of the population. The forcible 
introduction of the Thai alphabet for writing the Isan language is one example 
of these policies. 
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Figure 6-4 Map of Thailand, showing Isan (northeast Thailand) in red. 
It is bordered by Cambodia to the south and Laos to the north and east. 
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6.3.1.3  HbE and Thalassemia in Thailand  
Haemoglobin E (HbE) disease is the second most common 
haemoglobinopathy in humans and is often found in high frequencies in 
malaria endemic regions. HbE occurs in up to 50% of Khmer people living in 
the region of NE Thailand at which the borders of Thailand, Cambodia and 
Laos meet-an area which has been dubbed the “HbE triangle”[348]. It is 
asymptomatic in heterozygotes and homozygotes, but homozygotes have a 
microcytic anaemia of the same degree of severity as that seen in β 
thalassemia trait. There is linkage dysequilibrium evidence to suggest that it 
arose from a single mutation some 1,200 to 4,400 years ago with a rapid rise 
in allelic frequency [336] Possession of the HbE trait appears to protect 
against the development of severe malaria [349]. 
The thalassemias, both alpha and beta are found in high frequencies in 
Thailand, northern Thailand is generally recognised to have one of the highest 
frequencies of α-thalassemia in the world [350] and some estimations of the 
frequency of β-thalassaemia in Northern Thailand are as high as 10% [348] 
The initial evidence supporting malaria protection by both forms of 
thalassemia was derived from population genetic studies. Globally, the 
thalassaemias are the commonest single gene disorders thus far described. 
Overall, gene frequencies >0.10 are the norm in tropical populations, whereas 
frequencies are somewhat lower in the subtropics and rare in the temperate 
zones. 
In a series of classic studies conducted in the 1960s, a cline (or gradient) in 
the population frequencies of β-thalassemia in Sardinia that correlated with 
altitude [351]. Although malaria was no longer endemic in Sardinia when 
these studies were conducted, historically, the incidence of malaria was 
known to have correlated closely with altitude. The favoured hypothesis was 
that the cline represented selection for the thalassaemic β-globin gene under 
pressure from malaria. 
Support for this hypothesis has since come from the Pacific. While the gene 
frequency for beta thalassaemia followed a similar correlation with altitude in 
Papua New Guinea [352], it was the data for α-thalassemia collected from 
communities throughout Melanesia that was perhaps the more dramatic.   169
These data showed that α-thalassaemia was found in all malaria-exposed 
populations and at gene frequencies that were proportional to the incidence of 
malaria based on historical reports. 
α-thalassemia has also been shown to be protective against severe malaria 
[353] and β-thalassaemia has been shown to be associated with lower 
parasite densities in children with β-thalassaemia trait in Liberia compared 
with infected controls [354]. 
 
6.3.1.4  Endemic dRTA in NE Thailand 
 
Distal RTA is endemic in NE Thailand and is a cause of serious morbidity and 
mortality [306]. A large proportion of this burden is due to the G701D 
mutation: one study in NE Thailand found that 7 of 12 paediatric patients (5 of 
8 families) with dRTA had the G701D mutation, and further screening of first-
degree relatives found the G701D mutation in 16 out of 25 subjects [193]. The 
only study of its kind showed a gene frequency of >0.7% for G701D in NE 
Thailand [192]. 
 
6.3.2  Founder effect 
 
Individuals with the G701D mutation invariably carry the so-called ‘Memphis’ 
polymorphism  K56E  [63,  315],  demonstrating  a  ‘founder  effect’  and 
suggesting that the mutation originated from a single index case, and that it 
has undergone positive evolutionary selection. These observations have led 
previous  authors  to  speculate  that  AE1-associated  dRTA  may  also  be 
protective against malaria [63, 315]. 
 
6.3.3  Similarity to SAO 
This  is  similar  to  SAO,  another  AE1  mutation  (in  this  case  a  deletion  of 
residues  400-408).  Patients  with  SAO  are  obligate  heterozygotes,  as 
homozygosity is presumably being fatal in utero. SAO is endemic in malarial   170
areas of PNG [355]; while there is no difference in the rates of peripheral 
parasitaemia, there is a strong protective effect against cerebral malaria [260]. 
SAO is also linked with the Memphis polymorphism [356] mentioned earlier, 
again  suggesting  a  founder  effect.  SAO  erythrocytes  are  susceptible  to 
parasite invasion [264], in contrast to earlier reports [263]. Studies of SAO red 
cells  have  shown  a  temperature-dependent  monovalent  cation  leak  [258], 
reminiscent  of  the  cation  leaks  seen  in  HSt  red  cells;  as  have  SAO  AE1 
expressing Xenopus oocytes (H.Guizouarn unpublished observation). 
 
6.3.4  Red cell cation leaks in Thalassaemias and Haemoglobinopathies 
Indeed, increased membrane cation permeability of red cells from thalassemic 
patients has been reported, both in β-thalassemia [357] and α-thalassemia 
[358]. The mechanism for this is not clear, although it has been suggested 
that  it  may  be  due  to  precipitating  haemoglobin  subunits  [359]  and/or 
hemichromes [360] interacting with the membrane. Interestingly, it has been 
noted  that  red  cells  from  patients  with  thalassemia  major  undergo  large 
changes in cation contents when the blood collected from them is allowed to 
stand for a few hours before examination [357]. 
There are no reports of increased red cell membrane cation permeability in 
HbE,  but  it  is  well  documented  in  another  haemoglobinopathy,  sickle  cell 
disease. In sickle cell disease, deoxygenation induced sickling also induces a 
red cell membrane cation leak, which is inhibitable by stilbene compounds 
(which inhibit AE1) [361]. Whether HbE red cell membranes are cation leaky 
as well is, at the moment unknown. 
 
6.3.5  Hypothesis - Do red cell cation leaks protect against severe 
malaria? 
In it possible that the cation leak that we have found in the G701D mutant 
could be related to malaria resistance? In other words, could having a cation 
leaky AE1 molecule at the red cell membrane be advantageous in the event 
of malaria infection?   171
The malaria parasite undergoes its asexual cell cycle (schizogony) in the 
human erythrocyte with a periodicity of approximately 48 hours. A single 
parasite invades an erythrocyte, develops as a ring form, then as a 
trophozoite, undergoes cell division to produce 8-32 daughter merozoites 
before cell lysis occurs at 48 hours, releasing the merozoites to infect more 
erythrocytes.  Over this period, the parasite induces a number of anion and 
cation permeabilities in the erythrocyte membrane known as new permeability 
pathways (NPPs).  
 
Due to these NPPs, the intracellular Na
+ and K
+ concentrations reverse, to 
eventually approximate the Na
+/K
+ ratio of the extracellular milieu, with the 
erythrocyte expanding as it gains more Na
+ and water (Figure 6-5). This 
renders the schizont osmotically fragile-so much so, in fact, that models of the 
same process occurring in uninfected erythrocytes predict osmotic cell lysis 
when the relative cell volume reaches the lytic ratio of 1.8 at 44 hours post 
infection [362].  
 
However recent work has shown that at approximately 48 hours the 
falciparum-infected schizont undergoes an explosive lysis, which propels the 
merozoites into contact with uninfected erythrocytes [363]. Just before lysis 
the schizont exhibits a characteristic ‘flower’ appearance, as parasite 
proteases digest the erythrocyte cell membranes and cytoskeleton [364], 
presumably preparing the already osmotically stressed cell for explosive 
rupture (Figure 6-6 C-D). The parasite appears to delay early osmotic lysis 
until the red cell is sufficiently weakened by proteolysis for efficient explosive 
lysis to occur, by consuming haemoglobin in excess of its synthetic 
requirements, secreting the breakdown products and preventing oxidative 
damage from the released heme, to compensate for the cell volume increase 
[365]. That it expends so much metabolic effort to ensure this late explosive 
lysis underlines its importance to the parasite. This reconciles the observation 
that although merozoites are known to have a myosin motor complex, they 
are not motile until they are in contact with an erythrocyte to invade [366]. 
Explosive lysis would provide the dispersing force for merozoites to reach 
uninfected red cells. As Glushakova has suggested [363], explosive lysis may   172
be necessary for adequate dispersion and infection by the parasite when the 
lysing schizont is surrounded by other infected erythrocytes, such as occurs in 
the cerebral microcirculation in cerebral malaria, where the chances of 
merozoites ejected by non-explosive lysis coming into contact with non-
infected erythrocytes is much reduced. 
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Figure 6-5 Predicted changes in selected homeostatic variables of P 
falciparum–infected red cells during the asexual reproduction cycle of 
the parasite. 
The panels show the predicted changes in (A) host cell Na
+ and K
+ 
concentrations and (B) Hb content (Hb) and concentration ([Hb]); Hb content 
is expressed per 10
13 cells, the approximate number of cells contained in 1 
liter of normal, uninfected human red cells. (C) Relative cell volume of IRBCs 
(▼) and relative host (○) and parasite (●) volumes; all volumes are expressed 
relative to RBC volume at the time of invasion. The horizontal top line in panel 
C indicates the mean critical haemolytic RCV, and the vertical right hand line 
indicates the 48-hour end of the asexual cycle.   174
 
Figure 6-6 A cartoon of the proposed events in malarial asexual 
reproduction in infected erythrocytes 
(A-B) As the infected erythrocyte (A) develops NPPs, the intracellular Na
+ and 
K
+ concentrations reverse, to eventually approximate the Na
+/K
+ ratio of the 
extracellular milieu, with the erythrocyte expanding as it gains more Na
+ and 
water (B). 
(C-D) Just before lysis the schizont exhibits a characteristic ‘flower’ 
appearance (C), as parasite proteases digest the erythrocyte cell membranes 
and cytoskeleton, presumably preparing the already osmotically stressed cell 
for explosive rupture (D). 
(E) Cation leaky red cells are predisposed to earlier osmotic lysis, pre-empting 
explosive lysis, thus reducing the dispersal of merozoites and thus the 
parasites virulence.  
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If  ‘cation leaky’ erythrocytes were infected and their cation leak predisposed 
them to earlier osmotic lysis, late explosive lysis would be less likely to occur 
and so occur less frequently, thereby reducing parasite’s virulence (Figure 6-6 
E). This would be particularly important in the microcirculation, where reduced 
explosive lysis would mean that dense (infected) erythrocyte sequestration 
would become self-limiting (as has been observed in vitro [367]). This could 
explain the strong protective effect that SAO (with its cation leaky red cells) 
exhibits against cerebral malaria [260], and would predict a similar effect for 
G701D carriers. 
 
6.4  Alternative speculative mechanisms 
6.4.1  Accelerated Red Cell ‘Apoptosis’ 
 
An alternative mechanism could arise from the observation of apoptotic-like 
cell death in erythrocytes where old or damaged erythrocytes display cell 
shrinkage, cell membrane blebbing and phosphatidylserine asymmetry-all 
features of apoptosis in nucleated cells, which precede erythrocyte 
endocytosis by macrophages.  
 
Hyperosmotic shock opens non-selective cation permeabilities in the cell 
membrane [368], as does oxidative stress [369]. Calcium as well as 
monovalent cations can move through these new pathways[368, 369] (as it 
can in cation leaky SAO red cells [258]), and activate Ca
2+ sensitive K
+ 
Gardos channels and the increasing Ca
2+ concentration can activate 
erythrocyte scramblase [370], leading to the breakdown of phosphatidylserine 
symmetry [371]. The loss of K
+ from the cell in itself appears to play a part in 
this apoptosis like cell death, as cell shrinkage and phosphatidylserine 
exposure is blunted if the extracellular K
+ is increased, or the Gardos channel 
is inhibited (e.g. with clotrimazole) [372]. 
 
If the cation leaky AE1 leaks Ca
2+, as it may do in SAO, or even if it just 
transports monovalent cations, then it could plausibly accelerate these   176
processes. Falciparum infection of the erythrocyte induces apoptotic like 
changes on the cell [373], and whilst it is not clear whether the parasite 
benefits from this, or whether it is a native defence response, it will contribute 
to earlier cell clearance [374], especially if the erythrocyte has a pre-existing 
cation leak. 
 
6.4.2  ATP depletion 
 
Similarly, it is known that cation leaky SAO red cells, if stored in the cold, can 
exhaust their intracellular ATP due to the cation leak being larger at low 
temperatures and the Na
+/K
+ pump up-regulating in an attempt to compensate 
until it uses all of the available ATP [258].  
 
Malaria infected erythrocytes also develop large permeabilities to monovalent 
cations, and in a similar way, the Na
+/K
+ pump depletes intracellular ATP in 
an attempt to compensate for this, and starts to decline in activity because of 
this at about 36 hours post invasion [362, 375]. 
 
Erythrocytes are susceptible to apoptosis-like cell death when ATP-depleted 
[376] (which may be the reason that phosphate deficiency can lead to 
anaemia) and this might, therefore, provide another avenue for early 
clearance of malaria infected erythrocytes in individuals with cation leaky red 
cells. 
 
This is supported by the observation that P.Falciparum parasites can grow 
normally in erythrocytes that have the Na
+/K
+ pump inhibited by ouabain, and 
thus lose potassium via the basal cation leak, but do not become ATP deplete 
[377].  
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6.4.3  Low intra-erythrocytic potassium inhibiting parasite growth 
 
X-ray microanalysis has shown that the parasite maintains high intra-parasite 
potassium [378], despite the intra-erythrocytic potassium being low due to the 
NPP cation permeability. Could lower red cell potassium adversely affect the 
parasite’s growth, perhaps by depriving it of potassium? 
 
Data about the growth of Falciparum parasites in haemoglobin SA 
erythrocytes might support this idea. Friedman [379] found that parasite 
growth in haemoglobin SA erythrocytes was normal under an atmosphere of 
17% O2, but the parasites could not grow at 3% O2. The parasites could, 
however, grow normally in SA haemoglobin at 3% O2 tension if the culture 
medium contained high K
+ concentrations. The parasitised erythrocytes grown 
in the usual culture medium at low oxygen tension sickled and lost K
+. The 
parasitised erythrocytes still sickled in high K
+ medium, but the erythrocyte K
+ 
remained normal. 
 
Recent work with novel pharmacological agents has shown that agents that 
can cause loss of intra-parasitic potassium have anti-plasmodium activity, 
without causing haemolysis of the parasitised red cell [380]. 
 
 
6.5  High sodium/low potassium erythrocyte 
 
6.5.1.1  Animal resistance 
If the cationic milieu were important in ameliorating the efficiency of the 
plasmodium asexual cell cycle, then one would predict that red cells that are 
low in potassium and high in sodium for other reasons would also be 
inherently difficult for the parasite to reproduce in. Malaria affects other animal 
species, there are primate malarias, rodent malarias, avian rolarias and even 
saurine malarias, but these only occur in animals with high sodium   178
erythrocytes, there are no malarias in animals with high sodium and low 
potassium erythrocytes, such as dogs, cats, cows and horses [381].  
6.5.1.2  Babesia 
However, canine erythrocytes can be infected with Babesia [382], a protozoal 
intra-erythrocyte parasite that produces far fewer membrane permeabilities 
than plasmodium does [383], compatible with the concept that the low sodium 
cell cannot tolerate the greater NPPs induced by plasmodium. 
6.5.2  Possible further avenues of investigation 
If this hypothesis is correct, then the internal cationic state of the erythrocyte 
is of vital importance to the asexual cell cycle of plasmodium, and this implies 
that manipulation of this milieu might offer avenues for pharmacotherapy.  
 
Experimental compounds, which induce cation leaks in normal erythrocytes 
[384] should have a similar effect on schizonts that we predict with G701D 
and SAO. This might offer avenues for development of novel 
pharmacotherapy if the effect could be reproduced non-toxically in-vivo. 
 
Currently, there are 4 classes of anti-malarial drugs, quinoline derivatives, 
antifolates, artemisinin derivatives and antimicrobials. All act on the parasite, 
and with the exception of the artesemisin derivatives, parasite resistance is a 
growing problem. The prospect of a new class of drug, which acts to make the 
red cell membrane ‘cation leaky’, is attractive for a number of reasons, not 
least the possibilities afforded for combination therapy, a crucial therapeutic 
strategy against the development of plasmodial drug resistance. 
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7.  Appendix 1: Further experience with the 
Furosemide and Fludrocortisone test 
 
The physiology investigations day unit has been running urinary acidification 
tests using the furosemide and fludrocortisone protocol since 2007, shortly 
after I performed the measurements detailed in Chapter 3. 
 
In that time, 47 patients have been tested using the furosemide and 
fludrocortisone protocol (detailed below), which was based on the work 
detailed in Chapter 3. Of the 47 patients tested, 17 had positive tests (i.e. 
failed to acidify their urine to a pH of less than 5.3) and a further 6 had 
positive tests that were confirmed with a follow up ammonium chloride test. 24 
patients had negative tests, with normal urinary acidification. The difference 
between the average values (± s.e.m.) for the positive and negative tests is 
summarised graphically (Figure 7-1 A). The pattern of the negative results 
average results is similar to the equivalent in chapter 3, with the threshold pH 
being surpassed on average at 3 hours, and returning to baseline between 4-
5 hours. This pattern is not seen with the positive results. Of those that had a 
follow up ammonium chloride test, the same negative result was obtained; the 
average values are detailed below (Figure 7-1 B). 
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7.1  Protocol for the furosemide and fludrocortisone test 
 
•  The patient should be weighed and a baseline urine pH taken  
 
•  The patient should be given 40 mg of furosemide and 1mg of 
fludrocortisone. The patient is at liberty to eat and drink as they like. 
 
•  Urinary testing should start 1 hour after the dosing with furosemide and 
fludrocortisone and carry on hourly after this until the last sample, 
which should be 4-6 hours after dosing with NH4Cl started. 
 
•  All urinary pH testing should be done with the pH electrode meter as 
soon as the urine specimen is collected. As before the electrode pH 
meter needs to be calibrated against the supplied buffers before use 
each day that it is used. 
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Figure 7-1 Composite graph of urinary pH data for patients routinely 
receiving urinary acidification testing. 
The top graph shows the different average urinary pHs (± s.e.m.) for those 
with positive and negative results with the F+F test. The bottom graph shows 
the difference between urinary pH with the F+F and NH4Cl test in those who 
underwent both tests. 
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8.  Appendix 2: Potassium Excretion in AE1 and non-
AE1 dRTA patients 
 
In the experiments detailed in Chapter 3, I studied patients with dRTA, and 
some of these had hereditary dRTA caused by AE1 mutations. Unfortunately, 
only one such patient completed both tests, but two others also completed the 
ammonium chloride test. All three patients had the R589H mutation, two of 
the patients being siblings. 
The data is summarised in the figure (see Figure 8-1), where the one AE1 
dRTA patient (Figure 8-1 A) has a very large potassium excretion (particularly 
at the 2 hour peak) with the furosemide and fludrocortisone test, compared to 
the other dRTA patients with the same test.  
In the ammonium chloride test, potassium excretion was highest at 4 hours in 
the three patients with AE1 associated dRTA (Figure 8-1C), which was the 
time of peak acidification. In contrast, the non-AE1 associated dRTA patients 
had their lowest potassium excretion at this time, with the only uniformly high 
excretion being at the start of the test (Figure 8-1D). 
Although the numbers of subjects mean that the differences observed 
between these two groups are statistically not significant, the pattern seen in 
the furosemide and fludrocortisone test is the pattern one would expect if 
mutant AE1 caused an increased potassium permeability of the apical α-
intercalated cell membrane (either directly, or via the activation of another 
transporter), mediating potassium loss from the α-intercalated cell when the 
luminal is at its most electronegative. 
It is harder to try and interpret the differences in potassium excretion data in 
the ammonium chloride test-it is not immediately obvious why a theoretical 
increase in apical cation permeability would cause increased potassium loss 
when urinary acidification is increasing; this observation needs to be repeated 
before meriting further investigation. 
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Figure 8-1 Graphs showing potassium excretion. 
Graphs show those dRTA patients with AE1 mutations (A and C) and those 
without (B and D), using both the F+F (A and B) and NH4Cl (C and D) tests. 
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